
<html lang="en"     class="pb-page"  data-request-id="6c75e4dc-9e16-4d18-9aab-f7a47504b20b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.6b00989;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-18"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor" /></meta><meta name="dc.Creator" content="Devin M.  Swanson" /></meta><meta name="dc.Creator" content="Brad M.  Savall" /></meta><meta name="dc.Creator" content="Kevin J.  Coe" /></meta><meta name="dc.Creator" content="Freddy  Schoetens" /></meta><meta name="dc.Creator" content="Tatiana  Koudriakova" /></meta><meta name="dc.Creator" content="Judith  Skaptason" /></meta><meta name="dc.Creator" content="Jessica  Wall" /></meta><meta name="dc.Creator" content="Jason  Rech" /></meta><meta name="dc.Creator" content="Xiahou  Deng" /></meta><meta name="dc.Creator" content="Meri  De Angelis" /></meta><meta name="dc.Creator" content="Anita  Everson" /></meta><meta name="dc.Creator" content="Brian  Lord" /></meta><meta name="dc.Creator" content="Qi  Wang" /></meta><meta name="dc.Creator" content="Hong  Ao" /></meta><meta name="dc.Creator" content="Brian  Scott" /></meta><meta name="dc.Creator" content="Kia  Sepassi" /></meta><meta name="dc.Creator" content="Timothy W.  Lovenberg" /></meta><meta name="dc.Creator" content="Nicholas I.  Carruthers" /></meta><meta name="dc.Creator" content="Anindya  Bhattacharya" /></meta><meta name="dc.Creator" content="Michael A.  Letavic" /></meta><meta name="dc.Description" content="The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this t..." /></meta><meta name="Description" content="The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this t..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 8, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00989" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00989" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00989" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00989" /></link>
        
    
    

<title>Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00989" /></meta><meta property="og:title" content="Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0017.jpeg" /></meta><meta property="og:description" content="The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of 1 (JNJ 54166060). 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00989"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00989">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00989&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00989&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00989&amp;href=/doi/10.1021/acs.jmedchem.6b00989" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8535-8548</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00797" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00972" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Devin+M.++Swanson">Devin M. Swanson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brad+M.++Savall">Brad M. Savall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+J.++Coe">Kevin J. Coe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Freddy++Schoetens">Freddy Schoetens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana++Koudriakova">Tatiana Koudriakova</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judith++Skaptason">Judith Skaptason</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Wall">Jessica Wall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Rech">Jason Rech</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiahou++Deng">Xiahou Deng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meri++De+Angelis">Meri De Angelis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anita++Everson">Anita Everson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Lord">Brian Lord</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Wang">Qi Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Ao">Hong Ao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Scott">Brian Scott</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kia++Sepassi">Kia Sepassi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+W.++Lovenberg">Timothy W. Lovenberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+I.++Carruthers">Nicholas I. Carruthers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anindya++Bhattacharya">Anindya Bhattacharya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Letavic">Michael A. Letavic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Janssen Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121 United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Janssen Research & Development, Discovery Sciences, A Division of Janssen-Cilag, Jarama 75, 45007 Toledo, Spain</span></div><div class="corresp-info"><strong>*</strong>Tel: 1-858-320-3306. E-mail: <a href="/cdn-cgi/l/email-protection#096d7a7e68677a663849607d7a27636763276a6664"><span class="__cf_email__" data-cfemail="f99d8a8e98978a96c8b9908d8ad7939793d79a9694">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00989&amp;href=/doi/10.1021%2Facs.jmedchem.6b00989" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8535â8548</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 22, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 July 2016</li><li><span class="item_label"><b>Published</b> online</span>8 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00989" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00989</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8535%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDevin%2BM.%2BSwanson%252C%2BBrad%2BM.%2BSavall%252C%2BKevin%2BJ.%2BCoe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D18%26contentID%3Dacs.jmedchem.6b00989%26title%3DIdentification%2Bof%2B%2528R%2529-%25282-Chloro-3-%2528trifluoromethyl%2529phenyl%2529%25281-%25285-fluoropyridin-2-yl%2529-4-methyl-6%252C7-dihydro-1H-imidazo%255B4%252C5-c%255Dpyridin-5%25284H%2529-yl%2529methanone%2B%2528JNJ%2B54166060%2529%252C%2Ba%2BSmall%2BMolecule%2BAntagonist%2Bof%2Bthe%2BP2X7%2Breceptor%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8548%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00989"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1745</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00989" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Devin&quot;,&quot;last_name&quot;:&quot;M. Swanson&quot;},{&quot;first_name&quot;:&quot;Brad&quot;,&quot;last_name&quot;:&quot;M. Savall&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;J. Coe&quot;},{&quot;first_name&quot;:&quot;Freddy&quot;,&quot;last_name&quot;:&quot;Schoetens&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;Koudriakova&quot;},{&quot;first_name&quot;:&quot;Judith&quot;,&quot;last_name&quot;:&quot;Skaptason&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Wall&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Rech&quot;},{&quot;first_name&quot;:&quot;Xiahou&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Meri&quot;,&quot;last_name&quot;:&quot;De Angelis&quot;},{&quot;first_name&quot;:&quot;Anita&quot;,&quot;last_name&quot;:&quot;Everson&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Lord&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Ao&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Scott&quot;},{&quot;first_name&quot;:&quot;Kia&quot;,&quot;last_name&quot;:&quot;Sepassi&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;W. Lovenberg&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;I. Carruthers&quot;},{&quot;first_name&quot;:&quot;Anindya&quot;,&quot;last_name&quot;:&quot;Bhattacharya&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Letavic&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8535-8548&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00989&quot;},&quot;abstract&quot;:&quot;The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of 1 (JNJ 54166060). 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00989&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00989" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00989&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00989" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00989&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00989" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00989&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00989&amp;href=/doi/10.1021/acs.jmedchem.6b00989" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00989" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00989" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00989%26sid%3Dliteratum%253Aachs%26pmid%3D27548392%26genre%3Darticle%26aulast%3DSwanson%26date%3D2016%26atitle%3DIdentification%2Bof%2B%2528R%2529-%25282-Chloro-3-%2528trifluoromethyl%2529phenyl%2529%25281-%25285-fluoropyridin-2-yl%2529-4-methyl-6%252C7-dihydro-1H-imidazo%255B4%252C5-c%255Dpyridin-5%25284H%2529-yl%2529methanone%2B%2528JNJ%2B54166060%2529%252C%2Ba%2BSmall%2BMolecule%2BAntagonist%2Bof%2Bthe%2BP2X7%2Breceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D18%26spage%3D8535%26epage%3D8548%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/jmcmar.2016.59.issue-18/20160922/jmcmar.2016.59.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-<i>c</i>]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-<i>c</i>]pyridines ultimately leading to the identification of <b>1</b> (JNJ 54166060). <b>1</b> is a potent P2X7 antagonist with an ED<sub>50</sub> = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, <b>1</b> possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The P2X7 receptor is an ATP gated, purinergic ion channel that controls the release of pro inflammatory cytokines (IL-1Î² and IL-18) in both the periphery and the central nervous system.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The P2X7 receptor belongs to the P2X family of ionotropic receptors and is expressed peripherally in hematopoietic cells such as lymphocytes, monocytes, and macrophages and centrally in microglia and astrocytes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Of the seven subtypes, the P2X7 receptor possesses the lowest affinity for ATP, and thus under normal circumstances, the receptor remains silent. Upon increasing ATP concentrations, the P2X7 receptor is activated and triggers a proinflammatory cascade via Ca<sup>2+</sup> influx and subsequent IL-1Î² release.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> In addition to IL-1Î² signaling, P2X7 dependent release of glutamate, GABA, cathepsins, and chemokines have all been reported.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a></div><div class="NLM_p">The therapeutic importance of a P2X7 antagonist in humans is currently being assessed. At least two peripherally restricted compounds and one centrally penetrant compound have progressed into clinical trials. Pfizer reported their clinical candidate was tolerated but failed to show efficacy for the treatment of rheumatoid arthritis,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Astra Zeneca demonstrated efficacy in a proof of concept study in Crohnâs disease,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and GSK published safety and tolerability data for GSK 1482160.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Our interest in the P2X7 receptor is focused on its central role in neuroinflammation, specifically the relationship between P2X7 antagonism, IL-1Î² suppression, and improvements in the symptoms of depression. Indeed several laboratories have shown that IL-1Î² mediates stress induced depression and anhedonia in mice, while P2X7 knockouts are protected from depression like behavior.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">Recently, GSK and our own laboratories have disclosed a series of 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]pyrazines (1,2,4-triazolopyrazines), 4,5,6,7-tetrahydro-1<i>H</i>-[1,2,3]triazolo[4,5-<i>c</i>]pyridines (1,2,3-triazolopyridines), and related P2X7 antagonists with reasonable physiochemical properties and demonstrated target engagement in rats (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19">(14-19)</a> The 1,2,4-triazolopyrazines (<b>2</b>,<b>4</b>,<b>5</b>) and 1,2,3-triazolopyridine (<b>3</b>) were shown to be potent human P2X7 antagonists that found utility as in vivo tool compounds for the program. The SAR from these series are summarized in a recent review.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As an extension of this work, the 4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (imidazopyridine) core was explored to advance novel P2X7 chemotypes with an improved ADME and safety profile. Herein, we report the synthesis and SAR of the imidazopyridine series and the preclinical profile of <b>1</b> (JNJ 54166060).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <b>1</b> (JNJ 54166060) and previously disclosed triazolopyrazines and triazolopyridines (<b>2</b>â<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45337" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45337" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our initial exploration into the imidazopyridine core involved first replacing the triazole in compounds <b>2</b> and <b>3</b> with a 1<i>H</i>-imidazole. Starting from commercially available 1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>6</b>), we arylated the imidazole nitrogen using CâN coupling conditions to provide <b>7a</b> and <b>7b</b> as a 1:1 mixture of regioisomers which were separable by silica gel chromatography (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> From <b>7a</b>, we reduced the imidazopyridine ring by forming an <i>N</i>-alkylpyridinium ion with BnBr followed by NaBH<sub>4</sub> reduction to obtain <b>8</b>. Hydrogenolysis of the benzyl group and subsequent peptide coupling provided the final compounds, <b>10</b>â<b>17</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Imidazopyridine Compounds <b>10</b>â<b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>-X, Cu<sub>2</sub>O, 8-OH quinoline, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, microwave, 1 h, 140 Â°C, 17â40%; (b) BnBr, NaBH<sub>4</sub>, DCM, MeOH, rt, 68â87%; (c) H<sub>2</sub>, EtOH, Pd/C, rt, 24 h, 75â83%; (d) R<sup>1</sup>COOH, HATU, Et<sub>3</sub>N, DMF, rt, 22â96%.</p></p></figure><div class="NLM_p">Results from our initial analogues established that changing the core from a triazolopyridine to an imidazopyridine was tolerated with respect to hP2X7 affinity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Thus, compounds <b>10</b>â<b>17</b> all possessed a similar profile, with a hP2X7 IC<sub>50</sub> < 100 nM and rP2X7 IC<sub>50</sub> > 500 nM. Compound <b>12</b>, where R<sup>1</sup> = 2-Cl-3-CF<sub>3</sub> phenyl and R<sup>2</sup> = 2-pyridyl, provided the best combination of human and rat P2X7 affinity with a hP2X7 IC<sub>50</sub> = 4 nM and a rP2X7 IC<sub>50</sub> = 609 nM. The measured disconnect between human and rat P2X7 affinity has been previously observed in the triazolopyrazine and triazolopyridine templates as highlighted by compound <b>2</b>. Additionally, steep SAR was observed for the R<sup>1</sup> space where small changes to the 2-Cl-3-CF<sub>3</sub> phenyl substituent resulted in diminished hP2X7 affinity as seen with compounds <b>15</b>â<b>17</b>. Further profiling of these compounds identified microsomal stability as a liability for this template as measured extraction ratios (ERs) from human and rat liver microsomes (HLM/RLM) were all greater than 0.8 indicative of metabolic instability.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Human and Rat P2X7 IC<sub>50</sub>s and Microsomal Data for Compounds <b>10</b>â<b>17</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were found to be P2X7 antagonists using a human peripheral blood monocyte (HPBMC) assay prior to testing in FLIPR for confirmation of activity and IC<sub>50</sub> determination. The protocols for the HPBMC and FLIPR assays can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. Human FLIPR pIC<sub>50</sub> measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Rat FLIPR measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Stability in rat and human liver microsomes as measured by extraction ratio(s). Primary assays were run in triplicate with the mean value reported. Standard deviation in all cases was less than 2-fold.</p></div></div><div></div></div><div class="NLM_p">In the 1,2,4-triazolopyrazine series (<b>4</b>), methyl substitution on the core improved rat P2X7 affinity.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> As such, we wished to explore the impact of similar substitution on the imidazopyridine core and chose substitution on the 4-position due to synthetic accessibility. To synthesize these analogues, we utilized the route shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and kept the 2-chloro-3-trifluoromethylaryl group (R<sup>1</sup>) constant due the SAR observed in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Here, we added a methyl Grignard to an <i>N</i>-acylpyridinium ion, formed by <b>7a</b> and an acid chloride (<b>18</b>), to affect a 1,2 addition which gave intermediate <b>19</b>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This intermediate could then be reduced under hydrogenation conditions to provide the desired compounds, <b>20</b>â<b>27</b>, as racemic mixtures. Racemates of interest were then separated by chiral chromatography.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Imidazopyridine Compounds <b>1</b> and <b>20</b>â<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-Cl-3-CF3PhCOCl (<b>18</b>), MeMgBr, THF, rt, 3 h, 33â54%; (b) H<sub>2</sub>, EtOH, Pd/C, 24 h, 20â62%; (c) SFC chiral chromatography, 40â42%.</p></p></figure><div class="NLM_p">Shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> are the human and rat P2X7 IC<sub>50</sub>s and microsomal stability data for compounds <b>20</b>â<b>27</b>. Compound <b>21</b> provided the first indication of increased microsomal stability within the series. Thus, going from the unsubstituted phenyl (<b>20</b>) to a 4-F phenyl (<b>21</b>) saw measurable improvement in stability with <b>21</b> possessing a HLM/RLM ER = 0.32/0.59. The 4-F pyrimidine derivative (<b>23</b>) and 4-F pyridine derivative (<b>27</b>) were also equally stable in vitro, and both compounds possessed improved target affinity with a hP2X7 IC<sub>50</sub> = 10 and 14 nM, respectively. Modest gains in rat affinity were observed with 4-Me substitution on the imidazopyridine core. Compounds <b>20</b>, <b>25</b>, and <b>27</b> were 2- to 4-fold more active at the rat P2X7 receptor over their des methyl equivalents (<b>11</b>, <b>12</b>, and <b>14</b>) and prompted additional investigation of the single enantiomers.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Human and Rat P2X7 IC<sub>50</sub>s and Liver Microsomal Stability Data for Compounds <b>20</b>â<b>27</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Human FLIPR pIC<sub>50</sub> measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Rat FLIPR measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Stability in rat and human liver microsomes reported as hepatic extraction ratio(s). Primary assays have been run in triplicate with the mean value reported. Standard deviation in all cases was less than 2-fold.</p></div></div><div></div></div><div class="NLM_p">Four of the racemic imidazopyridine analogues (<b>21</b>, <b>23</b>, <b>25</b>, and <b>27</b>) were purified by chiral HPLC, and the enantiomers were submitted for testing (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). One enantiomer from each racemate was responsible for P2X7 affinity (<b>1</b>, <b>28</b>â<b>30</b>) with the other enantiomer possessing human and rat P2X7 IC<sub>50</sub>s > 1000 nM (data not shown). Importantly, the rat affinity for the active enantiomers was improved over the racemates with rP2X7 IC<sub>50</sub>s now in the 100 to 300 nM range. Mouse P2X7 IC<sub>50</sub>s and human P2X7 <i>K</i><sub>i</sub>s were generated for <b>1</b>, <b>28</b>â<b>30</b> and were found to be in good agreement with human Ca<sup>2+</sup> mobilization data. The active enantiomer of <b>27</b>, <b>1</b> (JNJ 54166060), possessed single digit potency in both human functional and binding assays with an hP2X7 IC<sub>50</sub> = 4 nM and hP2X7 <i>K</i><sub>i</sub> = 7 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Human, Rat, and Mouse P2X7 Data for Compounds <b>1</b> and <b>28</b>â<b>30</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Human FLIPR pIC<sub>50</sub> measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Rat FLIPR measured in a Ca<sup>2+</sup> flux assay.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Mouse FLIPR measured in a Ca<sup>2+</sup> flus assay.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Human <i>K</i><sub>i</sub> measured with [<sup>3</sup>H]-<b>5</b> as the binding ligand. All assay data have been run in triplicate with the mean value reported. Standard deviation in all cases was less than 2-fold.</p></div></div><div></div></div><div class="NLM_p">To confirm the structural assignment of our compounds, we submitted <b>1</b> and its enantiomer (<b>31</b>) for absolute stereochemical determination via X-ray crystallography. The single crystal X-ray structures for the two compounds are shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. The absolute stereochemistry of the compounds was determined as depicted with the Flack parameter<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> = â0.004 and â0.015 for <b>1</b> and <b>31</b>, respectively. There were no hydrogen bond interactions or solvates within the crystals with the pyridine and phenyl substituents off the imidazopyrazine core adopting planar geometry. The asymmetric unit contained one disordered molecule of <b>1</b> and one fully ordered molecule of <b>31</b>.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Single crystal structures and stereochemical assignment of <b>1</b> and <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further in vitro characterization of <b>1</b> and <b>28</b>â<b>30</b> are shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. The compounds were assessed for liver microsomal stability (HLM/RLM), plasma protein binding (PPB), cytochrome P450 (CYP) inhibition (5 isoforms), and solubility (pH2/pH7) and counter screened against the hERG channel. The compounds tested possessed no CYP or hERG liabilities, measurable solubility, and moderate free fraction in both human and rat plasma. Improvements in microsomal stability were observed with 4-F substitution at the R2 substituent with the nitrogen containing heterocycles enhancing solubility across physiologically relevant pH ranges. Indeed, a metabolite identification study on <b>1</b> in liver microsomes revealed no oxidation on the fluoropyridine substituent with the major metabolite in humans being oxidation on the imidazopyridine core. Subsequent isozyme mapping in recombinant human CYPs determined that the metabolism of <b>1</b> is primarily driven by the CYP3A isoform. There was no evidence of CYP3A time dependent inhibition (TDI) for <b>1</b> up to concentrations of 10 Î¼M. In combination with in vitro potency, <b>1</b> was identified as a lead candidate for the P2X7 program due to a number of favorable properties including metabolic stability in HLMs, high permeability with no evidence of efflux in Caco-2 cells, moderate free fractions in plasma, no hERG liability, measurable solubility, and P2X7 selectivity as assessed by a CEREP panel and Upstate kinase panel (Eurofins-CEREP, <a href="http://www.eurofins.com" class="extLink">www.eurofins.com</a>, EMD Millipore, <a href="http://www.emdmillipore.com" class="extLink">www.emdmillipore.com</a>, no inhibition >50% @ 1 Î¼M). The full in vitro profile of <b>1</b> is shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. ADME Data for Compounds <b>1</b> and <b>28</b>â<b>30</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Stability in rat and human liver microsomes reported as hepatic ratio(s).</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Human and rat plasma protein binding reported as % bound.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Screening CYP inhibition data obtained from human liver microsomes.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">hERG IC<sub>50</sub> as measured in an [<sup>3</sup>H]astemizole competition binding assay in HEK-293 cells expressing the hERG channel.</p></div></div><div></div></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro profile of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To gauge the viability of <b>1</b> for a CNS indication, central target engagement was assessed via ex vivo P2X7 occupancy in rat brain hippocampal tissue sections using tritiated <b>5</b> as the radiotracer.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Following oral administration, <b>1</b> exhibited dose dependent occupancy in the rat brain with an ED<sub>50</sub> = 2.3 mg/kg corresponding to an EC<sub>50</sub> = 125 ng/mL and 362 ng/mL in the plasma and brain, respectively. Although the brain concentrations are â¼3 fold greater than plasma levels, free plasma and free brain concentrations are similar after correcting for brain binding (1.5% free) and plasma protein binding (5.5% free) with an unbound brain to plasma partition ratio (<i>K</i><sub>pÂ u,u</sub>) of 0.84. Such a <i>K</i><sub>pu,u</sub> suggests a limited impact of efflux, in line with Caco-2 in vitro data. Additionally, the free IC<sub>50</sub>s from this study match in vitro P2X7 potency where the unbound plasma IC<sub>50</sub> = 6.4 ng/mL (15 nM) and the unbound brain IC<sub>50</sub> = 5.4 ng/mL (12 nM) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ex vivo P2X7 occupancy with compound <b>1</b> in rat brain; dose dependency following oral administration (<i>n</i> = 3 per dose Â± SEM). P2X7 occupancy was measured 30 min after drug administration using tritiated <b>5</b> as the radiotracer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacokinetic parameters for <b>1</b> in rats, dogs, and monkeys are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Across the three species, there is a strong correlation between predicted and measured clearance values. The predicted in vitro clearance from liver microsomal data for <b>1</b> was within 2-fold from the clearance observed in vivo: 35 mL/min/kg vs 30 mL/min/kg measured for rat; 10 mL/min/kg vs 5.5 mL/min/kg measured for dog; and 18 mL/min/kg vs 14 mL/min/kg measured for cynomolgus monkey. High oral bioavailability was observed across three species (% <i>F</i> > 50) with the <i>C</i><sub>max</sub> achieved at 1 h from oral administration. Given the high degree of concordance between in vitro and in vivo clearance values across three preclinical species, allometric scaling was considered suitable to predict the human dose of <b>1</b>. Since the human and rat P2X7 <i>K</i><sub>i</sub> and PPB values were similar (r/h P2X7 <i>K</i><sub>i</sub> = 7 nM, r/h PPB â¼ 95%), we used the plasma EC<sub>50</sub> from the rat doseâresponse experiment of 125 ng/mL as the trough for human plasma concentration. To maintain the plasma concentration above 125 ng/mL, a dose of 120 mg QD was predicted for <b>1</b> in humans with a CL = 2.8 mL/min/kg, <i>V</i><sub>ss</sub> =2.0 L/kg, <i>t</i><sub>1/2</sub> = 8.3 h, and <i>F</i> = 85%.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" align="center">in vitro from LMs</th><th class="rowsep1 colsep0" colspan="3" align="center">IV</th><th class="rowsep1 colsep0" colspan="3" align="center">PO</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">CL<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">CL<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub><a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub><a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">36.8</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">375</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">10.3</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">11.9</td><td class="colsep0 rowsep0" align="left">1249</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">18.2</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">389</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human (predicted)</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">85</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Clearance.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">IV half life.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Maximum concentration.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Time of maximum concentration.</p></div></div></div><div class="NLM_p">As part of the preclinical toxicology package, a single dose and repeat dose toleration study were run in male rats with <b>1</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). To meet the compound requirements for the studies, additional material was synthesized using <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, and the route was found to be scalable. In the repeat dose study, animals were administered <b>1</b> at 62.5, 125, or 250 mg/kg/day for 4 days with necropsy performed on day 5. <b>1</b> was well tolerated in both the single and repeat dose studies with adequate exposures and no noted CNS side effects. In the single dose experiment, increasing exposures were observed up to the 1000 mg/kg dose with a <i>t</i><sub>max</sub> of 24 h for all doses tested. In the repeat dose study, no conclusive trends could be extrapolated from the 1 and 4 day exposure data. The histology findings in both studies were considered mild with dose-related increases in total serum cholesterol observed at the 125 and 250 mg/kg/day repeat doses. In addition, one rat dosed at 250 mg/kg/day showed minimal central lobular hepatocellular degeneration and necrosis. Overall, the safety profile observed in the toleration studies supported further development of the molecule.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Single dose and repeat dose toleration studies of <b>1</b> in male rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the preclinical package for <b>1</b> nearing completion, a discrepancy was identified in a definitive CYP inhibition study. In this study, <b>1</b> was found to be a potent inhibitor of CYP3A with an IC<sub>50</sub> = 2 Î¼M. This data was at odds with the original screening CYP inhibition data, where <b>1</b> showed no significant CYP3A inhibition up to a concentration of 10 Î¼M. Further investigation of the screening CYP inhibition assay revealed that 1-OH-midazolam and 4-OH-midazolam, the two metabolites mediated by CYP3A, coeluted in the LC-MS assay.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> When these metabolites were chromatographically resolved, <b>1</b> was found to only inhibit the formation of 1-OH-midazolam (IC<sub>50</sub> = 2.2 Î¼M) and not 4-OH-midazolam (IC<sub>50</sub> > 10 Î¼M) (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Thus, the lack of inhibition of 4-OH-midazolam masked <b>1</b>âs CYP3A inhibition when these metabolites coeluted in the screening assay. The CYP3A enzyme contains a large active site that bears multiple binding orientations, such that the use of multiple CYP3A probes (e.g., midazolam, nifedipine, and testosterone) is required to adequately assess the inhibitory potential of drugs. However, to our knowledge this is the first report of the regioselective inhibition of midazolam by a potential drug candidate.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In contrast, ketoconazole, a widely recognized CYP3A inhibitor, exhibited similar inhibition potency at 1-OH midazolam and 4-OH midazolam with IC<sub>50</sub> values of 9.1 and 7.4 nM, respectively. Overall, given the drugâdrug interaction risk, both as perpetrator and as victim, with progressing a potent CYP3A inhibitor whose primary route of clearance is CYP3A mediated; development of <b>1</b> was stopped in favor of alternative compounds.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Percent Inhibition of 1-OH and 4-OH Midazolam Formation, <b>1</b> vs Ketoconazole</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="3" align="center"><b>1</b></th><th class="rowsep1 colsep0" colspan="3" align="center">ketoconazole (CYP3A4 positive control)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">concentration (Î¼M)</th><th class="colsep0 rowsep0" align="center">1-OH-midazolam %Â inhibition</th><th class="colsep0 rowsep0" align="center">4-OH-midazolam %Â inhibition</th><th class="colsep0 rowsep0" align="center">concentration (Î¼M)</th><th class="colsep0 rowsep0" align="center">1-OH-midazolam %Â inhibition</th><th class="colsep0 rowsep0" align="center">4-OH-midazolam %Â inhibition</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.313</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.625</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">â5</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.25</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">â10</td><td class="colsep0 rowsep0" align="left">0.02</td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">â13</td><td class="colsep0 rowsep0" align="left">0.04</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">â13</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">â4</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">95</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have demonstrated that this series of novel 4,5,6,7-tetrahydro-imidazo[4,5-<i>c</i>]pyridines are potent and selective P2X7 antagonists. Optimization of the imidazopyridine core led to compounds with improved liver microsomal stability and P2X7 rat affinity. Compound <b>1</b> (JNJ 54166060) was identified as a lead candidate for the P2X7 program with an excellent in vitro profile. In conjunction with ex vivo autoradiography and pharmacokinetic parameters across three preclinical species, we were able to predict the human PK profile for <b>1</b>, and this analysis suggested that <b>1</b> would have a human PK profile suitable to treat depressive disorders (i.e., 24 h coverage, oral administration, and brain penetration). Preclinical toxicology established that <b>1</b> was well tolerated in rats with no behavioral side effects and no major histopathology findings related to drug treatment. Finally, <b>1</b> was found to possess a unique CYP profile and was determined to be a regioselective inhibitor of CYP3A; inhibiting the formation of 1-OH midazolam but not 4-OH midazolam.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87865" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87865" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In obtaining the compounds described, the following experimental and analytical protocols were followed unless otherwise indicated. Anhydrous solvents were obtained from a GlassContour solvent dispensing system. Reagents were purchased from commercial suppliers and were used without purification. The reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were âdried,â they were generally dried over a drying agent such as Na<sub>2</sub>SO<sub>4</sub> or MgSO<sub>4</sub>. Where mixtures, solutions, and extracts were âconcentratedâ, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM Discover instrument. Normal-phase silica gel column chromatography (sgc) was performed on silica gel (SiO<sub>2</sub>) using prepackaged cartridges, eluting with 2 M NH<sub>3</sub>/MeOH in CH<sub>2</sub>Cl<sub>2</sub> or EtOAc in hexanes unless otherwise indicated. Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers. The format of the <sup>1</sup>H NMR data below is chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant <i>J</i> in Hz, integration). High resolution mass spectrometry data were obtained with a Bruker Î¼TOf detector in positive mode, a Zorbax SB-C18 3.5 Î¼M, 2.1 Ã 50 mm column at 40 Â°C, an acetonitrile/water with 0.05% formic acid gradient over 7 min, and a flow rate of 0.3 mL/min. Calculated (calcd.) mass corresponds to the exact mass. Chemical names were generated using ChemDraw Ultra 6.0.2 (CambridgeSoft Corp., Cambridge, MA) or ACD/Name Version 9 (Advanced Chemistry Development, Toronto, Ontario, Canada). All compounds tested were of a minimum of 98% purity as determined by HPLC. The HPLC methods used for purity determinations are as follows: Analytical LCMS was obtained on an Agilent 1100/1200 series LCMS with ESI in positive mode and a scan range of 100â700 amu. Samples were run on a Halo C18 column (2.7 Î¼m, 50 Ã 3 mm), with a mobile phase of 5â99% ACN in 0.05% TFA over 3.5 min and then held at 99% ACN for 0.5 min, at a flow rate of 1 mL/min (Temperature =50 Â°C). Analytical MS was obtained in flow injection mode on an Agilent 1100/1200 Series ESI-SQD in positive mode with a scan range of 100â1000 amu using a mobile phase of 75% ACN/24.9% H<sub>2</sub>O/0.1% TFA at a flow rate of 0.4 mL/min (temperature = 50 Â°C). Chiral compounds were analyzed by chiral HPLC or chiral SFC and demonstrated to have â¥98% ee.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Representative Procedure A</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Step 1. 1-(Pyridin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>7a</b>)</h4><div class="NLM_p last">A solution of 5-azabenzimidazole (1.00 g, 8.40 mmol), 2-bromopyridine (1.30 g, 8.40 mmol), copper(I) oxide (0.13 g, 0.84 mmol), 8-hydroxyquinoline (0.24 g, 1.68 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (5.50 g, 16.8 mmol) in DMSO (4 mL) was irradiated in a microwave apparatus for 1 h at 140 Â°C. The reaction was diluted with H<sub>2</sub>O (100 mL) and extracted with EtOAc (75 mL Ã 3). The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Chromatography of the resulting residue (SiO<sub>2</sub>; MeOH (NH<sub>3</sub>)/DCM) gave the title compound (0.45 g, 25%). <sup>1</sup>H NMR (600 MHz, DMSO) Î´ 9.18â9.04 (m, 2H), 8.71â8.63 (ddd, <i>J</i> = 4.7, 2.0, 0.9 Hz, 1H), 8.54â8.44 (d, <i>J</i> = 5.6 Hz, 1H), 8.32â8.23 (dd, <i>J</i> = 5.6, 1.0 Hz, 1H), 8.20â8.07 (ddd, <i>J</i> = 8.3, 7.4, 1.9 Hz, 1H), 8.05â7.97 (dt, <i>J</i> = 8.2, 1.0 Hz, 1H), 7.56â7.43 (ddd, <i>J</i> = 7.4, 4.9, 0.9 Hz, 1H). MS (ESI): mass calculated for C<sub>11</sub>H<sub>8</sub>N<sub>4</sub>, 196.07; <i>m</i>/<i>z</i> found 197.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Step 2. 5-Benzyl-1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>8</b>)</h4><div class="NLM_p last">To a solution of <b>7a</b> (0.20 g, 1.02 mmol) in DCM (25 mL) was added benzyl bromide (0.12 g, 1.02 mmol). The reaction was allowed to stir for 4 h then concentrated. The resulting solid was dissolved in MeOH (10 mL), and NaBH<sub>4</sub> (0.05 g, 1.4 mmol) was added slowly. After 5 h, the reaction was quenched with a small amount of water and concentrated. Chromatography of the resulting residue (SiO<sub>2</sub>; MeOH (NH<sub>3</sub>)/DCM) gave the title compound (0.20 g, 68%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.76â8.66 (m, 1H), 8.55â8.39 (m, 2H), 8.14â8.03 (m, 1H), 7.32 (ddt, <i>J</i> = 22.0, 11.6, 7.5 Hz, 6H), 3.89 (s, 1H), 3.78 (d, <i>J</i> = 5.4 Hz, 2H), 3.63 (s, 1H), 2.99 (t, <i>J</i> = 5.5 Hz, 1H), 2.83 (tt, <i>J</i> = 26.6, 5.6 Hz, 3H). MS (ESI): mass calculated for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>, 290.2; <i>m</i>/<i>z</i> found 291.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Step 3. 1-(Pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>9</b>)</h4><div class="NLM_p last">To a solution of 5-benzyl-1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (0.13 g, 0.45 mmol) in DCE (5 mL) was added 1-chloroethyl chloroformate (0.10 mL, 0.90 mmoL). The reaction was allowed to stir for 15 min, then heated at reflux for 4 h. The reaction was allowed to cool, concentrated, dissolved in MeOH, and heated again at 60 Â°C for 1 h. The reaction was concentrated, and the product was used in the next step without further purification (0.075 g, 83%). <sup>1</sup>H NMR (400 MHz, DMSO): Î´ 9.17 (s, 2H), 9.04 (d, <i>J</i> = 4.9 Hz, 1H), 7.72â7.28 (m, 2H), 4.46 (t, <i>J</i> = 1.3 Hz, 2H), 3.49 (t, <i>J</i> = 6.0 Hz, 2H), 3.38 (s, 2H). MS (ESI): mass calculated for C<sub>11</sub>H<sub>12</sub>N<sub>4</sub>, 200.1; <i>m</i>/<i>z</i> found 201.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Step 4. (2-Chloro-3-(trifluoromethyl)phenyl)(1-(pyridin-2-yl)-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>12</b>)</h4><div class="NLM_p last">A solution of 1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine (<b>9</b>) (0.050 g, 0.25 mmol), 2-chloro-3-trifluoromethyl benzoic acid (0.056 g, 0.25 mmol), and HATU (0.10 g, 0.26 mmol, and DIPEA (0.09 mL, 0.50 mmol) in DMF (2 mL) was stirred for 30 min. The reaction was diluted with EtOAc (15 mL) and washed with H<sub>2</sub>O (3 Ã 10 mL). The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Chromatography of the resulting residue (SiO<sub>2</sub>; MeOH (NH<sub>3</sub>)/DCM) gave the title compound (22 mg, 22%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.52 (dd, <i>J</i> = 4.9, 1.8 Hz, 1H), 8.02 (d, <i>J</i> = 18.1 Hz, 1H), 7.92â7.71 (m, 2H), 7.58â7.40 (m, 2H), 7.37â7.28 (m, 2H), 5.12â4.78 (m, 1H), 4.51â4.19 (m, 2H), 3.97 (ddd, <i>J</i> = 13.4, 12.7, 9.9 Hz, 1H), 3.61â3.45 (m, 1H), 3.27â2.82 (m, 2H). HRMS calc. for C<sub>19</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 407.0881, found 407.0869.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Representative Procedure B</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Step 1. 2-Chloro-3-(trifluoromethyl)benzoyl chloride (<b>18</b>)</h4><div class="NLM_p last">To a suspension of 2-chloro-3-(trifluoromethyl)benzoic acid (15 g, 67 mmol) and catalytic DMF (0.06 mL, 0.67 mmol) in DCM (150 mL) was added oxalyl chloride (6.8 mL, 80 mmol) dropwise. The reaction was allowed to stir (vigorous bubbling) for 4 h and concentrated to an oily solid which became solid after overnight drying on high vacuum.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Step 2. (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>19</b>)</h4><div class="NLM_p last">To a solution of <b>7a</b> (0.70 g, 3.27 mmol) in THF (20 mL) was added <b>18</b> (0.87 g, 3.60 mmol) dropwise. The reaction was allowed to stir for 1 h, then cooled to â78 Â°C. To the cooled solution was added 3 M MeMgBr in Et<sub>2</sub>O (1.31 mL, 3.92 mmoL), and the reaction was allowed to come to room temperature. The mixture was then quenched with 1 N NaOH (50 mL) and extracted with EtOAc (3 Ã 30 mL). The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Chromatography of the resulting residue (SiO<sub>2</sub>; MeOH (NH<sub>3</sub>)/DCM) gave the title compound (770 mg, 54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.43â8.34 (m, 1H), 7.92â7.73 (m, 2H), 7.70â7.33 (m, 4H), 6.08 (dtd, <i>J</i> = 19.7, 11.7, 8.0 Hz, 3H), 1.54 (t, <i>J</i> = 7.0 Hz, 3H). MS (ESI): mass calculated for C<sub>20</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>4</sub>O, 436.07; <i>m</i>/<i>z</i> found 437.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step 3. (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>27</b>)</h4><div class="NLM_p last">To a solution of <b>19</b> (0.80 g, 1.83 mmol) in degassed EtOH (25 mL) was added palladium on carbon (0.20 mg, 0.19 mmol). The reaction was placed under an atmosphere of hydrogen and allowed to stir for 48 h. The reaction was diluted with DCM and filtered through a pad of Celite. The solvent was concentrated, and chromatography of the resulting residue (SiO<sub>2</sub>; MeOH (NH<sub>3</sub>)/DCM) gave the title compound (500 mg, 62%). <sup>1</sup>H NMR (500 MHz, CDCl3) Î´ 8.45â8.30 (m, 1H), 7.94 (dd, <i>J</i> = 18.2, 10.7 Hz, 1H), 7.76 (d, <i>J</i> = 5.7 Hz, 1H), 7.67â7.43 (m, 3H), 7.43â7.30 (m, 1H), 5.81 (dd, <i>J</i> = 13.3, 6.7 Hz, 1H), 5.07 (d, <i>J</i> = 5.6 Hz, 1H), 4.52 (d, <i>J</i> = 6.7 Hz, 1H), 3.61â3.31 (m, 1H), 3.08â2.69 (m, 1H), 1.63â145 (m, 3H). HRMS calc. for C<sub>20</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 439.0943, found 439.0957.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step 4. (<i>R</i>)-(2-Chloro-3 (trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>1</b>)</h4><div class="NLM_p">The title compound was obtained as a single enantiomer by Chiral SFC purification performed using CHIRALCEL OD-H (5 Î¼m, 250 Ã 20 mm) and a mobile phase of 72% CO<sub>2</sub>, 28% 1:1 EtOH/iPrOH. The enantiomeric purity was confirmed by analytical SFC using Whelk-al (S,S) (250 Ã 4.6 mm) and a mobile phase of 60% CO<sub>2</sub>, 40% MeOH over 7 min (100% single enantiomer, 4.03 min retention time) (0.16 g, 41%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.43â8.32 (m, 1H), 7.94 (dd, <i>J</i> = 18.3, 11.2 Hz, 1H), 7.80â7.70 (m, 1H), 7.65â7.29 (m, 4H), 5.91â5.74 (m, 1H), 5.14â4.46 (m, 1H), 3.60â3.30 (m, 1H), 3.30â3.04 (m, 1H), 3.06â2.68 (m, 1H), 1.76â1.35 (m, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) Î´ 165.95â165.79 (s), 139.33â139.10 (d, <i>J</i> = 8.8 Hz), 137.50â137.15 (m), 135.54â135.31 (m), 131.24â131.08 (s), 130.68â130.52 (s), 130.42â130.26 (s), 128.08â127.83 (t, <i>J</i> = 5.7 Hz), 127.50â127.13 (m), 126.23â125.85 (dd, <i>J</i> = 20.4, 7.6 Hz), 123.69â123.54 (s), 122.56â122.40 (s), 116.00â115.72 (m), 52.32â52.16 (s), 47.41â47.25 (s), 41.25â41.09 (s), 35.57â35.41 (s), 24.49â24.19 (m), 19.96â18.59 (m). HRMS calc. for C<sub>20</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 439.0943, found 439.0957. Specific rotation: [Î±]<sup>20</sup><sub>D</sub> â 52.6 (c 0.5, CHCl<sub>3</sub>).</div><div class="NLM_p">The following intermediates were prepared in a manner analogous to representative procedure A, step 1.</div><div id="sec4_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 1-Phenyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(40%). MS (ESI): mass calculated for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>, 195.08; <i>m</i>/<i>z</i> found 196.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 1-(Pyrazin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(24%). MS (ESI): mass calculated for C<sub>10</sub>H<sub>7</sub>N<sub>5</sub>, 197.07; <i>m</i>/<i>z</i> found 198.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 1-(5-Fluoropyridin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(37%). MS (ESI): mass calculated for C<sub>11</sub>H<sub>7</sub>FN<sub>4</sub>, 214.07; <i>m</i>/<i>z</i> found 215.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 1-(4-Fluorophenyl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(34%) MS (ESI): mass calculated for C<sub>12</sub>H<sub>8</sub>FN<sub>3</sub>, 213.07; <i>m</i>/<i>z</i> found 214.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 1-(Pyrimidin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(24%) MS (ESI): mass calculated for C<sub>10</sub>H<sub>7</sub>N<sub>5</sub>, 197.07; <i>m</i>/<i>z</i> found 198.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 1-(5-Fluoropyrimidin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(17%) MS (ESI): mass calculated for C<sub>10</sub>H<sub>6</sub>FN<sub>5</sub>, 215.06; <i>m</i>/<i>z</i> found 216.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 1-(3-Fluoropyridin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p">(20%) MS (ESI): mass calculated for C<sub>11</sub>H<sub>7</sub>FN<sub>4</sub>, 214.07; <i>m</i>/<i>z</i> found 215.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The following intermediates were prepared in a manner analogous to representative procedure A, step 2.</div></div><div id="sec4_2_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 5-Benzyl-1-phenyl-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(89%). MS (ESI): mass calculated for C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>, 289.16; <i>m</i>/<i>z</i> found 290.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 5-Benzyl-1-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(69%). MS (ESI): mass calculated for C<sub>17</sub>H<sub>17</sub>N<sub>5</sub>, 291.15; <i>m</i>/<i>z</i> found 292.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 5-Benzyl-1-(5-fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p">(87%). MS (ESI): mass calculated for C<sub>18</sub>H<sub>17</sub>FN<sub>4</sub>, 308.14; <i>m</i>/<i>z</i> found 309.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The following intermediates were prepared in a manner analogous to representative procedure A, step 3.</div></div><div id="sec4_2_4_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-Phenyl-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(79%). MS (ESI): mass calculated for C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>, 199.11; <i>m</i>/<i>z</i> found 200.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-(Pyrazin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p last">(75%). MS (ESI): mass calculated for C<sub>10</sub>H<sub>11</sub>N<sub>5</sub>, 201.10; <i>m</i>/<i>z</i> found 202.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(5-Fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine</h5><div class="NLM_p">(78%). MS (ESI): mass calculated for C<sub>11</sub>H<sub>11</sub>FN<sub>4</sub>, 218.10; <i>m</i>/<i>z</i> found 219.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The following compounds were prepared in a manner analogous to representative procedure A, step 4.</div></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (2,3-Dichlorophenyl)(1-phenyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4H)-yl)methanone (<b>10</b>)</h4><div class="NLM_p last">(75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.67 (s, 0.4H), 7.60 (s, 0.6H), 7.56â7.39 (m, 4H), 7.33â7.20 (m, 5H), 4.96â4.90 (m, 1H), 4.46â4.20 (m, 2H), 4.03â3.92 (m, 1H), 3.60â3.43 (m, 1H), 2.67 (ddd, <i>J</i> = 20.9, 15.5, 6.8 Hz, 1H). HRMS calc. for C<sub>19</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 372.0665, found 372.0682.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-phenyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>11</b>)</h4><div class="NLM_p last">(90%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.79â7.74 (m, 1H), 7.68 (s, 0.4H), 7.60 (s, 0.6H), 7.56â7.39 (m, 5H), 7.34â7.28 (m, 2H), 4.99â4.90 (m, 1H), 4.45â4.27 (m, 2H), 3.93 (ddd, <i>J</i> = 12.8, 7.2, 5.2 Hz, 1H), 3.60â3.45 (m, 1H). HRMS calc. for C<sub>20</sub>H<sub>15</sub>ClF<sub>3</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 406.0929, found 406.0933.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2-Chloro-3-(trifluoromethyl)pheny1)(1-(pyrazin-2-yl)-6,7-dihydro-l<i>H</i>-imidazo[ 4,5-c]pyridin-5(4<i>H</i>)-yl) methanone (<b>13</b>)</h4><div class="NLM_p last">(47%) <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.81â8.75 (m, 1H), 8.64â8.42 (m, 2H), 8.16â8.02 (m, 1H), 7.83â7.71 (td, <i>J</i> = 7.5, 1.9 Hz, 1H), 7.60â7.40 (m, 2H), 5.08â4.80 (m, 1H), 4.50â4.23 (m, 2H), 4.10â3.94 (ddd, <i>J</i> = 13.0, 6.6, 5.6 Hz, 1H), 3.67â3.46 (m, 1H), 3.21â2.91 (m, 2H), 2.11â1.76 (m, 2H). HRMS calc. for C<sub>18</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 408.0833, found 408.0819.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-6,7-dihydro-l<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>14</b>)</h4><div class="NLM_p last">(45%) <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.59â8.51 (m, 1H), 8.28â8.17 (m, 1H), 8.04â7.92 (m, 2H), 7.84â7.63 (m, 3H), 4.91â4.54 (dd, <i>J</i> = 92.1, 16.0 Hz, 2H), 4.23â4.14 (d, <i>J</i> = 3.0 Hz, 1H), 3.51â3.36 (q, <i>J</i> = 5.9, 5.4 Hz, 2H), 3.08â2.79 (m, 2H). [M + H]<sup>+</sup>. HRMS calc. for C<sub>19</sub>H <sub>13</sub>CIF<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 425.0787, found 425.0781.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1-(5-Fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)(2-methyl-3-(trifluoromethyl)phenyl)methanone (<b>15</b>)</h4><div class="NLM_p last">(51%) <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.59â8.50 (m, 1H), 8.28â8.16 (m, 1H), 8.06â7.94 (m, 1H), 7.85â7.74 (dt, <i>J</i> = 9.1, 4.7 Hz, 2H), 7.63â7.46 (m, 2H), 4.95â4.48 (m, 1H), 4.22â4.06 (m, 1H), 3.49â3.37 (q, <i>J</i> = 4.8, 4.3 Hz, 2H), 2.43â2.20 (m, 3H). HRMS calc. for C<sub>20</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 405.1333, found 405.1332.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2,4-Dichlorophenyl)(1-(5-fluoropyridin-2-yl)-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>16</b>)</h4><div class="NLM_p last">(74%) <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.59â8.49 (m, 1H), 8.29â8.14 (m, 1H), 8.05â7.95 (ddd, <i>J</i> = 6.8, 3.9, 2.2 Hz, 1H), 7.81â7.73 (m, 2H), 7.59â7.40 (m, 2H), 4.85â4.51 (d, <i>J</i> = 16.0 Hz, 1H), 4.37â4.08 (m, 1H), 4.08â3.87 (m, 1H), 3.60â3.41 (m, 1H), 3.07â2.83 (m, 2H). HRMS calc. for C<sub>18</sub>H<sub>13</sub>Cl<sub>2</sub>FN<sub>4</sub>O [M + H]<sup>+</sup> 391.0523, found 391.0533.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2-Fluoro-3-(trifluoromethy l)pheny1)(1-(5-fluoropyri din-2-yl)-6,7-dihydro-l<i>H</i>-imidazo[ 4,5-c]pyridin-5 (4<i>H</i>)-yl)methanone (<b>17</b>)</h4><div class="NLM_p">(96%) <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.62â8.51 (m, 1H), 8.29â8.16 (m, 1H), 8.05â7.72 (m, 4H), 7.62â7.48 (m, 1H), 4.78â4.60 (s, 1H), 4.36â4.23 (s, 1H), 4.06â3.97 (t, <i>J</i> = 5.7 Hz, 1H), 3.61â3.48 (t, <i>J</i> = 5.6 Hz, 1H), 2.96 (m, 2H). HRMS calc. for C<sub>19</sub>H<sub>13</sub>F<sub>5</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 409.1082, found 409.1095.</div><div class="NLM_p">The following intermediates were prepared in a manner analogous to representative procedure B, step 3.</div><div id="sec4_2_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-phenyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(52%) MS (ESI): mass calculated for C<sub>21</sub>H<sub>15</sub>ClF<sub>3</sub>N<sub>3</sub>O, 417.09; <i>m</i>/<i>z</i> found 418.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(4-fluorophenyl)-4-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(49%) MS (ESI): mass calculated for C<sub>21</sub>H<sub>14</sub>ClF<sub>4</sub>N<sub>3</sub>O, 435.08; <i>m</i>/<i>z</i> found 436.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyrimidin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(35%) MS (ESI): mass calculated for C<sub>19</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>5</sub>O, 419.08; <i>m</i>/<i>z</i> found 420.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(37%) MS (ESI): mass calculated for C<sub>19</sub>H<sub>12</sub>ClF<sub>4</sub>N<sub>5</sub>O, 437.07; <i>m</i>/<i>z</i> found 438.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyrazin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(35%) MS (ESI): mass calculated for C<sub>19</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>5</sub>O, 419.08; <i>m</i>/<i>z</i> found 420.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyridin-2-yl)-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p last">(33%) MS (ESI): mass calculated for C<sub>20</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O, 418.08; <i>m</i>/<i>z</i> found 419.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(3-fluoropyridin-2-yl)-4-methyl-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone</h5><div class="NLM_p">(38%) MS (ESI): mass calculated for C<sub>20</sub>H<sub>13</sub>ClF<sub>4</sub>N<sub>4</sub>O, 436.07; <i>m</i>/<i>z</i> found 437.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The following compounds were prepared in a manner analogous to representative procedure B, step 3.</div></div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-phenyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>20</b>)</h4><div class="NLM_p last">(66%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.76 (dd, <i>J</i> = 5.1, 2.0 Hz, 1H), 7.65 (d, <i>J</i> = 15.1 Hz, 1H), 7.59â7.39 (m, 5H), 7.35â7.28 (m, 2H), 5.83 (dd, <i>J</i> = 13.5, 6.7 Hz, 1H), 5.07 (dd, <i>J</i> = 12.3, 10.6 Hz, 1H), 4.19â3.99 (m, 1H), 3.61â2.93 (m, 1H), 2.75â2.35 (m, 1H), 1.99â1.90 (m, 3H). HRMS calc. for C<sub>21</sub>H<sub>17</sub>ClF<sub>3</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 420.1085, found 420.1072.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(4-fluorophenyl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>21</b>)</h4><div class="NLM_p last">(40%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.79â7.73 (m, 1H), 7.62 (d, <i>J</i> = 1.3 Hz, 1H), 7.58â7.35 (m, 2H), 7.33â7.25 (m, 2H), 7.25â7.15 (m, 2H), 5.94â5.47 (m, 1H), 5.07â4.59 (m, 1H), 4.10â3.73 (m, 1H), 3.59â2.81 (m, 1H), 2.74â2.23 (m, 1H), 1.69â1.50 (m, 3H). HRMS calc. for C<sub>21</sub>H<sub>16</sub>ClF<sub>4</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 438.0991, found 438.0973.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyrimidin-2-yl)-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>22</b>)</h4><div class="NLM_p last">(58%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.75â8.49 (m, 3H), 7.76 (dt, <i>J</i> = 9.6, 4.8 Hz, 1H), 7.59â7.42 (m, 2H), 7.21 (ddd, <i>J</i> = 17.7, 8.0, 4.8 Hz, 1H), 5.91â5.67 (m, 1H), 5.16â4.55 (m, 1H), 3.60â2.87 (m, 4H), 1.72â1.56 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>15</sub>ClF<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 422.0990, found 422.0976.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>23</b>)</h4><div class="NLM_p last">(52%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.61â8.38 (m, 3H), 7.82â7.70 (m, 1H), 7.58â7.32 (m, 2H), 5.90â5.60 (m, 1H), 5.19â4.54 (m, 1H), 3.66â2.82 (m, 3H), 1.81â1.29 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>14</sub>ClF<sub>4</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 440.0896, found 440.0886.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-phenyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>24</b>)</h4><div class="NLM_p last">(44%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.65â8.45 (m, 3H), 7.80â7.70 (m, 1H), 7.58â7.42 (m, 2H), 7.24â7.18 (m, 1H), 5.91â5.71 (m, 1H), 5.10â4.70 (m, 1H), 3.60â2.88 (m, 4H), 1.70â1.57 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>15</sub>ClF<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 422.0990, found 422.0992.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyridin-2-yl)-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>25</b>)</h4><div class="NLM_p last">(40%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.58â8.44 (m, 1H), 7.99 (dt, <i>J</i> = 10.8, 8.7 Hz, 1H), 7.93â7.80 (m, 1H), 7.80â7.72 (m, 1H), 7.59â7.43 (m, 2H), 7.41â7.24 (m, 2H), 5.91â5.72 (m, 1H), 5.20â4.58 (m, 1H), 3.63â3.29 (m, 1H), 3.29â2.76 (m, 2H), 1.74â1.60 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 421.1037, found 421.1039.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(3-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>26</b>)</h4><div class="NLM_p last">(20%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.43â8.28 (m, 1H), 7.94 (dd, <i>J</i> = 23.2, 20.8 Hz, 1H), 7.81â7.61 (m, 2H), 7.59â7.29 (m, 3H), 5.82 (dt, <i>J</i> = 12.9, 6.5 Hz, 1H), 5.06 (dd, <i>J</i> = 13.5, 6.7 Hz, 1H), 4.76â4.37 (m, 1H), 3.63â2.62 (m, 2H), 1.86â1.55 (m, 3H). HRMS calc. for C<sub>20</sub>H<sub>14</sub>ClF<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 439.0943, found 439.0940.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>27</b>)</h4><div class="NLM_p">(62%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.61â8.38 (m, 3H), 7.82â7.70 (m, 1H), 7.58â7.32 (m, 2H), 5.90â5.60 (m, 1H), 5.19â4.54 (m, 1H), 3.66â2.82 (m, 3H), 1.81â1.29 (m, 3H). HRMS calc. for C<sub>20</sub>H<sub>14</sub>ClF<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 439.0943, found 439.0940.</div><div class="NLM_p last">The following compounds were prepared in a manner analogous to representative procedure B, step 4.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(4-fluorophenyl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>28</b>)</h4><div class="NLM_p last">(40%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.76 (dd, <i>J</i> = 5.1, 3.2 Hz, 1H), 7.62 (s, 1H), 7.58â7.36 (m, 2H), 7.33â7.24 (m, 2H), 7.24â7.14 (m, 2H), 5.89â5.78 (m, 1H), 5.07 (dt, <i>J</i> = 12.3, 6.0 Hz, 1H), 4.77â4.39 (m, 1H), 3.62â2.86 (m, 1H), 2.77â2.28 (m, 1H), 1.80â1.10 (m, 3H). HRMS calc. for C<sub>21</sub>H<sub>16</sub>ClF<sub>4</sub>N<sub>3</sub>O [M + H]<sup>+</sup> 438.0991, found 438.0988.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(4-methyl-1-(pyridin-2-yl)-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>29</b>)</h4><div class="NLM_p last">(44%) <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 8.59â8.45 (m, 1H), 8.01 (dd, <i>J</i> = 20.6, 15.5 Hz, 1H), 7.86 (tdd, <i>J</i> = 8.1, 5.7, 3.8 Hz, 1H), 7.76 (dd, <i>J</i> = 6.3, 4.7 Hz, 1H), 7.58â7.28 (m, 4H), 5.82 (dd, <i>J</i> = 14.3, 7.4 Hz, 1H), 4.58 (d, <i>J</i> = 6.5 Hz, 1H), 4.03 (dt, <i>J</i> = 12.2, 6.1 Hz, 1H), 3.34â2.80 (m, 2H), 1.69â1.44 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 421.1037, found 421.1039.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>R</i>)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-6,7-dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)methanone (<b>30</b>)</h4><div class="NLM_p last">(42%) <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.61â8.38 (m, 3H), 7.82â7.70 (m, 1H), 7.58â7.32 (m, 2H), 5.90â5.60 (m, 1H), 5.19â4.54 (m, 1H), 3.66â2.82 (m, 3H), 1.81â1.29 (m, 3H). HRMS calc. for C<sub>19</sub>H<sub>14</sub>ClF<sub>4</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 440.0896, found 440.0901.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> P2X7 Antagonism in Human Peripheral Blood Mononuclear Cells (PBMCs) and Mouse Human Whole Blood</h3><div class="NLM_p last">Human blood was collected using a blood donor program. PBMCs were isolated from blood using a Ficoll density gradient technique. Briefly, blood was laid on Ficoll solution and centrifuged at RT for 20 min at 2000 rpm. The buffy layer (between red blood cells and plasma) was carefully collected by aspiration, washed with PBS, and centrifuged again at 1500 rpm for 15 min. The resulting cell pellet was washed and plated on 96 well-plates for experiments. For the mouse human whole blood experiments, 150 Î¼L of either mouse or human blood was plated on 96 well plates. Lipopolysaccharide (LPS) (30 ng/mL) was added to each well and incubated for 1 h. Test compounds were then added and incubated for 30 min. The P2X7 agonist, 2â²(3â²)-0-(4-benzoylbenzoyl) adenosine 5â² triphosphate (Bz-ATP) was then added at a final concentration of 0.5 mM (PBMC) or 1 mM (blood). Cells were incubated for an additional 1.5 h. At that point, the supernatant was collected and stored for the IL-1Î² assay using the manufacturerâs protocol for the enzyme linked immunosorbent assay (ELISA). Data are expressed as the percent control, where the control is defined as the difference in IL-1Î² release in LPS+Bz-ATP samples and LPS only samples. Data were plotted as response (% control) versus concentration to generate IC<sub>50</sub> values.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> P2X7 Antagonism in Recombinant hP2X7 Cells: Ca<sup>2+</sup>Flux</h3><div class="NLM_p last">1321Nl cells expressing the recombinant human, rat, or mouse P2X7 channel was cultured in HyQ DME/(HyClone/Dulbeccoâs modified Eagleâs medium) high glucose supplemented with 10% fetal bovine serum (FBS) and the appropriate selection marker. Cells were seeded at a density of 25000 cells/well (96-well clear bottomed black walled plates) in 100 Î¼L volume/well. On the day of the experiment, cell plates were washed with assay buffer, containing (in mM): 130 NaCl, 2 KCl, 1 CaCl<sub>2</sub>, 1 MgCl 2, 10 HEPES, and 5 glucose; pH 7.40 and 300 mOs. After the wash, cells were loaded with the calcium-4 dye (Molecular Device) and incubated in the dark for 60 min. Test compounds were prepared at 250Ã the test concentration in neat DMSO. Intermediate 96-well compound plates were prepared by transferring 1.2 Î¼L of the compound into 300 Î¼L of assay buffer. A further 3Ã dilution occurred when transferring 50 Î¼L/well of the compound plate to 100 Î¼L/well in the cell plate. Cells were incubated with test compounds and dye for 30 min. Calcium dye fluorescence was monitored in FLIPR as the cells were challenged by adding 50 Î¼L/well of BzATP (final concentration is 250 Î¼M BzATP (human and rat) or 600 Î¼M (mouse)). The fluorescence change was measured 180 s after adding the agonist. Peak fluorescence was plotted as a function of test concentration to generate an IC<sub>50</sub> value.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> P2X7 Antagonism in Recombinant hP2X7 Cells: Radioligand Binding</h3><div class="NLM_p last">Human or rat P2X7 1321Nl cells were collected and frozen at â80 Â°C. On the day of the experiment, cell membrane preparations were made according to standard published methods. The total assay volume was 100 Î¼L: 10 Î¼L compound (l0x)+(b) 40 Î¼L tracer (2.5x)+50 Î¼L membrane (2Ã). The tracer used for the assay was tritiated A-804598. The compound can be prepared as described in the literature (Donnelly-Roberts, D. Neuropharmacology 2008, 56 (1), 223â229). Compounds, tracer, and membranes were incubated for 1 h at 4 Â°C. The assay was terminated by filtration (GFB filters presoaked with 0.3% PEI) and washed with washing buffer (Tris-HCl 50 mM). The IC<sub>50</sub> generated in the binding assay was corrected for tracer concentration and affinity of the tracer to derive the affinity (<i>K</i>) of the test compounds.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Caco-2 Permeability</h3><div class="NLM_p last">Caco-2 bidirectional permeability assays were conducted at CEREP according to the companyâs protocol. In brief, Caco-2 cells were seeded onto a 96-well Multiscreen plate (Millipore) at a cell density of 1 Ã 10<sup>5</sup> cells/cm<sup>2</sup> and cultured for at least 21 days before permeability studies were conducted. Test compounds were dissolved in DMSO and added to HBSS-HEPES, pH 7.4, culture media at a final concentration of 10 Î¼M (1% DMSO v/v). The working solution was applied to cells on the donor side and incubated at 37 Â°C with gentle agitation for 60 and 40 min to determine the A â B and B â A permeability, respectively. Samples were extracted from the donor side at time zero and the end-point and from the receiver side at the end-point time only. Samples were then processed for LC/MS/MS analyses to determine the apparent permeability coefficient (<i>P</i><sub>app</sub>) of the test compound in the Aâ B and B â A direction as well as the percent recovery.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Plasma Protein Binding</h3><div class="NLM_p last">Plasma protein binding was determined by equilibrium dialysis using the RED device (Thermo Scientific, Rockford, IL) consisting of a Teflon base block and RED device inserts comprising two (sample and buffer) side-by-side chambers separated by a dialysis membrane. Compounds were prepared as 100 Î¼M DMSO stocks and spiked into 1 mL of mouse, rat, and human plasma (Bioreclamations) to make a final concentration of 1 Î¼M. Plasma (300 Î¼L) was dispensed into wells separated by an 8 kDa-permeable cellulose membrane from wells containing 100 mM potassium phosphate, pH 7.4 (500 Î¼L). Each compound was tested in triplicate. The RED devise was sealed, and equilibrium was permitted for 6 h in a 37 Â°C incubator with gentle agitation at 100 rpm. After incubation, plasma samples were prepared by transferring 10 Î¼L from plasma wells to 90 Î¼L of fresh 100 mM potassium phosphate, pH 7.4, and buffer samples were prepared by transferring 90 Î¼L from buffer wells to 10 Î¼L of naÃ¯ve plasma. In addition, a reference sample without equilibration was prepared in triplicate by mixing 10 Î¼L of plasma containing 1 Î¼M compound with 90 Î¼L of buffer in order to determine compound recovery from the assay. Two-volumes of 1:1 acetonitrile/methanol spiked with the internal standard phenytoin (0.2 Î¼g/mL) were added to the reference and samples. Precipitation of plasma protein binding was allowed for 15 min before the reference and samples were centrifuged and clarified. The supernatant (10 Î¼L) was used for LC/MS/MS analyses.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Brain Tissue Binding</h3><div class="NLM_p">Brain tissue binding was assessed by equilibrium dialysis using the RED device similar to the procedure described for plasma protein binding. Rat brain tissue homogenate, prepared in PBS buffer, pH 7.4 (1:10, w/v), was spiked with compound DMSO stock solution to yield a final concentration of 5 Î¼M. The dialysis was carried out in a shaking incubator at 37 Â°C for 5 h in triplicate. After incubation, 25 Î¼L of homogenate or 50 Î¼L of buffer was extracted with 50 Î¼L of DMSO and 300 Î¼L of acetonitrile and analyzed by LC/MS/MS using the calibration curves across an appropriate concentration range and quality control samples. The apparent unbound fraction (<i>f</i><sub><i>u,app</i></sub>) was derived from the formula:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/jm-2016-00989h_m001.gif" alt="" /></img></span></div><div class="NLM_p">where [A]<sub><i>homogenate</i></sub> and [A]<sub><i>buffer</i></sub> are the concentrations measured in the homogenate and buffer, respectively. The unbound fraction in undiluted brain (<i>f</i><sub><i>u,Â brain</i></sub>) was calculated from the formula<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/jm-2016-00989h_m002.gif" alt="" /></img></span></div><div class="NLM_p last">where <i>D</i> is the dilution factor of 10. Subsequently, the percentage compound bound to brain tissue (% BTB) was calculated from the formula<span class="NLM_disp-formula" id="ueq3"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/jm-2016-00989h_m003.gif" alt="" /></img></span></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Liver Microsomal Stability</h3><div class="NLM_p last">Microsomal stability studies were conducted on a Biomek FX Robotic Liquid Handling Workstation (Beckman Coulter, Brea, CA), which consists of a 96-channel pipet head, a 12-postion workstation deck, and a plate incubator. Test compounds (1 Î¼M) were spiked in a reaction mix consisting of 100 mM potassium phosphate buffer (pH 7.4), 3 mM MgCl<sub>2</sub>, and 0.5 mg/mL liver microsomes from mice, rats, dogs, monkeys, and humans (BD Gentest). The reaction was brought to 37 Â°C and initiated by adding NADPH to a final concentration of 1 mM. After mixing on the plate-deck, 50 Î¼L aliquots were excised from the reaction plate at 0, 5, 10, 20, 40, and 60 min and quenched with four volumes of acetonitrile spiked with 500 Î¼g/nL of the internal standard phenytoin. Quenched plates were centrifuged at 5700 rpm for 10 min at 4 Â°C, and the supernatant was diluted 1:3 in water before LC/MS/MS analysis. The compound half-lives were derived from plots of the ln of percent remaining compound over time to determine the intrinsic clearance. The predicted hepatic clearance was derived from the intrinsic clearance value using equations from the well-stirred model where protein binding in plasma and microsomal proteins is assumed to be similar, and the blood to plasma concentration ratio is assumed to be one.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The hepatic extraction ratio (ER) was calculated by dividing the predicted hepatic clearance by species blood flow (<i>Q</i>), where <i>Q</i> is 90, 55, 31, 44, and 21.7 mL/min/kg for mice, rats, dogs, monkeys, and humans, respectively.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Solubility in Aqueous Systems</h3><div class="NLM_p last">Solubility in 30 mM phosphate buffers (pH 2 and pH 7), simulated gastric (SGF, 0.2% NaCl in 0.1 N HCl, pH 1.2), and intestinal fluids (FasSIF, 0.029 M phosphate buffer, 5 mM sodium taurocholate, and 1.5 mM lecithin, pH 6.8) was investigated. The compound was dissolved in DMSO solutions at a concentration of 10 mM and was used for the solubility experiment. DMSO solutions (20 Î¼L) are dispensed in 96-well plates, and the solvent is removed by evaporation using a Caliper TurboVap 96 set at 30 Â°C and a flow rate of 40 Fh. Buffers (400 Î¼L) of interest are added to the residual solids, and the resulting mixtures are stirred at room temperature for 3 days using magnetic stir bars. The samples are then filtered using an AcroPrep 1 mL 96 filter plate, and the supernatant is analyzed for compound concentration, against external standards.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Cocktail CYP Inhibition Assay</h3><div class="NLM_p last">DMSO stocks were prepared for test compounds (10 mM) and for the assay positive controls: furafylline (CYP1A2, 8 mM), quercetin (CYP2C8, 12 mM), sulfaphenazole (CYP2C9, 2 mM), <i>N</i>-3-benzyl-phenobarbital (CYP2C19, 1.2 mM), quinidine (CYP2D6, 0.16 mM), and ketoconazole (CYP3A, 0.16 mM). In a solution of 1:1 acetonitrile/water, stocks were diluted 10-fold and serial diluted in 2-fold increments. For test compounds, the final incubation concentrations were 10, 5, 2.5, 1.25, 0.63, and 0.3 Î¼M. To simultaneously measure the activity of multiple CYPs in the same incubation, a cocktail probe solution was prepared that contained six substrates at the following final concentrations: phenacetin (CYP1A2, 50 Î¼M), paclitaxel (CYP2C8, 10 Î¼M), diclofenac (CYP2C9, 4 Î¼M), <i>S</i>-mephenytoin (CYP2C19, 30 Î¼M), dextromethorphan (CYP2D6, 3 Î¼M), and midazolam (CYP3A, 2 Î¼M). Human liver microsomes (BD Gentest) from a mixed donor pool were prepared in 0.1 mM potassium phosphate buffer (pH 7.4) supplemented with 3 mM MgCl<sub>2</sub> and preincubated for 5 min at 37 Â°C. Human liver microsomes (0.1 mg of protein/mL) were then mixed with the cocktail probe solution, test compounds, or assay positive controls, and the reaction was initiated by the addition of NADPH (1 mM final concentration). The catalysis of probe substrates was permitted for 15 min at 37 Â°C and quenched in one volume of 1:1 acetonitrile/methanol mixture containing the internal standard phenytoin (0.2 Î¼g/mL). Samples were vortexed for 2 min and centrifuged for 10 min. Supernatant (300 Î¼L) was diluted in water (125 Î¼L), mixed, and used for LCMS/MS analysis. A 20-Î¼L aliquot was analyzed for probe metabolite formation using a Shimadzu LC-20A HPLC system and a Sciex API 5000 (Applied Biosystems, Foster City, CA) mass spectrometer in the multiple reaction monitoring (MRM) scan mode with electrospray ionization (ESI). The mobile phase consisted of water (A) and acetonitrile (B) both containing 0.1% formic acid. The chromatography was performed on Phenomenex Kinetex XB-C18 (2.0 Ã 50 mm, 5.0 Î¼M) column using a gradient elution method (2% B from 0.0 to 0.3 min, followed by a linear increase to 50% B over 2.7 min and subsequently 95% B for 0.1 min, and held at 95% B for an additional 0.0.9 min before returning back to 2% B) at a flow rate of 0.6 mL/min. The following transitions were monitored: <i>m</i>/<i>z</i> 152.1 â 110.0 (acetaminophen â CYP1A2), <i>m</i>/<i>z</i> 870.3 â 105.1 (6Î±-hydroxy-taxol â CYP2C8), <i>m</i>/<i>z</i> 312.1 â 230.0 (4-hydroxy-diclofenac â CYP2C9), <i>m</i>/<i>z</i> 235.3 â 150.2 (4-hydroxy-<i>S</i>-mephenytoin â CYP2C19), <i>m</i>/<i>z</i> 258.2 â 157.1 (dextrorphan â CYP2D6), <i>m</i>/<i>z</i> 342.2 â 297.1 (1-hydroxy-midazolam â CYP3A), and <i>m</i>/<i>z</i> 253.1 â 182.2 for phenytoin (internal standard). Data were processed using Analyst software with the probe metabolite to internal standard peak area ratios electronically exported into Excel 2000 (Microsoft Corp., Seattle, WA) format.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Definitive CYP Inhibition Assay</h3><div class="NLM_p last">Studies were conducted in human liver microsomes where each reaction consisted of a single probe coincubated with JNJ-54166060 at test concentrations ranging from 90â0.09 Î¼M. The following probes were incubated at approximately their <i>K</i><sub>M</sub> concentrations: phenacetin (CYP1A2, 80 Î¼M), coumarin (CYP2A6, 2 Î¼M), bupropion (CYP2B6, 20 Î¼M), amodiaquine (CYP2C8, 2 Î¼M), tolbutamide (CYP2C9, 100 Î¼M), diclofenac (CYP2C9, 5 Î¼M), <i>S</i>-mephenytoin (CYP2C19, 30 Î¼M), dextromethorphan (CYP2D6, 3 Î¼M), chlorzoxazone (CYP2E1, 45 Î¼M), testosterone (CYP3A, 25 Î¼M), midazolam (CYP3A, 2 Î¼M), and nifedipine (CYP3A, 10 Î¼M). Incubation conditions and LC/MS/MS methodology were optimized for the product formation and detection, respectively, of each probe metabolite, and IC<sub>50</sub> values were determined relative to activity observed in vehicle treated incubations.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> CYP3A Time Dependent Inhibition (TDI)</h3><div class="NLM_p last">DMSO stocks were prepared for test compounds (10 mM), the assay positive control troleandomycin (5 mM), and the assay negative control ketoconazole (0.3 mM) and diluted 25-fold in a mixture of acetonitrile/water (30/70, v/v). Human liver microsomes at 0.3 mg/mL in 100 mM potassium phosphate buffer (pH 7.4) supplemented with 3 mM MgCl<sub>2</sub> and 1 mM NADPH in a total volume of 0.1 mL were preincubated for 30 min at 37 Â°C in the absence or presence of various concentrations of test compounds and positive or negative control. Following a 30 min preincubation, blank liver microsomes were also spiked with test compounds and positive or negative controls. All samples were then mixed with 0.1 mL of 100 mM potassium phosphate buffer (pH 7.4) containing 3 mM MgCl<sub>2</sub>, 1 mM NADPH, and 50 Î¼M testosterone, and the secondary incubations were carried out for 10 min at 37 Â°C. The final inhibitor concentrations in secondary incubations were as follows: 0.04, 0.12, 0.37, 1.1, 3.3, and 10 Î¼M for test compounds; 0.02, 0.06, 0.19, 0.6, 1.7, and 5 Î¼M for troleandomycin; and 0.0012, 0.0037, 0.01, 0.03, 0.1, and 0.3 Î¼M for ketoconazole. The reaction was terminated by the addition of 0.2 mL of acetonitrile containing the internal standard (0.1 Î¼g/mL phenytoin). The samples were vortexed and centrifuged at 3,200 rpm for 10 min. The supernatant (0.2 mL) was removed and mixed with 0.1 mL of water in a fresh 96-well plate. A 20-Î¼L aliquot was analyzed for probe metabolite formation using Shimadzu SCL-10A HPLC and a Sciex API 4000 Q-Trap (Applied Biosystems, Foster City, CA) mass spectrometer in the MRM scan mode with ESI. The mobile phase consisted of water (A) and acetonitrile (B) both containing 0.1% formic acid. The chromatography was performed on an Agilent Zorbax SB-phenyl (2.1 Ã 50 mm, 5 Î¼m) column using a gradient elution method (10% B from 0.1 to 0.3 min, then to 95% B over 1.4 min, and held at 95% B for an additional 1.0 min before returning back to 10% B) at a flow rate of 0.8 mL/min. The transitions monitored were <i>m</i>/<i>z</i> 305 â 269 for 6Î²-hydroxy-testosterone and <i>m</i>/<i>z</i> 253.1 â 182.2 for phenytoin (internal standard). Data were processed using Analyst software and included 6Î²-hydroxy-testosterone to internal standard peak area ratios electronically exported into Excel 2000 (Microsoft Corp., Seattle, WA) format. The concentration required for 50% inhibition of CYP3A4 activity (IC<sub>50</sub>) was calculated using Janssen proprietary software from the percent CYP3A4 activity remaining after compound incubation at various concentrations relative to the vehicle, based on the 6Î²-hydroxy-testosterone to the internal standard peak ratio. The fold shift in the IC<sub>50</sub> was calculated as a ratio of the IC<sub>50</sub> values without and with preincubation. A greater than 2-fold shift in the IC<sub>50</sub> value as a result of preincubation was considered a threshold for time-dependent inhibition.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Metabolite Identification in Liver Microsomes</h3><div class="NLM_p last">From a 10 mM DMSO stock solution, the test compound (10 Î¼M) was incubated in liver microsomes (1 mg/mL protein concentration) from rats and humans in 100 mM potassium phosphate buffer (pH 7.4) fortified with 25 Î¼g/mL alamethicin, 3 mM MgCl<sub>2</sub>, 1 mM NADPH, 5 mM GSH, and 3 mM UDPGA. The reaction was allowed to take place for 60 min at 37 Â°C before being terminated with the addition of 1.5 volumes of ice-cold acetonitrile/methanol mixture (3:1, v/v). The samples were centrifuged for 10 min at 2880<i>g</i> to precipitate proteins prior to injecting a 100 Î¼L aliquot onto the LC/MS system. The LC/MS/MS analysis was conducted using a Surveyor HPLC system interfaced to a UV detector (214, 254, and 280 nm) and a LTQ-Orbitrap XL high resolution mass spectrometer (Thermo-Finnigan, San Jose, CA). The Fourier transform mass spectrometer (FTMS) of the LTQ-Orbitrap XL was operated in the positive mode set for four scan events. The first scan event, a full scan from 200â1000 <i>m</i>/<i>z</i> acquired at a resolution of 15,000 was followed by three data dependent MS2 scan events acquired at a resolution of 7,5000 to aid in the structural identification of JNJ-54175446 metabolites. Chromatographic separation was achieved on a Zorbax SB-C18 column (4.6 Ã 150 mm, 3.5 Î¼m particle size) using a gradient elution method (0â5 min, 5% B; 5â47 min, 80% B; 47â50 min, 80% B; 50â51 min, 80â98% B; 51â55 min, 98% B; 55.0â55.1 min, 98â5% B; and 55.1â60 min, 5% B) at a flow rate of 0.3 mL/min. The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The HPLC-MS/MS data were analyzed using Xcalibur MS software (Thermo-Finnigan, San Jose, CA) and Janssen Research & Development internal MS fragmentation prediction software PrISE 2.1.1, developed by Dotmatics Limited.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The assignment and localization of metabolites were determined from the observed molecular weights from full scan mass spectra and through the interpretation of fragment ions produced for metabolites relative to the unchanged drug from MS/MS spectra.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Single Crystal Growth Experiments</h3><div class="NLM_p last">A solubility assessment was carried out on <b>1</b> and <b>31</b> using 20 three solvents. <b>1</b> and <b>31</b> were treated with 20 Î¼L of each solvent at RT or 100 Î¼L of solvent at 50 Â°C in order to obtain clear solutions. Suspensions were matured between RT and 50 Â°C (4 h at each temperature â8 h cycle) for 3 weeks. Solutions were cooled to 5 Â°C and kept at this temperature for 48 h. If no solids were obtained, the solutions were then further cooled to â20 Â°C and kept at this temperature for 24 h. Any solutions or slurries obtained at 5 or â20 Â°C were then left to evaporate slowly at RT. All experiments were checked regularly for single crystals. Single crystals were obtained from slow evaporation from toluene and DMSO for compound <b>1</b> and from acetone and DMSO for compound <b>31</b>.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Single Crystal X-ray Diffraction</h3><div class="NLM_p last">Data were collected on a Rigaku Oxford Diffraction Supernova Dual Source, Cu at Zero, Atlas CCD diffractometer equipped with an Oxford Cryosystems Cobra cooling device. Data were collected using CuKÎ± radiation. Structures were typically solved using either the SHELXS programs and refined with the SHELXL program as part of the Bruker AXS SHELXTL suite (V6.10). Unless otherwise stated, hydrogen atoms attached to carbon were placed geometrically and allowed to refine with a riding isotropic displacement parameter. Hydrogen atoms attached to a heteroatom were located in a difference Fourier synthesis and were allowed to refine freely with an isotropic displacement parameter.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Pharmacokinetic Studies</h3><div class="NLM_p last">Single dose pharmacokinetic studies in preclinical species (male Balb/c mice, SpragueâDawley rats, beagle dogs, or cynomolgus monkeys) were conducted following iv (1 mg/kg) and po (5 mg/kg) administration as a solution in 20% hydroxypropyl-Î²- cyclodextrin (HP-Î²-CD). Blood was sampled at predose and at 0.033 (iv), 0.083 (iv), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h postdose. In dogs, instead of the 6 and 8 h time points blood was drawn at 7 h. Plasma concentrations were quantitated by LCMS/MS. Pharmacokinetic parameters were derived from noncompartmental analysis of the plasma concentration vs time data using WinNonlin software (Pharsight, Palo Alto, CA).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 1- and 4-Day Repeat Dose Oral Toxicology Studies</h3><div class="NLM_p last">For the single dose study, toxicology group animals were administered <b>1</b> at oral doses of 125, 250, 500, and 1000 mg/kg/day with necropsy performed on day 2. For the repeat dose toxicology group, animals were administered <b>1</b> at oral doses of 62.5, 125, or 250 mg/kg/day for 4 days, with necropsy performed on day five. The tissues from control and treated groups were embedded in paraffin, processed into slides by sectioning at 4 Î¼m, stained with hematoxylin and eosin, and examined microscopically.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00989">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00989" class="ext-link">10.1021/acs.jmedchem.6b00989</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Metabolite identification results and crystallography reports (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_001.csv">jm6b00989_si_001.csv (1.51 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_002.pdf">jm6b00989_si_002.pdf (2.41 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00989" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Devin M. Swanson</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ed899e9a8c839e82dcad84999ec3878387c38e8280"><span class="__cf_email__" data-cfemail="167265617778657927567f6265387c787c3875797b">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brad M. Savall</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin J. Coe</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Freddy Schoetens</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana Koudriakova</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judith Skaptason</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Wall</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Rech</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiahou Deng</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meri De Angelis</span> - <span class="hlFld-Affiliation affiliation">Janssen
Research & Development, Discovery Sciences, A Division of Janssen-Cilag, Jarama 75, 45007 Toledo, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anita Everson</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Lord</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Wang</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Ao</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Scott</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kia Sepassi</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy W. Lovenberg</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas I. Carruthers</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anindya Bhattacharya</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Letavic</span> - <span class="hlFld-Affiliation affiliation">Janssen
Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San
Diego, California 92121 United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d80e4046-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Heather Mcallister, Khoa Tran, Sandrine Jolly, and Laurence Queguiner for analytical support and Michael Ameriks for input and suggestions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> Abbreviations Used</h2><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">RO</td><td class="NLM_def"><p class="first last">receptor occupancy</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism and excretion</p></td></tr><tr><td class="NLM_term">BnBr</td><td class="NLM_def"><p class="first last">benzyl bromide</p></td></tr><tr><td class="NLM_term">NaBH<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium borohydride</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human Ether-Ã -go-go-Related Gene</p></td></tr><tr><td class="NLM_term">MET ID</td><td class="NLM_def"><p class="first last">metabolism identification</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">quaque die (once a day)</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatographyâmass spectrometry</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biber, K.</span><span> </span><span class="NLM_article-title">The microglial ATP-gated ion channel P2X7 as a CNS drug target</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">â</span> <span class="NLM_lpage">1787</span><span class="refDoi">Â DOI: 10.1002/glia.23001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Fglia.23001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=27219534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisleltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1772-1787&author=A.+Bhattacharyaauthor=K.+Biber&title=The+microglial+ATP-gated+ion+channel+P2X7+as+a+CNS+drug+target&doi=10.1002%2Fglia.23001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The microglial ATP-gated ion channel P2X7 as a CNS drug target</span></div><div class="casAuthors">Bhattacharya Anindya; Biber Knut; Biber Knut</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1772-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Based on promising preclinical evidence, microglial P2X7 has increasingly being recognized as a target for therapeutic intervention in neurological and psychiatric diseases.  However, despite this knowledge no P2X7-related drug has yet entered clinical trials with respect to CNS diseases.  We here discuss the current literature on P2X7 being a drug target and identify unsolved issues and still open questions that have hampered the development of P2X7 dependent therapeutic approaches for CNS diseases.  It is concluded here that the lack of brain penetrating P2X7 antagonists is a major obstacle in the field and that central P2X7 is a yet untested clinical drug target.  In the CNS, microglial P2X7 activation causes neuroinflammation, which in turn plays a role in various CNS disorders.  This has resulted in a surge of brain penetrant P2X7 antagonists.  P2X7 is a viable, clinically untested CNS drug target.  GLIA 2016;64:1772-1787.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4RW-TLVUR2UwlCcfExbvbfW6udTcc2ebbjUnOxUgurLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisleltA%253D%253D&md5=4ae4f32797df2460485f42185e3d7fd9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fglia.23001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.23001%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DBiber%26aufirst%3DK.%26atitle%3DThe%2520microglial%2520ATP-gated%2520ion%2520channel%2520P2X7%2520as%2520a%2520CNS%2520drug%2520target%26jtitle%3DGlia%26date%3D2016%26volume%3D64%26spage%3D1772%26epage%3D1787%26doi%3D10.1002%2Fglia.23001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Collo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosco-Vilbois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buell, G.</span><span> </span><span class="NLM_article-title">Tissue distribution of the P2X7 receptor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">â</span> <span class="NLM_lpage">1283</span><span class="refDoi">Â DOI: 10.1016/S0028-3908(97)00140-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2FS0028-3908%2897%2900140-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=1277-1283&author=G.+Colloauthor=S.+Neidhartauthor=E.+Kawashimaauthor=M.+Kosco-Vilboisauthor=R.+A.+Northauthor=G.+Buell&title=Tissue+distribution+of+the+P2X7+receptor&doi=10.1016%2FS0028-3908%2897%2900140-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900140-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900140-8%26sid%3Dliteratum%253Aachs%26aulast%3DCollo%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DS.%26aulast%3DKawashima%26aufirst%3DE.%26aulast%3DKosco-Vilbois%26aufirst%3DM.%26aulast%3DNorth%26aufirst%3DR.%2BA.%26aulast%3DBuell%26aufirst%3DG.%26atitle%3DTissue%2520distribution%2520of%2520the%2520P2X7%2520receptor%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D1277%26epage%3D1283%26doi%3D10.1016%2FS0028-3908%2897%2900140-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Solle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perregaux, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrushova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabel, C. A.</span><span> </span><span class="NLM_article-title">Altered cytokine production in mice lacking P2X(7) receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span><span class="refDoi">Â DOI: 10.1074/jbc.M006781200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1074%2Fjbc.M006781200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=125-132&author=M.+Solleauthor=J.+Labasiauthor=D.+G.+Perregauxauthor=E.+Stamauthor=N.+Petrushovaauthor=B.+H.+Kollerauthor=R.+J.+Griffithsauthor=C.+A.+Gabel&title=Altered+cytokine+production+in+mice+lacking+P2X%287%29+receptors&doi=10.1074%2Fjbc.M006781200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M006781200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M006781200%26sid%3Dliteratum%253Aachs%26aulast%3DSolle%26aufirst%3DM.%26aulast%3DLabasi%26aufirst%3DJ.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DStam%26aufirst%3DE.%26aulast%3DPetrushova%26aufirst%3DN.%26aulast%3DKoller%26aufirst%3DB.%2BH.%26aulast%3DGriffiths%26aufirst%3DR.%2BJ.%26aulast%3DGabel%26aufirst%3DC.%2BA.%26atitle%3DAltered%2520cytokine%2520production%2520in%2520mice%2520lacking%2520P2X%25287%2529%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D125%26epage%3D132%26doi%3D10.1074%2Fjbc.M006781200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Chataigneau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, T.</span><span> </span><span class="NLM_article-title">Exploring the ATP-binding site of P2X receptors</span> <span class="citation_source-journal">Front. Cell. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="refDoi">Â DOI: 10.3389/fncel.2013.00273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.3389%2Ffncel.2013.00273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=24415999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=273&author=T.+Chataigneauauthor=D.+Lemoineauthor=T.+Grutter&title=Exploring+the+ATP-binding+site+of+P2X+receptors&doi=10.3389%2Ffncel.2013.00273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the ATP-binding site of P2X receptors</span></div><div class="casAuthors">Chataigneau, Thierry; Lemoine, Damien; Grutter, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">273/1-273/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  P2X receptors are ATP-gated non-selective cation channels involved in many different physiol. processes, such as synaptic transmission, inflammation, and neuropathic pain.  They form homo-or hetero-trimeric complexes and contain three ATP-binding sites in their extracellular domain.  The recent detn. of X-ray structures of a P2X receptor solved in two states, a resting closed state and an ATP-bound, open-channel state, has provided unprecedented information not only regarding the three-dimensional shape of the receptor, but also on putative conformational changes that couple ATP binding to channel opening.  These data provide a structural template for interpreting the huge amt. of functional, mutagenesis, and biochem. data collected during more than fifteen years.  In particular, the interfacial location of the ATP binding site and ATP orientation have been successfully confirmed by these structural studies.  It appears that ATP binds to inter-subunit cavities shaped like open jaws, whose tightening induces the opening of the ion channel.  These structural data thus represent a firm basis for understanding the activation mechanism of P2X receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3sxk5d-OOLVg90H21EOLACvtfcHk0lj_WVDgPOC8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zP&md5=bcc5478f2078ddcd40676c74a0d5ef29</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2013.00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2013.00273%26sid%3Dliteratum%253Aachs%26aulast%3DChataigneau%26aufirst%3DT.%26aulast%3DLemoine%26aufirst%3DD.%26aulast%3DGrutter%26aufirst%3DT.%26atitle%3DExploring%2520the%2520ATP-binding%2520site%2520of%2520P2X%2520receptors%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D273%26doi%3D10.3389%2Ffncel.2013.00273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ando, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlagh, B.</span><span> </span><span class="NLM_article-title">The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain</span> <span class="citation_source-journal">Brain Res. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span><span class="refDoi">Â DOI: 10.1016/j.brainresbull.2012.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.brainresbull.2012.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=23047057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GktrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=80-85&author=R.+D.+Andoauthor=B.+Sperlagh&title=The+role+of+glutamate+release+mediated+by+extrasynaptic+P2X7+receptors+in+animal+models+of+neuropathic+pain&doi=10.1016%2Fj.brainresbull.2012.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain</span></div><div class="casAuthors">Ando, Romeo D.; Sperlagh, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purinergic signaling represents a major non-synaptic signaling mechanism in the normal and pathol. nervous system.  The expression of the purinergic ligand gated ion channel P2X7 receptor (P2rx7) has been described on nerve terminals as well as in non-neuronal cells, such as astrocytes and microglia.  The activation of P2rx7s results in Ca2+ influx and increased transmitter release in the brain.  P2rx7s previously suggested having a pivotal role in different pain modalities, including neuropathic pain.  Here we investigated whether the activation of P2rx7 leads to increased glutamate release from the spinal cord in an exptl. model of neuropathic pain (partial nerve ligation of the sciatic nerve, PNL).  One week after surgery, we studied the effects of PNL on tactile allodynia using aesthesiometry, in parallel with the in vitro release of [3H]glutamate from lumbar spinal cord slices.  The obsd. allodynia in wild-type (P2rx7+/+) mice one week after PNL surgery was lower that was obsd. in P2rx7 deficient (P2rx7-/-) animals.  Perfusion of spinal cord slices with ATP (10 mM) elicited [3H]glutamate release in both sham operated and neuropathic P2rx7+/+ animals.  The ATP-induced [3H]glutamate release was absent in P2rx7-/- mice.  Elec. evoked release of [3H]glutamate from spinal cord slices was not significantly altered in PNL animals and in P2rx7-/- mice.  The results suggest that activation of P2rx7 by ATP releases glutamate in the spinal cord, which might contribute to mech. allodynia following PNL.  On the other hand, this release does not contribute to glutamate efflux evoked by conventional neuronal activity, which is consistent with the idea that P2X7 receptors are either extrasynaptic or expressed on non-neuronal cells.This article is part of a Special Issue entitled 'Extrasynaptic ionotropic receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLu8btSdFCvLVg90H21EOLACvtfcHk0lj_WVDgPOC8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GktrzO&md5=7bb20defd142a00155509065ea667ec3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2012.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2012.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DR.%2BD.%26aulast%3DSperlagh%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520glutamate%2520release%2520mediated%2520by%2520extrasynaptic%2520P2X7%2520receptors%2520in%2520animal%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2013%26volume%3D93%26spage%3D80%26epage%3D85%26doi%3D10.1016%2Fj.brainresbull.2012.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Wang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. H.</span><span> </span><span class="NLM_article-title">Activation of P2X(7) receptors induced [(3)H]GABA release from the RBA-2 type-2 astrocyte cell line through a Cl(â)/HCO(3)(â)-dependent mechanism</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">â</span> <span class="NLM_lpage">18</span><span class="refDoi">Â DOI: 10.1002/glia.10004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Fglia.10004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=8-18&author=C.+M.+Wangauthor=Y.+Y.+Changauthor=J.+S.+Kuoauthor=S.+H.+Sun&title=Activation+of+P2X%287%29+receptors+induced+%5B%283%29H%5DGABA+release+from+the+RBA-2+type-2+astrocyte+cell+line+through+a+Cl%28%E2%88%92%29%2FHCO%283%29%28%E2%88%92%29-dependent+mechanism&doi=10.1002%2Fglia.10004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fglia.10004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DY.%2BY.%26aulast%3DKuo%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BH.%26atitle%3DActivation%2520of%2520P2X%25287%2529%2520receptors%2520induced%2520%255B%25283%2529H%255DGABA%2520release%2520from%2520the%2520RBA-2%2520type-2%2520astrocyte%2520cell%2520line%2520through%2520a%2520Cl%2528%25E2%2588%2592%2529%252FHCO%25283%2529%2528%25E2%2588%2592%2529-dependent%2520mechanism%26jtitle%3DGlia%26date%3D2002%26volume%3D37%26spage%3D8%26epage%3D18%26doi%3D10.1002%2Fglia.10004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Clark, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staniland, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaan, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcangio, M.</span><span> </span><span class="NLM_article-title">P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">â</span> <span class="NLM_lpage">582</span><span class="refDoi">Â DOI: 10.1523/JNEUROSCI.3295-09.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1523%2FJNEUROSCI.3295-09.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=20071520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=573-582&author=A.+K.+Clarkauthor=A.+A.+Stanilandauthor=F.+Marchandauthor=T.+K.+Kaanauthor=S.+B.+McMahonauthor=M.+Malcangio&title=P2X7-dependent+release+of+interleukin-1beta+and+nociception+in+the+spinal+cord+following+lipopolysaccharide&doi=10.1523%2FJNEUROSCI.3295-09.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7-dependent release of interleukin-1Î² and nociception in the spinal cord following lipopolysaccharide</span></div><div class="casAuthors">Clark, Anna K.; Staniland, Amelia A.; Marchand, Fabien; Kaan, Timothy K. Y.; McMahon, Stephen B.; Malcangio, Marzia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The cytokine interleukin-1Î² (IL-1Î²) released by spinal microglia in enhanced response states contributes significantly to neuronal mechanisms of chronic pain.  Here we examine the involvement of the purinergic P2X7 receptor in the release of IL-1Î² following activation of Toll-like receptor-4 (TLR4) in the dorsal horn, which is assocd. with nociceptive behavior and microglial activation.  We obsd. that lipopolysaccharide (LPS)-induced release of IL-1Î² was prevented by pharmacol. inhibition of the P2X7 receptor with A-438079, and was absent in spinal cord slices taken from P2X7 knock-out mice.  Application of ATP did not evoke release of IL-1Î² from the dorsal horn unless preceded by an LPS priming stimulus, and this release was dependent on P2X7 receptor activation.  Extensive phosphorylation of p38 MAPK in microglial cells in the dorsal horn was found to correlate with IL-1Î² secretion following both LPS and ATP.  In behavioral studies, intrathecal injection of LPS in the lumbar spinal cord produced mech. hyperalgesia in rat hindpaws, which was attenuated by concomitant injections of either a nonspecific (oxidized ATP) or a specific (A-438079) P2X7 antagonist.  In addn., LPS-induced hypersensitivity was obsd. in wild-type but not P2X7 knock-out mice.  These data suggest a crit. role for the P2X7 receptor in the enhanced nociceptive transmission assocd. with microglial activation and secretion of IL-1Î² in the dorsal horn.  We suggest that CNS-penetrant P2X7 receptor antagonists, by targeting microglia in pain-enhanced response states, may be beneficial for the treatment of persistent pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwimWWU-G4jbVg90H21EOLACvtfcHk0lj_WVDgPOC8vQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaht70%253D&md5=4d2c7edf6dc9f1c679375514c4b19cca</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3295-09.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3295-09.2010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DA.%2BK.%26aulast%3DStaniland%26aufirst%3DA.%2BA.%26aulast%3DMarchand%26aufirst%3DF.%26aulast%3DKaan%26aufirst%3DT.%2BK.%26aulast%3DMcMahon%26aufirst%3DS.%2BB.%26aulast%3DMalcangio%26aufirst%3DM.%26atitle%3DP2X7-dependent%2520release%2520of%2520interleukin-1beta%2520and%2520nociception%2520in%2520the%2520spinal%2520cord%2520following%2520lipopolysaccharide%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D573%26epage%3D582%26doi%3D10.1523%2FJNEUROSCI.3295-09.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Shiratori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozaki-Saitoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span> </span><span class="NLM_article-title">P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span><span class="refDoi">Â DOI: 10.1111/j.1471-4159.2010.06809.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1111%2Fj.1471-4159.2010.06809.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=20477948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslygur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=810-819&author=M.+Shiratoriauthor=H.+Tozaki-Saitohauthor=M.+Yoshitakeauthor=M.+Tsudaauthor=K.+Inoue&title=P2X7+receptor+activation+induces+CXCL2+production+in+microglia+through+NFAT+and+PKC%2FMAPK+pathways&doi=10.1111%2Fj.1471-4159.2010.06809.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways</span></div><div class="casAuthors">Shiratori, Miho; Tozaki-Saitoh, Hidetoshi; Yoshitake, Mai; Tsuda, Makoto; Inoue, Kazuhide</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-819</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microglia plays an important role in many neurodegenerative conditions.  ATP leaked or released by damaged cells triggers microglial activation through P2 receptors, and stimulates the release of oxygen radicals, proinflammatory cytokines and chemokines from activated microglia.  However, little is known about mechanisms underlying ATP-induced chemokine release from microglia.  In this study, we found that a high concn. of ATP induces the mRNA expression and release of CXCL2 from microglia.  A similar effect was obsd. following treatment of microglia with a P2X7 receptor (P2X7R) agonist, 2'-and 3'-O-(4-benzoylbenzoyl) ATP, and this was inhibited by pre-treatment with a P2X7R antagonist, Brilliant Blue G.  ATP induced both activation of nuclear factor of activated T cells (NFAT) and MAPKs (p38, ERK, and JNK) through P2X7R.  ATP-induced mRNA expression of CXCL2 was inhibited by INCA-6 (an NFAT inhibitor), SB203580 (a p38 inhibitor), U0126 (a MEK-ERK inhibitor) and JNK inhibitor II (a JNK inhibitor).  However, MAPK inhibitors did not inhibit activation of NFAT.  In addn., protein kinase C inhibitors suppressed ATP-induced ERK and JNK activation, and also inhibited ATP-induced CXCL2 expression in microglia.  These results suggest that ATP increased CXCL2 prodn. via both NFAT and protein kinase C/MAPK signaling pathways through P2X7 receptor stimulation in microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbvEVmlRM37Vg90H21EOLACvtfcHk0liX2jTkHB8QdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslygur4%253D&md5=4fd0e02a638856399b95479c184e0631</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.06809.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.06809.x%26sid%3Dliteratum%253Aachs%26aulast%3DShiratori%26aufirst%3DM.%26aulast%3DTozaki-Saitoh%26aufirst%3DH.%26aulast%3DYoshitake%26aufirst%3DM.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DK.%26atitle%3DP2X7%2520receptor%2520activation%2520induces%2520CXCL2%2520production%2520in%2520microglia%2520through%2520NFAT%2520and%2520PKC%252FMAPK%2520pathways%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D114%26spage%3D810%26epage%3D819%26doi%3D10.1111%2Fj.1471-4159.2010.06809.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Stock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishaq, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span><span class="refDoi">Â DOI: 10.3899/jrheum.110874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.3899%2Fjrheum.110874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=22382341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=720-727&author=T.+C.+Stockauthor=B.+J.+Bloomauthor=N.+Weiauthor=S.+Ishaqauthor=W.+Parkauthor=X.+Wangauthor=P.+Guptaauthor=C.+A.+Mebus&title=Efficacy+and+safety+of+CE-224%2C535%2C+an+antagonist+of+P2X7+receptor%2C+in+treatment+of+patients+with+rheumatoid+arthritis+inadequately+controlled+by+methotrexate&doi=10.3899%2Fjrheum.110874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span></div><div class="casAuthors">Stock, Thomas C.; Bloom, Bradley J.; Wei, Nathan; Ishaq, Saliha; Park, Won; Wang, Xin; Gupta, Pankaj; Mebus, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">720-727</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">To evaluate efficacy and safety of CE-224,535, a selective P2X7 receptor antagonist, vs. placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).  In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A6341009), patients aged â¥ 18 years with active RA were randomized to receive either CE-224,535 (500 mg bid) or placebo for 12 wk; all patients continued a stable background dose of â¥ 7.5 mg MTX.  The American College of Rheumatol. 20% (ACR20) response rate (primary efficacy endpoint) was not significantly different from placebo for CE-224,535 (34.0% vs 36.2%; p = 0.591) at Week 12, or at any timepoint over the 12-wk treatment period.  There was no significant difference at Week 12 for the ACR20 response rate following subgroup analyses by age, sex, baseline disease activity, baseline duration of disease, geog. region, or concomitant use of steroids.  ACR50/ACR70 response rates and change from baseline in Disease Activity Score 28-joint C-reactive protein (DAS28-3-CRP) and Health Assessment Questionnaire-Disability Index for CE-224,535 were not significant at Week 12 vs. placebo.  Treatment-emergent adverse events (AE) were reported by 62.3% (CE-224,535) and 55.3% (placebo) of patients; the most common AE were nausea (11.3%, CE-224,535; 4.3%, placebo) and diarrhea (7.5%, CE-224,535; 4.3%, placebo).  The proportion of patients discontinuing due to an AE was 9.4% (CE-224,535) and 6.4% (placebo); no deaths were reported.  Serious AE occurred in 3.8% (CE-224,535) and 2.1% (placebo) of patients; none was considered treatment-related.  CE-224,535 was not efficacious, compared with placebo, for the treatment of RA in patients with an inadequate response to MTX.  CE-224,535 demonstrated an acceptable safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorblWg-aNBNLVg90H21EOLACvtfcHk0liX2jTkHB8QdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D&md5=dc919436c3c6e7f3f624c57b77c5dbb2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.110874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.110874%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DWei%26aufirst%3DN.%26aulast%3DIshaq%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520CE-224%252C535%252C%2520an%2520antagonist%2520of%2520P2X7%2520receptor%252C%2520in%2520treatment%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%2520inadequately%2520controlled%2520by%2520methotrexate%26jtitle%3DJ.%2520Rheumatol.%26date%3D2012%26volume%3D39%26spage%3D720%26epage%3D727%26doi%3D10.3899%2Fjrheum.110874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Eser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutgeerts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelsang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braddock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinisch, W.</span><span> </span><span class="NLM_article-title">Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohnâs disease: A randomized placebo-controlled, double-blind, phase IIa study</span> <span class="citation_source-journal">Inflamm. Bowel Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2247</span><span class="NLM_x">â</span> <span class="NLM_lpage">2253</span><span class="refDoi">Â DOI: 10.1097/MIB.0000000000000514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1097%2FMIB.0000000000000514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26197451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2247-2253&author=A.+Eserauthor=J.+F.+Colombelauthor=P.+Rutgeertsauthor=S.+Vermeireauthor=H.+Vogelsangauthor=M.+Braddockauthor=T.+Perssonauthor=W.+Reinisch&title=Safety+and+efficacy+of+an+oral+inhibitor+of+the+purinergic+receptor+P2X7+in+adult+patients+with+moderately+to+severely+active+crohn%E2%80%99s+disease%3A+A+randomized+placebo-controlled%2C+double-blind%2C+phase+IIa+study&doi=10.1097%2FMIB.0000000000000514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span></div><div class="casAuthors">Eser Alexander; Colombel Jean-Frederic; Rutgeerts Paul; Vermeire Severine; Vogelsang Harald; Braddock Martin; Persson Tore; Reinisch Walter</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2247-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD).  The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD.  METHODS:  We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely active CD as defined by a CD Activity Index (CDAI) of at least 220.  Patients were randomized in a 2:1 mode either to 200 mg of AZD9056 administered orally as a tablet once daily for 28 days or matching placebo.  Primary endpoint was the change in CDAI from baseline at day 28, and secondary endpoints included clinical remission (CDAI < 150) and CDAI 70 response and improvement in the quality of life measures Short Form 36 and Inflammatory Bowel Disease Questionnaire.  Changes in serum C-reactive protein and fecal calprotectin were assessed.  RESULTS:  In total, 34 patients were enrolled, 24 to AZD9056 and 10 to placebo.  The CDAI dropped in AZD9056-treated subjects from a baseline mean of 311 to 242 and from 262 to 239 in placebo-treated subjects (P = 0.049).  Remission and response rates were numerically higher with AZD9056 versus placebo, (n = 5, 24% versus n = 1, 11%, P = 0.43 and n = 11, 52% versus n = 2, 22%, P = 0.13, respectively).  Marked decrease in disease activity was observed for the CDAI subcomponents, pain and general well-being.  Apart from a statistically significant improvement in the Mental Component Score of Short Form 36 for AZD9056 versus placebo (P = 0.017), no other differences in measurements of quality of life could be observed.  There was no decrease in concentrations of serum C-reactive protein and fecal calprotectin during treatment.  AZD9056 was well-tolerated, and no serious adverse events were reported.  CONCLUSIONS:  Our data suggest that the purinergic receptor P2X7 antagonist AZD9056 has the potential to improve symptoms in patients with moderate-to-severe CD combined with a beneficial risk profile.  Although the lack in change of inflammatory biomarkers questions its anti-inflammatory potential, the results obtained in this study rather suggest P2X7 antagonism for the treatment of chronic abdominal pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHjK0qgS5fO0g6wdEZmT2rfW6udTcc2eYE0nIhZMjMmLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D&md5=8ade69d316c57adae49fb595e35ab2f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2FMIB.0000000000000514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMIB.0000000000000514%26sid%3Dliteratum%253Aachs%26aulast%3DEser%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVogelsang%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DReinisch%26aufirst%3DW.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%2520oral%2520inhibitor%2520of%2520the%2520purinergic%2520receptor%2520P2X7%2520in%2520adult%2520patients%2520with%2520moderately%2520to%2520severely%2520active%2520crohn%25E2%2580%2599s%2520disease%253A%2520A%2520randomized%2520placebo-controlled%252C%2520double-blind%252C%2520phase%2520IIa%2520study%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2015%26volume%3D21%26spage%3D2247%26epage%3D2253%26doi%3D10.1097%2FMIB.0000000000000514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ali, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurijssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostenfeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott-Stevens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosking, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewit, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">207</span><span class="refDoi">Â DOI: 10.1111/j.1365-2125.2012.04320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1111%2Fj.1365-2125.2012.04320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=22568863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=197-207&author=Z.+Aliauthor=B.+Laurijssensauthor=T.+Ostenfeldauthor=S.+McHughauthor=A.+Stylianouauthor=P.+Scott-Stevensauthor=L.+Hoskingauthor=O.+Dewitauthor=J.+C.+Richardsonauthor=C.+Chen&title=Pharmacokinetic+and+pharmacodynamic+profiling+of+a+P2X7+receptor+allosteric+modulator+GSK1482160+in+healthy+human+subjects&doi=10.1111%2Fj.1365-2125.2012.04320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span></div><div class="casAuthors">Ali, Zahid; Laurijssens, Bart; Ostenfeld, Thor; McHugh, Simon; Stylianou, Anastasia; Scott-Stevens, Paul; Hosking, Louise; Dewit, Odile; Richardson, Jill C.; Chen, Chao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT â¢ P2X7 receptors are involved in the prodn. of pro-inflammatory cytokines, such as Il-1Î², by central and peripheral immune cells.  Il-1Î² has been implicated as an important mediator of inflammation.  Therefore, the P2X7 receptor is an attractive therapeutic target for inflammatory diseases.  WHAT THIS STUDY ADDS â¢ Findings in pharmacokinetics, pharmacodynamics, safety and tolerability of a P2X7 receptor modulator, GSK1482160, from the first human study for the mol. are described.  A pharmacokinetic/pharmacodynamic model for LPS-stimulated ATP-induced Il-1Î² prodn. in blood allowed the integration of all relevant data and provided in vivo evidence of the nature of the drug-receptor interaction.  The model has the potential to be used to simulate future trials.  AIMS This paper describes findings from the first-in-human study for GSK1482160, an orally available allosteric P2X7 receptor modulator.  The study aimed to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of the compd. in healthy subjects.  METHODS Escalating single doses of up to 1 g were administered to healthy subjects in a single-blind and placebo-controlled fashion.  Safety, tolerability, blood drug concns. and ex vivo Il-1Î² prodn. in blood were evaluated.  RESULTS. Drug concn. peaked within 3.5 h of dosing under fasting conditions and declined thereafter with a relatively short half-life of less than 4.5 h.  Exposure was proportional to dose with between subject variability of less than 60%.  A PK/PD model quantified Il-1Î² as a function of drug exposure.  The model allowed simulation of in vivo pharmacol. for various untested dose levels and regimens.  Furthermore, the mechanistic model supported the hypothesis that the compd. reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity.  No major safety or tolerability concerns were identified in this small study (n= 29), except for one case of asymptomatic accelerated idioventricular rhythm at the top dose.  CONCLUSION. The model-based approach maximized anal. power by integrating all biomarker data and revealed mechanistic insight into the pharmacol. of P2X7 modulation by GSK1482160.  Simulations by this model ultimately led to the discontinuation of the development of this compd.  The therapeutic relevance of the P2X7 receptor remains to be tested in patients.  The mechanistic-model-based approach can be applied widely to drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41Bz54gV-qLVg90H21EOLACvtfcHk0ljcelcnER0MPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF&md5=835023636e0c5b039245344c2a9a207a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04320.x%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%26aulast%3DLaurijssens%26aufirst%3DB.%26aulast%3DOstenfeld%26aufirst%3DT.%26aulast%3DMcHugh%26aufirst%3DS.%26aulast%3DStylianou%26aufirst%3DA.%26aulast%3DScott-Stevens%26aufirst%3DP.%26aulast%3DHosking%26aufirst%3DL.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DRichardson%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520profiling%2520of%2520a%2520P2X7%2520receptor%2520allosteric%2520modulator%2520GSK1482160%2520in%2520healthy%2520human%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D197%26epage%3D207%26doi%3D10.1111%2Fj.1365-2125.2012.04320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutheil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banasr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duric, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glasebrook, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koester, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R. S.</span><span> </span><span class="NLM_article-title">Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2 Ã 7 receptor</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><span class="refDoi">Â DOI: 10.1016/j.biopsych.2015.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.biopsych.2015.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26831917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2murw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2016&pages=12-22&author=M.+Iwataauthor=K.+T.+Otaauthor=X.+Y.+Liauthor=F.+Sakaueauthor=N.+Liauthor=S.+Dutheilauthor=M.+Banasrauthor=V.+Duricauthor=T.+Yamanashiauthor=K.+Kanekoauthor=K.+Rasmussenauthor=A.+Glasebrookauthor=A.+Koesterauthor=D.+Songauthor=K.+A.+Jonesauthor=S.+Zornauthor=G.+Smaginauthor=R.+S.+Duman&title=Psychological+stress+activates+the+inflammasome+via+release+of+adenosine+triphosphate+and+stimulation+of+the+purinergic+type+2+%C3%97+7+receptor&doi=10.1016%2Fj.biopsych.2015.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor</span></div><div class="casAuthors">Iwata, Masaaki; Ota, Kristie T.; Li, Xiao-Yuan; Sakaue, Fumika; Li, Nanxin; Dutheil, Sophie; Banasr, Mounira; Duric, Vanja; Yamanashi, Takehiko; Kaneko, Koichi; Rasmussen, Kurt; Glasebrook, Andrew; Koester, Anja; Song, Dekun; Jones, Kenneth A.; Zorn, Stevin; Smagin, Gennady; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-22</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The mechanisms underlying stress-induced inflammation that contribute to major depressive disorder are unknown.  We examine the role of the ATP (ATP)/purinergic type 2X7 receptor (P2X7R) pathway and the NLRP3 (nucleotide-binding, leucine-rich repeat, pyrin domain contg. 3) inflammasome in interleukin (IL)-1Î² and depressive behavioral responses to stress.  The influence of acute restraint stress on extracellular ATP, glutamate, IL-1Î², and tumor necrosis factor alpha in hippocampus was detd. by microdialysis, and the influence of acute restraint stress on the NLRP3 inflammasome was detd. by Western blot anal.  The influence of P2X7R antagonist administration on IL-1Î² and tumor necrosis factor alpha and on anxiety and depressive behaviors was detd. in the chronic unpredictable stress rodent model.  The role of the NLRP3 inflammasome was detd. by anal. of Nlrp3 null mice.  Acute restraint stress rapidly increased extracellular ATP, an endogenous agonist of P2X7R; the inflammatory cytokine IL-1Î²; and the active form of the NLRP3 inflammasome in the hippocampus.  Administration of a P2X7R antagonist completely blocked the release of IL-1Î² and tumor necrosis factor alpha, another stress-induced cytokine, and activated NLRP3.  Moreover, P2X7R antagonist administration reversed the anhedonic and anxiety behaviors caused by chronic unpredictable stress exposure, and deletion of the Nlrp3 gene rendered mice resistant to development of depressive behaviors caused by chronic unpredictable stress.  These findings demonstrate that psychol. "stress" is sensed by the innate immune system in the brain via the ATP/P2X7R-NLRP3 inflammasome cascade, and they identify novel therapeutic targets for the treatment of stress-related mood disorders and comorbid illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPT4PeBplcG7Vg90H21EOLACvtfcHk0ljcelcnER0MPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2murw%253D&md5=f17ad7ff32906696e07f3b9e52a7591e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DOta%26aufirst%3DK.%2BT.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DSakaue%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DDutheil%26aufirst%3DS.%26aulast%3DBanasr%26aufirst%3DM.%26aulast%3DDuric%26aufirst%3DV.%26aulast%3DYamanashi%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DK.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DGlasebrook%26aufirst%3DA.%26aulast%3DKoester%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DK.%2BA.%26aulast%3DZorn%26aufirst%3DS.%26aulast%3DSmagin%26aufirst%3DG.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DPsychological%2520stress%2520activates%2520the%2520inflammasome%2520via%2520release%2520of%2520adenosine%2520triphosphate%2520and%2520stimulation%2520of%2520the%2520purinergic%2520type%25202%2520%25C3%2597%25207%2520receptor%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D80%26spage%3D12%26epage%3D22%26doi%3D10.1016%2Fj.biopsych.2015.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Basso, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bratcher, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span> </span><span class="NLM_article-title">Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">â</span> <span class="NLM_lpage">90</span><span class="refDoi">Â DOI: 10.1016/j.bbr.2008.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bbr.2008.10.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2009&pages=83-90&author=A.+M.+Bassoauthor=N.+A.+Bratcherauthor=R.+R.+Harrisauthor=M.+F.+Jarvisauthor=M.+W.+Deckerauthor=L.+E.+Rueter&title=Behavioral+profile+of+P2X7+receptor+knockout+mice+in+animal+models+of+depression+and+anxiety%3A+relevance+for+neuropsychiatric+disorders&doi=10.1016%2Fj.bbr.2008.10.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DBasso%26aufirst%3DA.%2BM.%26aulast%3DBratcher%26aufirst%3DN.%2BA.%26aulast%3DHarris%26aufirst%3DR.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26atitle%3DBehavioral%2520profile%2520of%2520P2X7%2520receptor%2520knockout%2520mice%2520in%2520animal%2520models%2520of%2520depression%2520and%2520anxiety%253A%2520relevance%2520for%2520neuropsychiatric%2520disorders%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2009%26volume%3D198%26spage%3D83%26epage%3D90%26doi%3D10.1016%2Fj.bbr.2008.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Savall, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=671-676&author=B.+M.+Savallauthor=D.+Wuauthor=M.+De+Angelisauthor=N.+I.+Carruthersauthor=H.+Aoauthor=Q.+Wangauthor=B.+Lordauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Synthesis%2C+SAR%2C+and+pharmacological+characterization+of+brain+penetrant+P2X7+receptor+antagonists&doi=10.1021%2Facsmedchemlett.5b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span></div><div class="casAuthors">Savall, Brad M.; Wu, Duncan; De Angelis, Meri; Carruthers, Nicholas I.; Ao, Hong; Wang, Qi; Lord, Brian; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of 1,2,3-triazolopiperidines, e.g., I, as a novel series of potent, brain penetrant P2X7 antagonists was described.  Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low soly.  Further work in this series, which focused on the SAR of the N-linked heterocycle, not only increased the potency at the human P2X7R but also provided compds. with good potency at the rat P2X7R.  These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochem. properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfae7yM_oV1bVg90H21EOLACvtfcHk0ljuU2KEITrpPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D&md5=11d93747bb8b71d0ca108a3946e3a758</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00089%26sid%3Dliteratum%253Aachs%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520characterization%2520of%2520brain%2520penetrant%2520P2X7%2520receptor%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D671%26epage%3D676%26doi%3D10.1021%2Facsmedchemlett.5b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Rudolph, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcazar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrovian, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3157</span><span class="NLM_x">â</span> <span class="NLM_lpage">3163</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2015.06.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3157-3163&author=D.+A.+Rudolphauthor=J.+Alcazarauthor=M.+K.+Ameriksauthor=A.+B.+Antonauthor=H.+Aoauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+C.+Chrovianauthor=M.+De+Angelisauthor=B.+Lordauthor=J.+C.+Rechauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=J.+I.+Andresauthor=M.+A.+Letavic&title=Novel+methyl+substituted+1-%285%2C6-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%29methanones+are+P2X7+antagonists&doi=10.1016%2Fj.bmcl.2015.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%2BA.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DAnton%26aufirst%3DA.%2BB.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520methyl%2520substituted%25201-%25285%252C6-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%2529methanones%2520are%2520P2X7%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3157%26epage%3D3163%26doi%3D10.1016%2Fj.bmcl.2015.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Dean, D. K.; Munoz-Muriedas, J.; Sime, M.; Steadman, J.; A, G.; Thewlis, R. A. E.; Trani, G.; Walter, D. S.</span> PCT Int. Appl. WO 2010125102,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dean%2C+D.+K.%3B+Munoz-Muriedas%2C+J.%3B+Sime%2C+M.%3B+Steadman%2C+J.%3B+A%2C+G.%3B+Thewlis%2C+R.+A.+E.%3B+Trani%2C+G.%3B+Walter%2C+D.+S.+PCT+Int.+Appl.+WO+2010125102%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DD.%2BK.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savall, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2015.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26707399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKrtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=257-261&author=M.+K.+Ameriksauthor=H.+Aoauthor=N.+I.+Carruthersauthor=B.+Lordauthor=S.+Ravulaauthor=J.+C.+Rechauthor=B.+M.+Savallauthor=J.+L.+Wallauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Preclinical+characterization+of+substituted+6%2C7-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-8%285H%29-one+P2X7+receptor+antagonists&doi=10.1016%2Fj.bmcl.2015.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists</span></div><div class="casAuthors">Ameriks, Michael K.; Ao, Hong; Carruthers, Nicholas I.; Lord, Brian; Ravula, Suchitra; Rech, Jason C.; Savall, Brad M.; Wall, Jessica L.; Wang, Qi; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-261</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis, SAR, and preclin. characterization of a series of substituted 6,7-dihydro[1,2,4]triazolo[4,3]pyrazin-8(5H)-one P2X7 receptor antagonists are described.  Optimized leads from this series comprise some of the most potent human P2X7R antagonists reported to date (IC50s < 1 nM).  They also exhibit sufficient potency and oral bioavailability in rat to enable extensive in vivo profiling.  Although many of the disclosed compds. are peripherally restricted, compd. I is brain penetrant and upon oral administration demonstrated dose-dependent target engagement in rat hippocampus as detd. by ex vivo receptor occupancy with radiotracer II (ED50 = 0.8 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre9WCgWhiM_rVg90H21EOLACvtfcHk0lixhJVOU5YSkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKrtbjL&md5=d1a36bd7f088f4533308ad49fee7fa5b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DRavula%26aufirst%3DS.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWall%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520characterization%2520of%2520substituted%25206%252C7-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-8%25285H%2529-one%2520P2X7%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D257%26epage%3D261%26doi%3D10.1016%2Fj.bmcl.2015.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ziff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shireman, B. T.</span><span> </span><span class="NLM_article-title">Substituted 5,6-(dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 antagonists</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span><span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00304</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00304" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvVemsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=498-504&author=J.+Ziffauthor=D.+A.+Rudolphauthor=B.+Stenneauthor=T.+Koudriakovaauthor=B.+Lordauthor=P.+Bonaventureauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=A.+Bhattacharyaauthor=M.+A.+Letavicauthor=B.+T.+Shireman&title=Substituted+5%2C6-%28dihydropyrido%5B3%2C4-d%5Dpyrimidin-7%288H%29-yl%29-methanones+as+P2X7+antagonists&doi=10.1021%2Facschemneuro.5b00304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists</span></div><div class="casAuthors">Ziff, Jeannie; Rudolph, Dale A.; Stenne, Brice; Koudriakova, Tatiana; Lord, Brian; Bonaventure, Pascal; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Bhattacharya, Anindya; Letavic, Michael A.; Shireman, Brock T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-504</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the synthesis of a novel class of brain penetrating P2X7 antagonists with high potency at both the rat and human P2X7 receptors.  Disclosed herein are druglike mols. with demonstrated target engagement of the rat P2X7 receptors after an oral dose.  Specifically, compd. 20 occupied the P2X7 receptors >80% over the 6 h time course as measured by an ex vivo radioligand binding expt.  In a dose-response assay, this mol. has a plasma EC50 of 8 ng/mL.  Overall, 20 has suitable druglike properties and pharmacokinetics in rat and dog.  This mol. and others disclosed herein will serve as addnl. tools to elucidate the role of the P2X7 receptor in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4iuRhC8lPbVg90H21EOLACvtfcHk0lixhJVOU5YSkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvVemsA%253D%253D&md5=7f3f1afa4dad4db259189b98d97c8ae9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00304%26sid%3Dliteratum%253Aachs%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DD.%2BA.%26aulast%3DStenne%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26atitle%3DSubstituted%25205%252C6-%2528dihydropyrido%255B3%252C4-d%255Dpyrimidin-7%25288H%2529-yl%2529-methanones%2520as%2520P2X7%2520antagonists%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D498%26epage%3D504%26doi%3D10.1021%2Facschemneuro.5b00304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Chrovian, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soyode-Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacani, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Novel phenyl-substituted 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists with robust target engagement in rat brain</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">â</span> <span class="NLM_lpage">497</span><span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlGmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=490-497&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=H.+Aoauthor=G.+M.+Bacaniauthor=N.+I.+Carruthersauthor=B.+Lordauthor=L.+Nguyenauthor=J.+C.+Rechauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Novel+phenyl-substituted+5%2C6-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazine+P2X7+antagonists+with+robust+target+engagement+in+rat+brain&doi=10.1021%2Facschemneuro.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Ao, Hong; Bacani, Genesis M.; Carruthers, Nicholas I.; Lord, Brian; Nguyen, Leslie; Rech, Jason C.; Wang, Qi; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">490-497</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists were optimized to allow for good blood-brain barrier permeability and high P2X7 target engagement in the brain of rats.  Compd. I (huP2X7 IC50 = 9 nM; rat P2X7 IC50 = 42 nM) achieved 80% receptor occupancy for 6 h when dosed orally at 10 mg/kg in rats as measured by ex vivo radioligand binding autoradiog.  Structure-activity relationships within this series are described, as well as in vitro ADME results.  In vivo pharmacokinetic data for key compds. is also included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFc11o0pApUbVg90H21EOLACvtfcHk0lixhJVOU5YSkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlGmsA%253D%253D&md5=a51ac05ebd3115489ddbabecf0cd1170</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520phenyl-substituted%25205%252C6-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazine%2520P2X7%2520antagonists%2520with%2520robust%2520target%2520engagement%2520in%2520rat%2520brain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D490%26epage%3D497%26doi%3D10.1021%2Facschemneuro.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savall, B. M.</span><span> </span><span class="NLM_article-title">The evolution of P2X7 antagonists with a focus on CNS indications</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3838</span><span class="NLM_x">â</span> <span class="NLM_lpage">3845</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2016.06.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=27426304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOitL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3838-3845&author=J.+C.+Rechauthor=A.+Bhattacharyaauthor=M.+A.+Letavicauthor=B.+M.+Savall&title=The+evolution+of+P2X7+antagonists+with+a+focus+on+CNS+indications&doi=10.1016%2Fj.bmcl.2016.06.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of P2X7 antagonists with a focus on CNS indications</span></div><div class="casAuthors">Rech, Jason C.; Bhattacharya, Anindya; Letavic, Michael A.; Savall, Brad M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3838-3845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The P2X7 receptor is an ATP-gated nonselective cation channel that has been linked to a no. of inflammatory diseases.  Activation of the P2X7 receptor by elevated levels of ATP results in the release of proinflammatory cytokines and elevated levels of these cytokines has been assocd. with a variety of disease states.  A no. of research groups in both industry and academia have explored the identification of P2X7R antagonists as therapeutic agents.  Much of this early effort focused on the treatment of diseases related to peripheral inflammation and resulted in several clin. candidates, none of which were advanced to market.  The emerging role of the P2X7 receptor in neuroinflammation and related diseases has resulted in a shift in medicinal chem. efforts toward the development of centrally penetrant antagonists.  This review will highlight the biol. supporting the role of P2X7 in diseases related to neuroinflammation and review the recent medicinal chem. efforts to identify centrally penetrant antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaLGUAKgul7Vg90H21EOLACvtfcHk0lgBWCjFp613nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOitL3L&md5=04046ec16457c856c96dd50632b96efe</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26atitle%3DThe%2520evolution%2520of%2520P2X7%2520antagonists%2520with%2520a%2520focus%2520on%2520CNS%2520indications%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3838%26epage%3D3845%26doi%3D10.1016%2Fj.bmcl.2016.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Alcazar, J.; Andres, J. I.; Chrovian, C. C.; Coate, H. R.; De Angelis, M.; Dvorak, C. A.; Gelin, C. F.; Letavic, M. A.; Savall, B. M.; Soyode-Johnson, A.; Stenne, B. M.; Swanson, D. M.</span> PCT Int. Appl. US 20140275015,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alcazar%2C+J.%3B+Andres%2C+J.+I.%3B+Chrovian%2C+C.+C.%3B+Coate%2C+H.+R.%3B+De+Angelis%2C+M.%3B+Dvorak%2C+C.+A.%3B+Gelin%2C+C.+F.%3B+Letavic%2C+M.+A.%3B+Savall%2C+B.+M.%3B+Soyode-Johnson%2C+A.%3B+Stenne%2C+B.+M.%3B+Swanson%2C+D.+M.+PCT+Int.+Appl.+US+20140275015%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcazar%26aufirst%3DJ.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Altman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">4,7-Dimethoxy-1,10-phenanthroline: an excellent ligand for the Cu-catalyzed N-arylation of imidazoles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2779</span><span class="NLM_x">â</span> <span class="NLM_lpage">2782</span><span class="refDoi">Â DOI: 10.1021/ol0608505</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0608505" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=2779-2782&author=R.+A.+Altmanauthor=S.+L.+Buchwald&title=4%2C7-Dimethoxy-1%2C10-phenanthroline%3A+an+excellent+ligand+for+the+Cu-catalyzed+N-arylation+of+imidazoles&doi=10.1021%2Fol0608505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">4,7-Dimethoxy-1,10-phenanthroline: An excellent ligand for the Cu-catalyzed N-arylation of imidazoles</span></div><div class="casAuthors">Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2779-2782</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4,7-Dimethoxy-1,10-phenanthroline was found to be an efficient ligand for the copper-catalyzed N-arylation of imidazole with aryl iodides and bromides under mild conditions.  A variety of hindered and functionalized imidazoles and aryl halides were transformed in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhYwSzg5IKQ7Vg90H21EOLACvtfcHk0lgBWCjFp613nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSnt7c%253D&md5=83f85e6503605f82ef5e37c8a6974ac8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol0608505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0608505%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3D4%252C7-Dimethoxy-1%252C10-phenanthroline%253A%2520an%2520excellent%2520ligand%2520for%2520the%2520Cu-catalyzed%2520N-arylation%2520of%2520imidazoles%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D2779%26epage%3D2782%26doi%3D10.1021%2Fol0608505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Comins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, A. H.</span><span> </span><span class="NLM_article-title">Regioselective addition of Grignard reagents to 1-acylpyridinium salts. A convenient method for the synthesis of 4-alkyl(aryl)pyridines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4315</span><span class="refDoi">Â DOI: 10.1021/jo00143a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00143a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADyaL38Xls1aktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1982&pages=4315&author=D.+L.+Cominsauthor=A.+H.+Abdullah&title=Regioselective+addition+of+Grignard+reagents+to+1-acylpyridinium+salts.+A+convenient+method+for+the+synthesis+of+4-alkyl%28aryl%29pyridines&doi=10.1021%2Fjo00143a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective addition of Grignard reagents to 1-acylpyridinium salts.  A convenient method for the synthesis of 4-alkyl(aryl)pyridines</span></div><div class="casAuthors">Comins, Daniel L.; Abdullah, Abdul H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4315-19</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The addn. of Grignard reagents to 1-acylpyridinium salts afforded 1-acyl-2-alkyl(aryl)-1,2-dihydropyridines and 1-acyl-4-alkyl(aryl)-1,4-dihydropyridines.  The regioselectivity of this reaction, 1,2- vs. 1,4-addn., was dependent upon the structures of the Grignard reagent and the 1-acyl group.  Pyridine, 2-picoline, and 3-picoline were studied, and in most cases, significant amts. of 1,4-addn. occurred.  When a catalytic amt. of cuprous iodide was present, nearly exclusive 1,4-addn. resulted.  The crude 1,4-dihydropyridines were aromatized by heating with sulfur to provide 4-substituted pyridines and picolines in good yield and high isomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIy6pHYlQv6bVg90H21EOLACvtfcHk0lgBWCjFp613nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xls1aktbs%253D&md5=07d917e4be8c04c0c5abdeecf19086bc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo00143a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00143a028%26sid%3Dliteratum%253Aachs%26aulast%3DComins%26aufirst%3DD.%2BL.%26aulast%3DAbdullah%26aufirst%3DA.%2BH.%26atitle%3DRegioselective%2520addition%2520of%2520Grignard%2520reagents%2520to%25201-acylpyridinium%2520salts.%2520A%2520convenient%2520method%2520for%2520the%2520synthesis%2520of%25204-alkyl%2528aryl%2529pyridines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1982%26volume%3D47%26spage%3D4315%26doi%3D10.1021%2Fjo00143a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Flack, H. D.</span><span> </span><span class="NLM_article-title">On enantiomorph-polarity estimation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. A: Found. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">881</span><span class="refDoi">Â DOI: 10.1107/S0108767383001762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1107%2FS0108767383001762" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1983&pages=876-881&author=H.+D.+Flack&title=On+enantiomorph-polarity+estimation&doi=10.1107%2FS0108767383001762"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS0108767383001762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767383001762%26sid%3Dliteratum%253Aachs%26aulast%3DFlack%26aufirst%3DH.%2BD.%26atitle%3DOn%2520enantiomorph-polarity%2520estimation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D1983%26volume%3D39%26spage%3D876%26epage%3D881%26doi%3D10.1107%2FS0108767383001762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourgeaud, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vliegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verluyten, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haspeslagh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span> </span><span class="NLM_article-title">A novel radioligand for the ATP-gated ion channel P2X7: [H] JNJ-54232334</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">765</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">559</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2015.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.ejphar.2015.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26386289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFOrs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=765&publication_year=2015&pages=551-559&author=B.+Lordauthor=M.+K.+Ameriksauthor=Q.+Wangauthor=L.+Fourgeaudauthor=M.+Vliegenauthor=W.+Verluytenauthor=P.+Haspeslaghauthor=N.+I.+Carruthersauthor=T.+W.+Lovenbergauthor=P.+Bonaventureauthor=M.+A.+Letavicauthor=A.+Bhattacharya&title=A+novel+radioligand+for+the+ATP-gated+ion+channel+P2X7%3A+%5BH%5D+JNJ-54232334&doi=10.1016%2Fj.ejphar.2015.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334</span></div><div class="casAuthors">Lord, Brian; Ameriks, Michael K.; Wang, Qi; Fourgeaud, Lawrence; Vliegen, Maarten; Verluyten, Willy; Haspeslagh, Pieter; Carruthers, Nicholas I.; Lovenberg, Timothy W.; Bonaventure, Pascal; Letavic, Michael A.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">765</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">551-559</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATP-gated ion channel P2X7 has emerged as a potential central nervous system (CNS) drug target based on the hypotheses that pro-inflammatory cytokines such as IL-1Î² that are released by microglia, may contribute to the etiol. of various disorders of the CNS including depression.  In this study, we identified two closely related P2X7 antagonists, JNJ-54232334 and JNJ-54140515, and then tritium labeled the former to produce a new radioligand for P2X7.  JNJ-54232334 is a high affinity ligand for the rat P2X7 with a pKi of 9.3Â±0.1.  In rat cortical membranes, [3H] JNJ-54232334 reached saturable binding with equil. dissocn. (Kd) const. of 4.9Â±1.3 nM.  The compd. displayed monophasic assocn. and dissocn. kinetics with fast on and off rates.  In rat brain sections, specific binding of [3H] JNJ-54232334 was markedly improved compared to the previously described P2X7 radioligand, [3H] A-804598.  In P2X7 knockout mouse brain sections, [3H] A-804598 bound to non-P2X7 binding sites in contrast to [3H] JNJ-54232334.  In rat or wild type mouse brain sections [3H] JNJ-54232334 bound in a more homogenous and region independent manner.  The ubiquitous expression of P2X7 receptors was confirmed with immunohistochem. in rat brain sections.  The partial displacement of [3H] A-804598 binding resulted in the underestimation of the level of ex vivo P2X7 occupancy for JNJ-54140515.  Higher levels of P2X7 ex vivo occupancy were measured using [3H] JNJ-54232334 due to less non-specific binding.  In summary, we describe [3H] JNJ-54232334 as a novel P2X7 radioligand, with improved properties over [3H] A-804598.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqr6Nqq14QSLVg90H21EOLACvtfcHk0ljXnf5MA-seFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFOrs7zP&md5=b7d9da772882fa3d9e405fa54444d0f3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DB.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFourgeaud%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DM.%26aulast%3DVerluyten%26aufirst%3DW.%26aulast%3DHaspeslagh%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3DA%2520novel%2520radioligand%2520for%2520the%2520ATP-gated%2520ion%2520channel%2520P2X7%253A%2520%255BH%255D%2520JNJ-54232334%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D765%26spage%3D551%26epage%3D559%26doi%3D10.1016%2Fj.ejphar.2015.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mastey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panneton, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varin, F.</span><span> </span><span class="NLM_article-title">Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography</span> <span class="citation_source-journal">J. Chromatogr., Biomed. Appl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">655</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">310</span><span class="refDoi">Â DOI: 10.1016/0378-4347(94)00096-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2F0378-4347%2894%2900096-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=8081479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2mtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=655&publication_year=1994&pages=305-310&author=V.+Masteyauthor=A.+C.+Pannetonauthor=F.+Donatiauthor=F.+Varin&title=Determination+of+midazolam+and+two+of+its+metabolites+in+human+plasma+by+high-performance+liquid+chromatography&doi=10.1016%2F0378-4347%2894%2900096-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography</span></div><div class="casAuthors">Mastey, V.; Panneton, A.-C.; Donati, F.; Varin, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B:  Biomedical Sciences and Applications</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">655</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-10</span>CODEN:
                <span class="NLM_cas:coden">JCBBEP</span>;
        ISSN:<span class="NLM_cas:issn">1387-2273</span>.
    </div><div class="casAbstract">A high-performance liq. chromatog. assay coupled with UV detection (254 nm) has been developed for the detn. of midazolam and two of its hydroxylated metabolites, 1-hydroxymidazolam (1-OH) and 4-hydroxymidazolam (4-OH), in human plasma.  Following a novel solid-phase extn. procedure, midazolam and its metabolites are well recovered from plasma.  The analytes were extd. with C1 cartridges and the exts. were evapd. to dryness.  The dry residues were dissolved in 200 Î¼L of mobile phase [0.02 M ammonium phosphate monobasic buffer-methanol-acetonitrile (60:35:5, vol./vol.) (300 mL), 600 Î¼L of 0.2 M tetrabutylammonium bromide soln., adjusted to a pH* (apparent pH) of 4.10].  The sepn. of the analytes was performed on a Spherisorb C8 column (10 cmÃ4.6 mm I.D.) maintained at 30Â°.  The mobile phase was pumped at a flow-rate of 1.5 mL/min.  The method has a lower limit of quantitation of 15 ng/mL of plasma for midazolam and proved to be reproducible (inter-assay precision 5.4%) and accurate (94%) over the therapeutic range of concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP33ulUfltLrVg90H21EOLACvtfcHk0ljXnf5MA-seFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2mtr8%253D&md5=39e9e62c81924a169903923a8c32eac2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0378-4347%2894%2900096-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-4347%252894%252900096-4%26sid%3Dliteratum%253Aachs%26aulast%3DMastey%26aufirst%3DV.%26aulast%3DPanneton%26aufirst%3DA.%2BC.%26aulast%3DDonati%26aufirst%3DF.%26aulast%3DVarin%26aufirst%3DF.%26atitle%3DDetermination%2520of%2520midazolam%2520and%2520two%2520of%2520its%2520metabolites%2520in%2520human%2520plasma%2520by%2520high-performance%2520liquid%2520chromatography%26jtitle%3DJ.%2520Chromatogr.%252C%2520Biomed.%2520Appl.%26date%3D1994%26volume%3D655%26spage%3D305%26epage%3D310%26doi%3D10.1016%2F0378-4347%2894%2900096-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. M.</span><span> </span><span class="NLM_article-title">Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">â</span> <span class="NLM_lpage">1319</span><span class="refDoi">Â DOI: 10.1124/dmd.30.12.1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1124%2Fdmd.30.12.1311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=12433797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVyisrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1311-1319&author=R.+Yuanauthor=S.+Madaniauthor=X.+X.+Weiauthor=K.+Reynoldsauthor=S.+M.+Huang&title=Evaluation+of+cytochrome+P450+probe+substrates+commonly+used+by+the+pharmaceutical+industry+to+study+in+vitro+drug+interactions&doi=10.1124%2Fdmd.30.12.1311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions</span></div><div class="casAuthors">Yuan, Rae; Madani, Soraya; Wei, Xiao-Xiong; Reynolds, Kellie; Huang, Shiew-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1319</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pharmaceutical industry investigators routinely evaluate the potential for a new drug to modify cytochrome P 450 (P 450) activities by detg. the effect of the drug on in vitro probe reactions that represent activity of specific P 450 enzymes.  The in vitro findings obtained with one probe substrate are usually extrapolated to the compd.'s potential to affect all substrates of the same enzyme.  Due to this practice, it is important to use the right probe substrate and to conduct the expt. under optimal conditions.  Surveys conducted by reviewers in CDER indicated that the most common in vitro probe reactions used by industry investigators include the following: phenacetin O-deethylation for CYP1A2, coumarin 7-hydroxylation for CYP2A6, 7-ethoxy-4-trifluoromethyl coumarin O-dealkylation for CYP2B6, tolbutamide 4'-hydroxylation for CYP2C9, S-mephenytoin 4-hydroxylation for CYP2C19, bufuralol 1'-hydroxylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, and testosterone 6Î²-hydroxylation for CYP3A4.  We reviewed the validation information in the literature on these reactions and other frequently used reactions, including caffeine N3-demethylation for CYP1A2, S-mephenytoin N-demethylation for CYP2B6, S-warfarin 7'-hydroxylation for CYP2C9, dextromethorphan O-demethylation for CYP2D6, and midazolam 1'-hydroxylation for CYP3A4.  The available information indicates that we need to continue the search for better probe substrates for some enzymes.  For CYP3A4-based drug interactions it may be necessary to evaluate two or more probe substrates.  In many cases, the probe reaction represents a particular enzyme activity only under specific exptl. conditions.  Investigators must consider appropriateness of probe substrates and exptl. conditions when conducting in vitro drug interaction studies and when extrapolating the results to in vivo situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplsZYxa2pKkbVg90H21EOLACvtfcHk0ljXnf5MA-seFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVyisrY%253D&md5=336badc64bac1da8353f163e655cd89d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1311%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DMadani%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DX.%2BX.%26aulast%3DReynolds%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DEvaluation%2520of%2520cytochrome%2520P450%2520probe%2520substrates%2520commonly%2520used%2520by%2520the%2520pharmaceutical%2520industry%2520to%2520study%2520in%2520vitro%2520drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1311%26epage%3D1319%26doi%3D10.1124%2Fdmd.30.12.1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">van Breemen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">Caco-2 cell permeability assays to measure drug absorption</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.1517/17425255.1.2.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1517%2F17425255.1.2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=16922635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKltLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=175-185&author=R.+B.+van+Breemenauthor=Y.+Li&title=Caco-2+cell+permeability+assays+to+measure+drug+absorption&doi=10.1517%2F17425255.1.2.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Caco-2 cell permeability assays to measure drug absorption</span></div><div class="casAuthors">van Breemen, Richard B.; Li, Yongmei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-185</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Caco-2 cells are a human colon epithelial cancer cell line used as a model of human intestinal absorption of drugs and other compds.  When cultured as a monolayer, Caco-2 cells differentiate to form tight junctions between cells to serve as a model of paracellular movement of compds. across the mono-layer.  In addn., Caco-2 cells express transporter proteins, efflux proteins, and Phase II conjugation enzymes to model a variety of transcellular pathways as well as metabolic transformation of test substances.  In many respects, the Caco-2 cell monolayer mimics the human intestinal epithelium.  One of the functional differences between normal cells and Caco-2 cells is the lack of expression of the cytochrome P 450 isoenzymes and in particular, CYP3A4, which is normally expressed at high levels in the intestine.  However, Caco-2 cells may be induced to express higher levels of CYP3A4 by treatment with vitamin D3.  Caco-2 cell monolayers are usually cultured on semipermeable plastic supports that may be fitted into the wells of multi-well culture plates.  Test compds. are then added to either the apical or basolateral sides of the monolayer.  After incubation for various lengths of time, aliquots of the buffer in opposite chambers are removed for the detn. of the concn. of test compds. and the computation of the rates of permeability for each compd. (called the apparent permeability coeffs.).  Although radiolabeled compds. were used in the original Caco-2 cells monolayer assays, radio-labeled compds. have been replaced in most labs. by the use of liq. chromatog.-mass spectrometry (LC-MS) and LC-tandem mass spectrometry (LC-MS-MS).  Mass spectrometry not only eliminates the need for radiolabeled compds., but permits the simultaneous measurement of multiple compds.  The measurement of multiple compds. per assay reduces the no. of incubations that need to be carried out, thereby increasing the throughput of the expts.  Furthermore, LC-MS and LC-MS-MS add another dimension to Caco-2 assays by facilitating the investigation of the metab. of compds. by Caco-2 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcV-AZvy78ILVg90H21EOLACvtfcHk0lj_lFggjdPxPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKltLbK&md5=7bd0b875ffa9c840f904bab6513b7e3f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.1.2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.1.2.175%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DCaco-2%2520cell%2520permeability%2520assays%2520to%2520measure%2520drug%2520absorption%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2005%26volume%3D1%26spage%3D175%26epage%3D185%26doi%3D10.1517%2F17425255.1.2.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Houston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetin, A.</span><span> </span><span class="NLM_article-title">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">â</span> <span class="NLM_lpage">951</span><span class="refDoi">Â DOI: 10.2174/138920008786485164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.2174%2F138920008786485164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=18991591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=940-951&author=J.+B.+Houstonauthor=A.+Galetin&title=Methods+for+predicting+in+vivo+pharmacokinetics+using+data+from+in+vitro+assays&doi=10.2174%2F138920008786485164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span></div><div class="casAuthors">Houston, J. Brian; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-951</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Strategies for optimizing in vivo predictions from in vitro data on metabolic stability and CYP inhibition are discussed.  Potential pitfalls and areas of inaccuracy are highlighted together with recommendations for best practice.  The use of both hepatic microsomes and isolated hepatocytes for the assessment of metabolic stability is discussed in terms of scaling from the in vitro system up to whole liver.  The importance of integrating metabolic stability data together with other drug pharmacokinetic characteristics (e.g., protein binding and red blood cell uptake) as well as blood flow are presented within the context of different liver models.  The assessment of CYP inhibition potential requires in vitro data on the inhibitor potency either in the form of Ki (for reversible inhibition) or Kl and kinact (for time-dependent inhibition).  The integration of these in vitro parameters together with other pharmacokinetic information is essential for the in vivo prediction.  While a qual. assessment may be made from the I/Ki ratio, a no. of addnl. victim drug and enzyme-related parameters are required for quant. prediction.  Of particular importance is the parameter fmCYP (the fraction of the metabolic clearance of the victim drug that is catalyzed by the enzyme subject to the inhibition).  Impact of other victim drug properties (e.g., fractional importance of the intestine) and enzyme properties (e.g., kdeg for time-dependent inhibition) on the drug-drug interaction prediction is discussed.  In addn., mechanisms by which false negatives and false positives may result from in vitro strategies are summarized.  Finally perspectives for future application and improvements in these predictions strategies are outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SQoxJv6217Vg90H21EOLACvtfcHk0lj_lFggjdPxPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D&md5=8ec402521f33f7704edc184f7cab9a35</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F138920008786485164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485164%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DMethods%2520for%2520predicting%2520in%2520vivo%2520pharmacokinetics%2520using%2520data%2520from%2520in%2520vitro%2520assays%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D940%26epage%3D951%26doi%3D10.2174%2F138920008786485164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Hill, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortishire-Smith, R. J.</span><span> </span><span class="NLM_article-title">Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3111</span><span class="NLM_x">â</span> <span class="NLM_lpage">3118</span><span class="refDoi">Â DOI: 10.1002/rcm.2177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Frcm.2177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1eht7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=3111-3118&author=A.+Hillauthor=R.+J.+Mortishire-Smith&title=Automated+assignment+of+high-resolution+collisionally+activated+dissociation+mass+spectra+using+a+systematic+bond+disconnection+approach&doi=10.1002%2Frcm.2177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach</span></div><div class="casAuthors">Hill, Alastair W.; Mortishire-Smith, Russell J.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3111-3118</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An essential component of the process of characterizing chem. unknowns via mass spectrometry is the anal. of collisionally activated dissocn. (CAD) mass spectra.  Existing tools for the automated assignment of CAD spectra typically use a rule-based approach which identifies those bonds that probably break.  While valuable, the failure of explicitly rule-based approaches to suggest rationalisations for a significant proportion of obsd. product ions led the authors to develop an alternative approach (elucidation of product ion connectivity, EPIC) based on high-resoln. mass spectrometry, systematic bond disconnection of the precursor structure, and ranking of the resulting substructures.  The authors exemplify this approach with a reanal. of published MS/MS data for two compds. taken from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombopgCxuQFLVg90H21EOLACvtfcHk0lgNqtIQYAzgxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1eht7jF&md5=c35ea9808c5794c3bf10379e1d190a13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Frcm.2177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.2177%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%26aulast%3DMortishire-Smith%26aufirst%3DR.%2BJ.%26atitle%3DAutomated%2520assignment%2520of%2520high-resolution%2520collisionally%2520activated%2520dissociation%2520mass%2520spectra%2520using%2520a%2520systematic%2520bond%2520disconnection%2520approach%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2005%26volume%3D19%26spage%3D3111%26epage%3D3118%26doi%3D10.1002%2Frcm.2177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Allen T. Hopper, Martin Juhl, Jorrit Hornberg, Lassina Badolo, John Paul Kilburn, Annemette Thougaard, Gennady Smagin, Dekun Song, Londye Calice, Veena Menon, Elena Dale, Hong Zhang, Manuel Cajina, Megan E. Nattini, Adarsh Gandhi, Michel Grenon, Ken Jones, Tanzilya Khayrullina, Gamini Chandrasena, Christian Thomsen, Stevin H. Zorn, Robb Brodbeck, Suresh Babu Poda, Roland Staal, <span class="NLM_string-name hlFld-ContribAuthor">Thomas MÃ¶ller</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4891-4902. <a href="https://doi.org/10.1021/acs.jmedchem.0c02249" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02249%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Bthe%252BNovel%252BRodent-Active%252Band%252BCNS-Penetrant%252BP2X7%252BReceptor%252BAntagonist%252BLu%252BAF27139%26aulast%3DHopper%26aufirst%3DAllen%2BT.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28122020%26date%3D06042021%26volume%3D64%26issue%3D8%26spage%3D4891%26epage%3D4902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christa C. Chrovian, Akinola Soyode-Johnson, Brice Stenne, Daniel J. Pippel, Jeffrey Schoellerman, Brian Lord, Alexandra S. Needham, Chungfang Xia, Kevin J. Coe, Kia Sepassi, Freddy Schoetens, Brian Scott, Leslie Nguyen, Xiaohui Jiang, Tatiana Koudriakova, Bartosz Balana, <span class="NLM_string-name hlFld-ContribAuthor">Michael A. Letavic</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9181-9196. <a href="https://doi.org/10.1021/acs.jmedchem.9b02113" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02113%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BPreclinical%252BEvaluation%252Bof%252B3-Methyl-6-%2525285-thiophenyl%252529-1%25252C3-dihydro-imidazo%25255B4%25252C5-b%25255Dpyridin-2-ones%252Bas%252BSelective%252BGluN2B%252BNegative%252BAllosteric%252BModulators%252Bfor%252Bthe%252BTreatment%252Bof%252BMood%252BDisorders%26aulast%3DChrovian%26aufirst%3DChrista%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06022020%26date%3D28082020%26date%3D31072020%26volume%3D63%26issue%3D17%26spage%3D9181%26epage%3D9196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christa C.  Chrovian</span>, <span class="hlFld-ContribAuthor ">Akinola  Soyode-Johnson</span>, <span class="hlFld-ContribAuthor ">Alexander A.  Peterson</span>, <span class="hlFld-ContribAuthor ">Christine F.  Gelin</span>, <span class="hlFld-ContribAuthor ">Xiaohu  Deng</span>, <span class="hlFld-ContribAuthor ">Curt A.  Dvorak</span>, <span class="hlFld-ContribAuthor ">Nicholas I.  Carruthers</span>, <span class="hlFld-ContribAuthor ">Brian  Lord</span>, <span class="hlFld-ContribAuthor ">Ian  Fraser</span>, <span class="hlFld-ContribAuthor ">Leah  Aluisio</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Coe</span>, <span class="hlFld-ContribAuthor ">Brian  Scott</span>, <span class="hlFld-ContribAuthor ">Tatiana  Koudriakova</span>, <span class="hlFld-ContribAuthor ">Freddy  Schoetens</span>, <span class="hlFld-ContribAuthor ">Kia  Sepassi</span>, <span class="hlFld-ContribAuthor ">David J.  Gallacher</span>, <span class="hlFld-ContribAuthor ">Anindya  Bhattacharya</span>, and <span class="hlFld-ContribAuthor ">Michael A.  Letavic</span>  . </span><span class="cited-content_cbyCitation_article-title">A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (1)
                                     , 207-223. <a href="https://doi.org/10.1021/acs.jmedchem.7b01279" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01279%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BDipolar%252BCycloaddition%252BReaction%252BTo%252BAccess%252B6-Methyl-4%25252C5%25252C6%25252C7-tetrahydro-1H-%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-c%25255Dpyridines%252BEnables%252Bthe%252BDiscovery%252BSynthesis%252Band%252BPreclinical%252BProfiling%252Bof%252Ba%252BP2X7%252BAntagonist%252BClinical%252BCandidate%26aulast%3DChrovian%26aufirst%3DChrista%2BC.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D28082017%26date%3D20122017%26date%3D11012018%26date%3D06122017%26volume%3D61%26issue%3D1%26spage%3D207%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael A.  Letavic</span>, <span class="hlFld-ContribAuthor ">Brad M.  Savall</span>, <span class="hlFld-ContribAuthor ">Brett D.  Allison</span>, <span class="hlFld-ContribAuthor ">Leah  Aluisio</span>, <span class="hlFld-ContribAuthor ">Jose Ignacio  Andres</span>, <span class="hlFld-ContribAuthor ">Meri  De Angelis</span>, <span class="hlFld-ContribAuthor ">Hong  Ao</span>, <span class="hlFld-ContribAuthor ">Derek A.  Beauchamp</span>, <span class="hlFld-ContribAuthor ">Pascal  Bonaventure</span>, <span class="hlFld-ContribAuthor ">Stewart  Bryant</span>, <span class="hlFld-ContribAuthor ">Nicholas I.  Carruthers</span>, <span class="hlFld-ContribAuthor ">Marc  Ceusters</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Coe</span>, <span class="hlFld-ContribAuthor ">Curt A.  Dvorak</span>, <span class="hlFld-ContribAuthor ">Ian C.  Fraser</span>, <span class="hlFld-ContribAuthor ">Christine F.  Gelin</span>, <span class="hlFld-ContribAuthor ">Tatiana  Koudriakova</span>, <span class="hlFld-ContribAuthor ">Jimmy  Liang</span>, <span class="hlFld-ContribAuthor ">Brian  Lord</span>, <span class="hlFld-ContribAuthor ">Timothy W.  Lovenberg</span>, <span class="hlFld-ContribAuthor ">Monicah A.  Otieno</span>, <span class="hlFld-ContribAuthor ">Freddy  Schoetens</span>, <span class="hlFld-ContribAuthor ">Devin M.  Swanson</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Alan D.  Wickenden</span>, and <span class="hlFld-ContribAuthor ">Anindya  Bhattacharya</span>  . </span><span class="cited-content_cbyCitation_article-title">4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (11)
                                     , 4559-4572. <a href="https://doi.org/10.1021/acs.jmedchem.7b00408" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00408</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00408%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Methyl-6%25252C7-dihydro-4H-triazolo%25255B4%25252C5-c%25255Dpyridine-Based%252BP2X7%252BReceptor%252BAntagonists%25253A%252BOptimization%252Bof%252BPharmacokinetic%252BProperties%252BLeading%252Bto%252Bthe%252BIdentification%252Bof%252Ba%252BClinical%252BCandidate%26aulast%3DLetavic%26aufirst%3DMichael%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D14032017%26date%3D25052017%26date%3D08062017%26date%3D11052017%26volume%3D60%26issue%3D11%26spage%3D4559%26epage%3D4572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul R.  Territo</span>, <span class="hlFld-ContribAuthor ">Hamideh  Zarrinmayeh</span>. </span><span class="cited-content_cbyCitation_article-title">P2X7 Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular Neuroscience</span><span> <strong>2021,</strong> <em>15 </em><a href="https://doi.org/10.3389/fncel.2021.617036" title="DOI URL">https://doi.org/10.3389/fncel.2021.617036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fncel.2021.617036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffncel.2021.617036%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520Neuroscience%26atitle%3DP2X7%252BReceptors%252Bin%252BNeurodegeneration%25253A%252BPotential%252BTherapeutic%252BApplications%252BFrom%252BBasic%252Bto%252BClinical%252BApproaches%26aulast%3DTerrito%26aufirst%3DPaul%2BR.%26date%3D2021%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Calzaferri</span>, <span class="hlFld-ContribAuthor ">Cristina  RuizâRuiz</span>, <span class="hlFld-ContribAuthor ">Antonio M. G.  Diego</span>, <span class="hlFld-ContribAuthor ">Ricardo  Pascual</span>, <span class="hlFld-ContribAuthor ">Iago  MÃ©ndezâLÃ³pez</span>, <span class="hlFld-ContribAuthor ">MarÃ­a F.  CanoâAbad</span>, <span class="hlFld-ContribAuthor ">Victoria  Maneu</span>, <span class="hlFld-ContribAuthor ">CristÃ³bal  RÃ­os</span>, <span class="hlFld-ContribAuthor ">Luis  GandÃ­a</span>, <span class="hlFld-ContribAuthor ">Antonio G.  GarcÃ­a</span>. </span><span class="cited-content_cbyCitation_article-title">The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2427-2465. <a href="https://doi.org/10.1002/med.21710" title="DOI URL">https://doi.org/10.1002/med.21710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21710%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DThe%252Bpurinergic%252BP2X7%252Breceptor%252Bas%252Ba%252Bpotential%252Bdrug%252Btarget%252Bto%252Bcombat%252Bneuroinflammation%252Bin%252Bneurodegenerative%252Bdiseases%26aulast%3DCalzaferri%26aufirst%3DFrancesco%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2427%26epage%3D2465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roberta  Andrejew</span>, <span class="hlFld-ContribAuthor ">Ãgatha  Oliveira-Giacomelli</span>, <span class="hlFld-ContribAuthor ">Deidiane Elisa  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Talita  Glaser</span>, <span class="hlFld-ContribAuthor ">Vanessa Fernandes  Arnaud-Sampaio</span>, <span class="hlFld-ContribAuthor ">Claudiana  Lameu</span>, <span class="hlFld-ContribAuthor ">Henning  Ulrich</span>. </span><span class="cited-content_cbyCitation_article-title">The P2X7 Receptor: Central Hub of Brain Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Neuroscience</span><span> <strong>2020,</strong> <em>13 </em><a href="https://doi.org/10.3389/fnmol.2020.00124" title="DOI URL">https://doi.org/10.3389/fnmol.2020.00124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnmol.2020.00124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnmol.2020.00124%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Neuroscience%26atitle%3DThe%252BP2X7%252BReceptor%25253A%252BCentral%252BHub%252Bof%252BBrain%252BDiseases%26aulast%3DAndrejew%26aufirst%3DRoberta%26date%3D2020%26date%3D2020%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romain  Lara</span>, <span class="hlFld-ContribAuthor ">Elena  Adinolfi</span>, <span class="hlFld-ContribAuthor ">Catherine A.  Harwood</span>, <span class="hlFld-ContribAuthor ">Mike  Philpott</span>, <span class="hlFld-ContribAuthor ">Julian A.  Barden</span>, <span class="hlFld-ContribAuthor ">Francesco  Di Virgilio</span>, <span class="hlFld-ContribAuthor ">Shaun  McNulty</span>. </span><span class="cited-content_cbyCitation_article-title">P2X7 in Cancer: From Molecular Mechanisms to Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00793" title="DOI URL">https://doi.org/10.3389/fphar.2020.00793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00793%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DP2X7%252Bin%252BCancer%25253A%252BFrom%252BMolecular%252BMechanisms%252Bto%252BTherapeutics%26aulast%3DLara%26aufirst%3DRomain%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">StÃ©phane  GÃ©rard</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems: Three Heteroatoms 2:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00021-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00021-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00021-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00021-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%25253A%252BThree%252BHeteroatoms%252B2%25253A1%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine F.  Gelin</span>, <span class="hlFld-ContribAuthor ">Anindya  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Michael A.  Letavic</span>. </span><span class="cited-content_cbyCitation_article-title">P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 63-99. <a href="https://doi.org/10.1016/bs.pmch.2019.11.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2019.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2019.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2019.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DP2X7%252Breceptor%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bsystemic%252Binflammatory%252Bdisorders%26aulast%3DGelin%26aufirst%3DChristine%2BF.%26date%3D2020%26spage%3D63%26epage%3D99%26pub%3DElsevier%26date%3D2020%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hamideh  Zarrinmayeh</span>, <span class="hlFld-ContribAuthor ">Paul R.  Territo</span>. </span><span class="cited-content_cbyCitation_article-title">Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications. </span><span class="cited-content_cbyCitation_journal-name">Molecular Imaging</span><span> <strong>2020,</strong> <em>19 </em>, 153601212092760. <a href="https://doi.org/10.1177/1536012120927609" title="DOI URL">https://doi.org/10.1177/1536012120927609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1536012120927609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1536012120927609%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Imaging%26atitle%3DPurinergic%252BReceptors%252Bof%252Bthe%252BCentral%252BNervous%252BSystem%25253A%252BBiology%25252C%252BPET%252BLigands%25252C%252Band%252BTheir%252BApplications%26aulast%3DZarrinmayeh%26aufirst%3DHamideh%26date%3D2020%26date%3D2020%26volume%3D19%26spage%3D153601212092760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">PaweÅ  Zajdel</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111569. <a href="https://doi.org/10.1016/j.ejmech.2019.111569" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111569%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DImidazopyridine-based%252Bselective%252Band%252Bmultifunctional%252Bligands%252Bof%252Bbiological%252Btargets%252Bassociated%252Bwith%252Bpsychiatric%252Band%252Bneurodegenerative%252Bdiseases%26aulast%3DVanda%26aufirst%3DDavid%26date%3D2019%26volume%3D181%26spage%3D111569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mathilde  Pauton</span>, <span class="hlFld-ContribAuthor ">RaphaÃ«l  Gillet</span>, <span class="hlFld-ContribAuthor ">Catherine  Aubert</span>, <span class="hlFld-ContribAuthor ">Guillaume  Bluet</span>, <span class="hlFld-ContribAuthor ">Florence  Gruss-Leleu</span>, <span class="hlFld-ContribAuthor ">SÃ©bastien  Roy</span>, <span class="hlFld-ContribAuthor ">CÃ©cile  Perrio</span>. </span><span class="cited-content_cbyCitation_article-title">The first radiosynthesis of 2-amino-5-[
              18
              F]fluoropyridines
              via
              a âminimalistâ radiofluorination/palladium-catalyzed amination sequence from anisyl(2-bromopyridinyl)iodonium triflate. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (26)
                                     , 6359-6363. <a href="https://doi.org/10.1039/C9OB01187K" title="DOI URL">https://doi.org/10.1039/C9OB01187K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01187K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01187K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Bfirst%252Bradiosynthesis%252Bof%252B2-amino-5-%25255B%252B18%252BF%25255Dfluoropyridines%252Bvia%252Ba%252B%2525E2%252580%25259Cminimalist%2525E2%252580%25259D%252Bradiofluorination%25252Fpalladium-catalyzed%252Bamination%252Bsequence%252Bfrom%252Banisyl%2525282-bromopyridinyl%252529iodonium%252Btriflate%26aulast%3DPauton%26aufirst%3DMathilde%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D26%26spage%3D6359%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel T. G.  Gonzaga</span>, <span class="hlFld-ContribAuthor ">Felipe H.  Oliveira</span>, <span class="hlFld-ContribAuthor ">N. L. von  Ranke</span>, <span class="hlFld-ContribAuthor ">G. Q.  Pinho</span>, <span class="hlFld-ContribAuthor ">Juliana P.  Salles</span>, <span class="hlFld-ContribAuthor ">Murilo L.  Bello</span>, <span class="hlFld-ContribAuthor ">Carlos R.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Helena C.  Castro</span>, <span class="hlFld-ContribAuthor ">Hellen V. C. M. de  Souza</span>, <span class="hlFld-ContribAuthor ">Caroline R. C.  Reis</span>, <span class="hlFld-ContribAuthor ">Rennan P. P.  Leme</span>, <span class="hlFld-ContribAuthor ">JoÃ£o C. M.  Mafra</span>, <span class="hlFld-ContribAuthor ">Luiz C. S.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Lucas V. B.  Hoelz</span>, <span class="hlFld-ContribAuthor ">Nubia  Boechat</span>, <span class="hlFld-ContribAuthor ">Robson X.  Faria</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Biological Evaluation, and Molecular Modeling Studies of New Thiadiazole Derivatives as Potent P2X7 Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2019,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00261" title="DOI URL">https://doi.org/10.3389/fchem.2019.00261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00261%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DSynthesis%25252C%252BBiological%252BEvaluation%25252C%252Band%252BMolecular%252BModeling%252BStudies%252Bof%252BNew%252BThiadiazole%252BDerivatives%252Bas%252BPotent%252BP2X7%252BReceptor%252BInhibitors%26aulast%3DGonzaga%26aufirst%3DDaniel%2BT.%2BG.%26date%3D2019%26date%3D2019%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Adinolfi</span>, <span class="hlFld-ContribAuthor ">Anna Lisa  Giuliani</span>, <span class="hlFld-ContribAuthor ">Elena  De Marchi</span>, <span class="hlFld-ContribAuthor ">Anna  Pegoraro</span>, <span class="hlFld-ContribAuthor ">Elisa  Orioli</span>, <span class="hlFld-ContribAuthor ">Francesco  Di Virgilio</span>. </span><span class="cited-content_cbyCitation_article-title">The P2X7 receptor: A main player in inflammation. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>151 </em>, 234-244. <a href="https://doi.org/10.1016/j.bcp.2017.12.021" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.12.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.12.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DThe%252BP2X7%252Breceptor%25253A%252BA%252Bmain%252Bplayer%252Bin%252Binflammation%26aulast%3DAdinolfi%26aufirst%3DElena%26date%3D2018%26volume%3D151%26spage%3D234%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Chen</span>, <span class="hlFld-ContribAuthor ">Lu  He</span>, <span class="hlFld-ContribAuthor ">Lanfang  Li</span>, <span class="hlFld-ContribAuthor ">Linxi  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases. </span><span class="cited-content_cbyCitation_journal-name">Clinica Chimica Acta</span><span> <strong>2018,</strong> <em>479 </em>, 196-207. <a href="https://doi.org/10.1016/j.cca.2018.01.032" title="DOI URL">https://doi.org/10.1016/j.cca.2018.01.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cca.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cca.2018.01.032%26sid%3Dliteratum%253Aachs%26jtitle%3DClinica%2520Chimica%2520Acta%26atitle%3DThe%252BP2X7%252Bpurinergic%252Breceptor%25253A%252BAn%252Bemerging%252Btherapeutic%252Btarget%252Bin%252Bcardiovascular%252Bdiseases%26aulast%3DChen%26aufirst%3DZhe%26date%3D2018%26volume%3D479%26spage%3D196%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linyu  Wei</span>, <span class="hlFld-ContribAuthor ">Sharifah A  Syed Mortadza</span>, <span class="hlFld-ContribAuthor ">Jing  Yan</span>, <span class="hlFld-ContribAuthor ">Libin  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yaling  Yin</span>, <span class="hlFld-ContribAuthor ">Chaokun  Li</span>, <span class="hlFld-ContribAuthor ">Sylvie  Chalon</span>, <span class="hlFld-ContribAuthor ">Patrick  Emond</span>, <span class="hlFld-ContribAuthor ">Catherine  Belzung</span>, <span class="hlFld-ContribAuthor ">Dongliang  Li</span>, <span class="hlFld-ContribAuthor ">Chengbiao  Lu</span>, <span class="hlFld-ContribAuthor ">Sebastien  Roger</span>, <span class="hlFld-ContribAuthor ">Lin-Hua  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">ATP-activated P2X7 receptor in the pathophysiology of mood disorders and as an emerging target for the development of novel antidepressant therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience & Biobehavioral Reviews</span><span> <strong>2018,</strong> <em>87 </em>, 192-205. <a href="https://doi.org/10.1016/j.neubiorev.2018.02.005" title="DOI URL">https://doi.org/10.1016/j.neubiorev.2018.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neubiorev.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neubiorev.2018.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520%2526%2520Biobehavioral%2520Reviews%26atitle%3DATP-activated%252BP2X7%252Breceptor%252Bin%252Bthe%252Bpathophysiology%252Bof%252Bmood%252Bdisorders%252Band%252Bas%252Ban%252Bemerging%252Btarget%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bnovel%252Bantidepressant%252Btherapeutics%26aulast%3DWei%26aufirst%3DLinyu%26date%3D2018%26volume%3D87%26spage%3D192%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anindya  Bhattacharya</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in CNS P2X7 Physiology and Pharmacology: Focus on Neuropsychiatric Disorders. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.00030" title="DOI URL">https://doi.org/10.3389/fphar.2018.00030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.00030%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DRecent%252BAdvances%252Bin%252BCNS%252BP2X7%252BPhysiology%252Band%252BPharmacology%25253A%252BFocus%252Bon%252BNeuropsychiatric%252BDisorders%26aulast%3DBhattacharya%26aufirst%3DAnindya%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tetiana  Shvydenko</span>, <span class="hlFld-ContribAuthor ">Kostiantyn  Nazarenko</span>, <span class="hlFld-ContribAuthor ">Kostiantyn  Shvydenko</span>, <span class="hlFld-ContribAuthor ">Sergey  Boron</span>, <span class="hlFld-ContribAuthor ">Oleksii  Gutov</span>, <span class="hlFld-ContribAuthor ">Andrey  Tolmachev</span>, <span class="hlFld-ContribAuthor ">Aleksandr  Kostyuk</span>. </span><span class="cited-content_cbyCitation_article-title">Reduction of imidazolium salts â An approach to diazocines and diazocanes. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2017,</strong> <em>73 </em>
                                    (49)
                                     , 6942-6953. <a href="https://doi.org/10.1016/j.tet.2017.10.053" title="DOI URL">https://doi.org/10.1016/j.tet.2017.10.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2017.10.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2017.10.053%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DReduction%252Bof%252Bimidazolium%252Bsalts%252B%2525E2%252580%252593%252BAn%252Bapproach%252Bto%252Bdiazocines%252Band%252Bdiazocanes%26aulast%3DShvydenko%26aufirst%3DTetiana%26date%3D2017%26volume%3D73%26issue%3D49%26spage%3D6942%26epage%3D6953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yajun  Zheng</span>, <span class="hlFld-ContribAuthor ">Colin M.  Tice</span>, <span class="hlFld-ContribAuthor ">Suresh B.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational control in structure-based drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (13)
                                     , 2825-2837. <a href="https://doi.org/10.1016/j.bmcl.2017.04.079" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.079%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DConformational%252Bcontrol%252Bin%252Bstructure-based%252Bdrug%252Bdesign%26aulast%3DZheng%26aufirst%3DYajun%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2825%26epage%3D2837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tara L.S.  Kishbaugh</span>, <span class="hlFld-ContribAuthor ">Katherine  Lehman</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 383-439. <a href="https://doi.org/10.1016/B978-0-08-102310-5.00012-6" title="DOI URL">https://doi.org/10.1016/B978-0-08-102310-5.00012-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102310-5.00012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102310-5.00012-6%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%26aulast%3DKishbaugh%26aufirst%3DTara%2BL.S.%26date%3D2017%26spage%3D383%26epage%3D439%26pub%3DElsevier%26date%3D2017%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. <b>1</b> (JNJ 54166060) and previously disclosed triazolopyrazines and triazolopyridines (<b>2</b>â<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Imidazopyridine Compounds <b>10</b>â<b>17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>-X, Cu<sub>2</sub>O, 8-OH quinoline, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, microwave, 1 h, 140 Â°C, 17â40%; (b) BnBr, NaBH<sub>4</sub>, DCM, MeOH, rt, 68â87%; (c) H<sub>2</sub>, EtOH, Pd/C, rt, 24 h, 75â83%; (d) R<sup>1</sup>COOH, HATU, Et<sub>3</sub>N, DMF, rt, 22â96%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Imidazopyridine Compounds <b>1</b> and <b>20</b>â<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-Cl-3-CF3PhCOCl (<b>18</b>), MeMgBr, THF, rt, 3 h, 33â54%; (b) H<sub>2</sub>, EtOH, Pd/C, 24 h, 20â62%; (c) SFC chiral chromatography, 40â42%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Single crystal structures and stereochemical assignment of <b>1</b> and <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro profile of <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ex vivo P2X7 occupancy with compound <b>1</b> in rat brain; dose dependency following oral administration (<i>n</i> = 3 per dose Â± SEM). P2X7 occupancy was measured 30 min after drug administration using tritiated <b>5</b> as the radiotracer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/medium/jm-2016-00989h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Single dose and repeat dose toleration studies of <b>1</b> in male rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00989/20160916/images/large/jm-2016-00989h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00989&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biber, K.</span><span> </span><span class="NLM_article-title">The microglial ATP-gated ion channel P2X7 as a CNS drug target</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1772</span><span class="NLM_x">â</span> <span class="NLM_lpage">1787</span><span class="refDoi">Â DOI: 10.1002/glia.23001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Fglia.23001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=27219534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisleltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1772-1787&author=A.+Bhattacharyaauthor=K.+Biber&title=The+microglial+ATP-gated+ion+channel+P2X7+as+a+CNS+drug+target&doi=10.1002%2Fglia.23001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The microglial ATP-gated ion channel P2X7 as a CNS drug target</span></div><div class="casAuthors">Bhattacharya Anindya; Biber Knut; Biber Knut</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1772-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Based on promising preclinical evidence, microglial P2X7 has increasingly being recognized as a target for therapeutic intervention in neurological and psychiatric diseases.  However, despite this knowledge no P2X7-related drug has yet entered clinical trials with respect to CNS diseases.  We here discuss the current literature on P2X7 being a drug target and identify unsolved issues and still open questions that have hampered the development of P2X7 dependent therapeutic approaches for CNS diseases.  It is concluded here that the lack of brain penetrating P2X7 antagonists is a major obstacle in the field and that central P2X7 is a yet untested clinical drug target.  In the CNS, microglial P2X7 activation causes neuroinflammation, which in turn plays a role in various CNS disorders.  This has resulted in a surge of brain penetrant P2X7 antagonists.  P2X7 is a viable, clinically untested CNS drug target.  GLIA 2016;64:1772-1787.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4RW-TLVUR2UwlCcfExbvbfW6udTcc2eZp0masOj3eErntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisleltA%253D%253D&md5=4ae4f32797df2460485f42185e3d7fd9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fglia.23001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.23001%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DBiber%26aufirst%3DK.%26atitle%3DThe%2520microglial%2520ATP-gated%2520ion%2520channel%2520P2X7%2520as%2520a%2520CNS%2520drug%2520target%26jtitle%3DGlia%26date%3D2016%26volume%3D64%26spage%3D1772%26epage%3D1787%26doi%3D10.1002%2Fglia.23001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Collo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidhart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosco-Vilbois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">North, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buell, G.</span><span> </span><span class="NLM_article-title">Tissue distribution of the P2X7 receptor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1277</span><span class="NLM_x">â</span> <span class="NLM_lpage">1283</span><span class="refDoi">Â DOI: 10.1016/S0028-3908(97)00140-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2FS0028-3908%2897%2900140-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=1277-1283&author=G.+Colloauthor=S.+Neidhartauthor=E.+Kawashimaauthor=M.+Kosco-Vilboisauthor=R.+A.+Northauthor=G.+Buell&title=Tissue+distribution+of+the+P2X7+receptor&doi=10.1016%2FS0028-3908%2897%2900140-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900140-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900140-8%26sid%3Dliteratum%253Aachs%26aulast%3DCollo%26aufirst%3DG.%26aulast%3DNeidhart%26aufirst%3DS.%26aulast%3DKawashima%26aufirst%3DE.%26aulast%3DKosco-Vilbois%26aufirst%3DM.%26aulast%3DNorth%26aufirst%3DR.%2BA.%26aulast%3DBuell%26aufirst%3DG.%26atitle%3DTissue%2520distribution%2520of%2520the%2520P2X7%2520receptor%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D1277%26epage%3D1283%26doi%3D10.1016%2FS0028-3908%2897%2900140-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Solle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labasi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perregaux, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrushova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabel, C. A.</span><span> </span><span class="NLM_article-title">Altered cytokine production in mice lacking P2X(7) receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span><span class="refDoi">Â DOI: 10.1074/jbc.M006781200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1074%2Fjbc.M006781200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=125-132&author=M.+Solleauthor=J.+Labasiauthor=D.+G.+Perregauxauthor=E.+Stamauthor=N.+Petrushovaauthor=B.+H.+Kollerauthor=R.+J.+Griffithsauthor=C.+A.+Gabel&title=Altered+cytokine+production+in+mice+lacking+P2X%287%29+receptors&doi=10.1074%2Fjbc.M006781200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M006781200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M006781200%26sid%3Dliteratum%253Aachs%26aulast%3DSolle%26aufirst%3DM.%26aulast%3DLabasi%26aufirst%3DJ.%26aulast%3DPerregaux%26aufirst%3DD.%2BG.%26aulast%3DStam%26aufirst%3DE.%26aulast%3DPetrushova%26aufirst%3DN.%26aulast%3DKoller%26aufirst%3DB.%2BH.%26aulast%3DGriffiths%26aufirst%3DR.%2BJ.%26aulast%3DGabel%26aufirst%3DC.%2BA.%26atitle%3DAltered%2520cytokine%2520production%2520in%2520mice%2520lacking%2520P2X%25287%2529%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D125%26epage%3D132%26doi%3D10.1074%2Fjbc.M006781200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Chataigneau, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, T.</span><span> </span><span class="NLM_article-title">Exploring the ATP-binding site of P2X receptors</span> <span class="citation_source-journal">Front. Cell. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="refDoi">Â DOI: 10.3389/fncel.2013.00273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.3389%2Ffncel.2013.00273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=24415999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=273&author=T.+Chataigneauauthor=D.+Lemoineauthor=T.+Grutter&title=Exploring+the+ATP-binding+site+of+P2X+receptors&doi=10.3389%2Ffncel.2013.00273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the ATP-binding site of P2X receptors</span></div><div class="casAuthors">Chataigneau, Thierry; Lemoine, Damien; Grutter, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Dec.</span>),
    <span class="NLM_cas:pages">273/1-273/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  P2X receptors are ATP-gated non-selective cation channels involved in many different physiol. processes, such as synaptic transmission, inflammation, and neuropathic pain.  They form homo-or hetero-trimeric complexes and contain three ATP-binding sites in their extracellular domain.  The recent detn. of X-ray structures of a P2X receptor solved in two states, a resting closed state and an ATP-bound, open-channel state, has provided unprecedented information not only regarding the three-dimensional shape of the receptor, but also on putative conformational changes that couple ATP binding to channel opening.  These data provide a structural template for interpreting the huge amt. of functional, mutagenesis, and biochem. data collected during more than fifteen years.  In particular, the interfacial location of the ATP binding site and ATP orientation have been successfully confirmed by these structural studies.  It appears that ATP binds to inter-subunit cavities shaped like open jaws, whose tightening induces the opening of the ion channel.  These structural data thus represent a firm basis for understanding the activation mechanism of P2X receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ3sxk5d-OOLVg90H21EOLACvtfcHk0ljFQw0yQb2WNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCit7zP&md5=bcc5478f2078ddcd40676c74a0d5ef29</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2013.00273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2013.00273%26sid%3Dliteratum%253Aachs%26aulast%3DChataigneau%26aufirst%3DT.%26aulast%3DLemoine%26aufirst%3DD.%26aulast%3DGrutter%26aufirst%3DT.%26atitle%3DExploring%2520the%2520ATP-binding%2520site%2520of%2520P2X%2520receptors%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2013%26volume%3D7%26spage%3D273%26doi%3D10.3389%2Ffncel.2013.00273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ando, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlagh, B.</span><span> </span><span class="NLM_article-title">The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain</span> <span class="citation_source-journal">Brain Res. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">â</span> <span class="NLM_lpage">85</span><span class="refDoi">Â DOI: 10.1016/j.brainresbull.2012.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.brainresbull.2012.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=23047057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GktrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=80-85&author=R.+D.+Andoauthor=B.+Sperlagh&title=The+role+of+glutamate+release+mediated+by+extrasynaptic+P2X7+receptors+in+animal+models+of+neuropathic+pain&doi=10.1016%2Fj.brainresbull.2012.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain</span></div><div class="casAuthors">Ando, Romeo D.; Sperlagh, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purinergic signaling represents a major non-synaptic signaling mechanism in the normal and pathol. nervous system.  The expression of the purinergic ligand gated ion channel P2X7 receptor (P2rx7) has been described on nerve terminals as well as in non-neuronal cells, such as astrocytes and microglia.  The activation of P2rx7s results in Ca2+ influx and increased transmitter release in the brain.  P2rx7s previously suggested having a pivotal role in different pain modalities, including neuropathic pain.  Here we investigated whether the activation of P2rx7 leads to increased glutamate release from the spinal cord in an exptl. model of neuropathic pain (partial nerve ligation of the sciatic nerve, PNL).  One week after surgery, we studied the effects of PNL on tactile allodynia using aesthesiometry, in parallel with the in vitro release of [3H]glutamate from lumbar spinal cord slices.  The obsd. allodynia in wild-type (P2rx7+/+) mice one week after PNL surgery was lower that was obsd. in P2rx7 deficient (P2rx7-/-) animals.  Perfusion of spinal cord slices with ATP (10 mM) elicited [3H]glutamate release in both sham operated and neuropathic P2rx7+/+ animals.  The ATP-induced [3H]glutamate release was absent in P2rx7-/- mice.  Elec. evoked release of [3H]glutamate from spinal cord slices was not significantly altered in PNL animals and in P2rx7-/- mice.  The results suggest that activation of P2rx7 by ATP releases glutamate in the spinal cord, which might contribute to mech. allodynia following PNL.  On the other hand, this release does not contribute to glutamate efflux evoked by conventional neuronal activity, which is consistent with the idea that P2X7 receptors are either extrasynaptic or expressed on non-neuronal cells.This article is part of a Special Issue entitled 'Extrasynaptic ionotropic receptors'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLu8btSdFCvLVg90H21EOLACvtfcHk0lhZmNu1dsM_nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GktrzO&md5=7bb20defd142a00155509065ea667ec3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2012.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2012.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DR.%2BD.%26aulast%3DSperlagh%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520glutamate%2520release%2520mediated%2520by%2520extrasynaptic%2520P2X7%2520receptors%2520in%2520animal%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2013%26volume%3D93%26spage%3D80%26epage%3D85%26doi%3D10.1016%2Fj.brainresbull.2012.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Wang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. H.</span><span> </span><span class="NLM_article-title">Activation of P2X(7) receptors induced [(3)H]GABA release from the RBA-2 type-2 astrocyte cell line through a Cl(â)/HCO(3)(â)-dependent mechanism</span> <span class="citation_source-journal">Glia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">â</span> <span class="NLM_lpage">18</span><span class="refDoi">Â DOI: 10.1002/glia.10004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Fglia.10004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2002&pages=8-18&author=C.+M.+Wangauthor=Y.+Y.+Changauthor=J.+S.+Kuoauthor=S.+H.+Sun&title=Activation+of+P2X%287%29+receptors+induced+%5B%283%29H%5DGABA+release+from+the+RBA-2+type-2+astrocyte+cell+line+through+a+Cl%28%E2%88%92%29%2FHCO%283%29%28%E2%88%92%29-dependent+mechanism&doi=10.1002%2Fglia.10004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fglia.10004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%2BM.%26aulast%3DChang%26aufirst%3DY.%2BY.%26aulast%3DKuo%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DS.%2BH.%26atitle%3DActivation%2520of%2520P2X%25287%2529%2520receptors%2520induced%2520%255B%25283%2529H%255DGABA%2520release%2520from%2520the%2520RBA-2%2520type-2%2520astrocyte%2520cell%2520line%2520through%2520a%2520Cl%2528%25E2%2588%2592%2529%252FHCO%25283%2529%2528%25E2%2588%2592%2529-dependent%2520mechanism%26jtitle%3DGlia%26date%3D2002%26volume%3D37%26spage%3D8%26epage%3D18%26doi%3D10.1002%2Fglia.10004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Clark, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staniland, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaan, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcangio, M.</span><span> </span><span class="NLM_article-title">P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">â</span> <span class="NLM_lpage">582</span><span class="refDoi">Â DOI: 10.1523/JNEUROSCI.3295-09.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1523%2FJNEUROSCI.3295-09.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=20071520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=573-582&author=A.+K.+Clarkauthor=A.+A.+Stanilandauthor=F.+Marchandauthor=T.+K.+Kaanauthor=S.+B.+McMahonauthor=M.+Malcangio&title=P2X7-dependent+release+of+interleukin-1beta+and+nociception+in+the+spinal+cord+following+lipopolysaccharide&doi=10.1523%2FJNEUROSCI.3295-09.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7-dependent release of interleukin-1Î² and nociception in the spinal cord following lipopolysaccharide</span></div><div class="casAuthors">Clark, Anna K.; Staniland, Amelia A.; Marchand, Fabien; Kaan, Timothy K. Y.; McMahon, Stephen B.; Malcangio, Marzia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The cytokine interleukin-1Î² (IL-1Î²) released by spinal microglia in enhanced response states contributes significantly to neuronal mechanisms of chronic pain.  Here we examine the involvement of the purinergic P2X7 receptor in the release of IL-1Î² following activation of Toll-like receptor-4 (TLR4) in the dorsal horn, which is assocd. with nociceptive behavior and microglial activation.  We obsd. that lipopolysaccharide (LPS)-induced release of IL-1Î² was prevented by pharmacol. inhibition of the P2X7 receptor with A-438079, and was absent in spinal cord slices taken from P2X7 knock-out mice.  Application of ATP did not evoke release of IL-1Î² from the dorsal horn unless preceded by an LPS priming stimulus, and this release was dependent on P2X7 receptor activation.  Extensive phosphorylation of p38 MAPK in microglial cells in the dorsal horn was found to correlate with IL-1Î² secretion following both LPS and ATP.  In behavioral studies, intrathecal injection of LPS in the lumbar spinal cord produced mech. hyperalgesia in rat hindpaws, which was attenuated by concomitant injections of either a nonspecific (oxidized ATP) or a specific (A-438079) P2X7 antagonist.  In addn., LPS-induced hypersensitivity was obsd. in wild-type but not P2X7 knock-out mice.  These data suggest a crit. role for the P2X7 receptor in the enhanced nociceptive transmission assocd. with microglial activation and secretion of IL-1Î² in the dorsal horn.  We suggest that CNS-penetrant P2X7 receptor antagonists, by targeting microglia in pain-enhanced response states, may be beneficial for the treatment of persistent pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwimWWU-G4jbVg90H21EOLACvtfcHk0lhZmNu1dsM_nQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaht70%253D&md5=4d2c7edf6dc9f1c679375514c4b19cca</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3295-09.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3295-09.2010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DA.%2BK.%26aulast%3DStaniland%26aufirst%3DA.%2BA.%26aulast%3DMarchand%26aufirst%3DF.%26aulast%3DKaan%26aufirst%3DT.%2BK.%26aulast%3DMcMahon%26aufirst%3DS.%2BB.%26aulast%3DMalcangio%26aufirst%3DM.%26atitle%3DP2X7-dependent%2520release%2520of%2520interleukin-1beta%2520and%2520nociception%2520in%2520the%2520spinal%2520cord%2520following%2520lipopolysaccharide%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D573%26epage%3D582%26doi%3D10.1523%2FJNEUROSCI.3295-09.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Shiratori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozaki-Saitoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshitake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, K.</span><span> </span><span class="NLM_article-title">P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">810</span><span class="NLM_x">â</span> <span class="NLM_lpage">819</span><span class="refDoi">Â DOI: 10.1111/j.1471-4159.2010.06809.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1111%2Fj.1471-4159.2010.06809.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=20477948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslygur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=810-819&author=M.+Shiratoriauthor=H.+Tozaki-Saitohauthor=M.+Yoshitakeauthor=M.+Tsudaauthor=K.+Inoue&title=P2X7+receptor+activation+induces+CXCL2+production+in+microglia+through+NFAT+and+PKC%2FMAPK+pathways&doi=10.1111%2Fj.1471-4159.2010.06809.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways</span></div><div class="casAuthors">Shiratori, Miho; Tozaki-Saitoh, Hidetoshi; Yoshitake, Mai; Tsuda, Makoto; Inoue, Kazuhide</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">810-819</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microglia plays an important role in many neurodegenerative conditions.  ATP leaked or released by damaged cells triggers microglial activation through P2 receptors, and stimulates the release of oxygen radicals, proinflammatory cytokines and chemokines from activated microglia.  However, little is known about mechanisms underlying ATP-induced chemokine release from microglia.  In this study, we found that a high concn. of ATP induces the mRNA expression and release of CXCL2 from microglia.  A similar effect was obsd. following treatment of microglia with a P2X7 receptor (P2X7R) agonist, 2'-and 3'-O-(4-benzoylbenzoyl) ATP, and this was inhibited by pre-treatment with a P2X7R antagonist, Brilliant Blue G.  ATP induced both activation of nuclear factor of activated T cells (NFAT) and MAPKs (p38, ERK, and JNK) through P2X7R.  ATP-induced mRNA expression of CXCL2 was inhibited by INCA-6 (an NFAT inhibitor), SB203580 (a p38 inhibitor), U0126 (a MEK-ERK inhibitor) and JNK inhibitor II (a JNK inhibitor).  However, MAPK inhibitors did not inhibit activation of NFAT.  In addn., protein kinase C inhibitors suppressed ATP-induced ERK and JNK activation, and also inhibited ATP-induced CXCL2 expression in microglia.  These results suggest that ATP increased CXCL2 prodn. via both NFAT and protein kinase C/MAPK signaling pathways through P2X7 receptor stimulation in microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbbvEVmlRM37Vg90H21EOLACvtfcHk0lgPCsNIcgtP-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslygur4%253D&md5=4fd0e02a638856399b95479c184e0631</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.06809.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.06809.x%26sid%3Dliteratum%253Aachs%26aulast%3DShiratori%26aufirst%3DM.%26aulast%3DTozaki-Saitoh%26aufirst%3DH.%26aulast%3DYoshitake%26aufirst%3DM.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DK.%26atitle%3DP2X7%2520receptor%2520activation%2520induces%2520CXCL2%2520production%2520in%2520microglia%2520through%2520NFAT%2520and%2520PKC%252FMAPK%2520pathways%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D114%26spage%3D810%26epage%3D819%26doi%3D10.1111%2Fj.1471-4159.2010.06809.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Stock, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishaq, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mebus, C. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">â</span> <span class="NLM_lpage">727</span><span class="refDoi">Â DOI: 10.3899/jrheum.110874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.3899%2Fjrheum.110874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=22382341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=720-727&author=T.+C.+Stockauthor=B.+J.+Bloomauthor=N.+Weiauthor=S.+Ishaqauthor=W.+Parkauthor=X.+Wangauthor=P.+Guptaauthor=C.+A.+Mebus&title=Efficacy+and+safety+of+CE-224%2C535%2C+an+antagonist+of+P2X7+receptor%2C+in+treatment+of+patients+with+rheumatoid+arthritis+inadequately+controlled+by+methotrexate&doi=10.3899%2Fjrheum.110874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate</span></div><div class="casAuthors">Stock, Thomas C.; Bloom, Bradley J.; Wei, Nathan; Ishaq, Saliha; Park, Won; Wang, Xin; Gupta, Pankaj; Mebus, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">720-727</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">To evaluate efficacy and safety of CE-224,535, a selective P2X7 receptor antagonist, vs. placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).  In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A6341009), patients aged â¥ 18 years with active RA were randomized to receive either CE-224,535 (500 mg bid) or placebo for 12 wk; all patients continued a stable background dose of â¥ 7.5 mg MTX.  The American College of Rheumatol. 20% (ACR20) response rate (primary efficacy endpoint) was not significantly different from placebo for CE-224,535 (34.0% vs 36.2%; p = 0.591) at Week 12, or at any timepoint over the 12-wk treatment period.  There was no significant difference at Week 12 for the ACR20 response rate following subgroup analyses by age, sex, baseline disease activity, baseline duration of disease, geog. region, or concomitant use of steroids.  ACR50/ACR70 response rates and change from baseline in Disease Activity Score 28-joint C-reactive protein (DAS28-3-CRP) and Health Assessment Questionnaire-Disability Index for CE-224,535 were not significant at Week 12 vs. placebo.  Treatment-emergent adverse events (AE) were reported by 62.3% (CE-224,535) and 55.3% (placebo) of patients; the most common AE were nausea (11.3%, CE-224,535; 4.3%, placebo) and diarrhea (7.5%, CE-224,535; 4.3%, placebo).  The proportion of patients discontinuing due to an AE was 9.4% (CE-224,535) and 6.4% (placebo); no deaths were reported.  Serious AE occurred in 3.8% (CE-224,535) and 2.1% (placebo) of patients; none was considered treatment-related.  CE-224,535 was not efficacious, compared with placebo, for the treatment of RA in patients with an inadequate response to MTX.  CE-224,535 demonstrated an acceptable safety and tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorblWg-aNBNLVg90H21EOLACvtfcHk0lgPCsNIcgtP-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOnsro%253D&md5=dc919436c3c6e7f3f624c57b77c5dbb2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.110874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.110874%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DWei%26aufirst%3DN.%26aulast%3DIshaq%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DMebus%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520CE-224%252C535%252C%2520an%2520antagonist%2520of%2520P2X7%2520receptor%252C%2520in%2520treatment%2520of%2520patients%2520with%2520rheumatoid%2520arthritis%2520inadequately%2520controlled%2520by%2520methotrexate%26jtitle%3DJ.%2520Rheumatol.%26date%3D2012%26volume%3D39%26spage%3D720%26epage%3D727%26doi%3D10.3899%2Fjrheum.110874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Eser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutgeerts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelsang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braddock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinisch, W.</span><span> </span><span class="NLM_article-title">Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active crohnâs disease: A randomized placebo-controlled, double-blind, phase IIa study</span> <span class="citation_source-journal">Inflamm. Bowel Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2247</span><span class="NLM_x">â</span> <span class="NLM_lpage">2253</span><span class="refDoi">Â DOI: 10.1097/MIB.0000000000000514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1097%2FMIB.0000000000000514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26197451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2247-2253&author=A.+Eserauthor=J.+F.+Colombelauthor=P.+Rutgeertsauthor=S.+Vermeireauthor=H.+Vogelsangauthor=M.+Braddockauthor=T.+Perssonauthor=W.+Reinisch&title=Safety+and+efficacy+of+an+oral+inhibitor+of+the+purinergic+receptor+P2X7+in+adult+patients+with+moderately+to+severely+active+crohn%E2%80%99s+disease%3A+A+randomized+placebo-controlled%2C+double-blind%2C+phase+IIa+study&doi=10.1097%2FMIB.0000000000000514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study</span></div><div class="casAuthors">Eser Alexander; Colombel Jean-Frederic; Rutgeerts Paul; Vermeire Severine; Vogelsang Harald; Braddock Martin; Persson Tore; Reinisch Walter</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2247-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD).  The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD.  METHODS:  We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely active CD as defined by a CD Activity Index (CDAI) of at least 220.  Patients were randomized in a 2:1 mode either to 200 mg of AZD9056 administered orally as a tablet once daily for 28 days or matching placebo.  Primary endpoint was the change in CDAI from baseline at day 28, and secondary endpoints included clinical remission (CDAI < 150) and CDAI 70 response and improvement in the quality of life measures Short Form 36 and Inflammatory Bowel Disease Questionnaire.  Changes in serum C-reactive protein and fecal calprotectin were assessed.  RESULTS:  In total, 34 patients were enrolled, 24 to AZD9056 and 10 to placebo.  The CDAI dropped in AZD9056-treated subjects from a baseline mean of 311 to 242 and from 262 to 239 in placebo-treated subjects (P = 0.049).  Remission and response rates were numerically higher with AZD9056 versus placebo, (n = 5, 24% versus n = 1, 11%, P = 0.43 and n = 11, 52% versus n = 2, 22%, P = 0.13, respectively).  Marked decrease in disease activity was observed for the CDAI subcomponents, pain and general well-being.  Apart from a statistically significant improvement in the Mental Component Score of Short Form 36 for AZD9056 versus placebo (P = 0.017), no other differences in measurements of quality of life could be observed.  There was no decrease in concentrations of serum C-reactive protein and fecal calprotectin during treatment.  AZD9056 was well-tolerated, and no serious adverse events were reported.  CONCLUSIONS:  Our data suggest that the purinergic receptor P2X7 antagonist AZD9056 has the potential to improve symptoms in patients with moderate-to-severe CD combined with a beneficial risk profile.  Although the lack in change of inflammatory biomarkers questions its anti-inflammatory potential, the results obtained in this study rather suggest P2X7 antagonism for the treatment of chronic abdominal pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHjK0qgS5fO0g6wdEZmT2rfW6udTcc2eYONi-UOYigObntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FltVSqtA%253D%253D&md5=8ade69d316c57adae49fb595e35ab2f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1097%2FMIB.0000000000000514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMIB.0000000000000514%26sid%3Dliteratum%253Aachs%26aulast%3DEser%26aufirst%3DA.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DRutgeerts%26aufirst%3DP.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DVogelsang%26aufirst%3DH.%26aulast%3DBraddock%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DT.%26aulast%3DReinisch%26aufirst%3DW.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%2520oral%2520inhibitor%2520of%2520the%2520purinergic%2520receptor%2520P2X7%2520in%2520adult%2520patients%2520with%2520moderately%2520to%2520severely%2520active%2520crohn%25E2%2580%2599s%2520disease%253A%2520A%2520randomized%2520placebo-controlled%252C%2520double-blind%252C%2520phase%2520IIa%2520study%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2015%26volume%3D21%26spage%3D2247%26epage%3D2253%26doi%3D10.1097%2FMIB.0000000000000514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ali, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurijssens, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostenfeld, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott-Stevens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosking, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewit, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">â</span> <span class="NLM_lpage">207</span><span class="refDoi">Â DOI: 10.1111/j.1365-2125.2012.04320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1111%2Fj.1365-2125.2012.04320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=22568863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=197-207&author=Z.+Aliauthor=B.+Laurijssensauthor=T.+Ostenfeldauthor=S.+McHughauthor=A.+Stylianouauthor=P.+Scott-Stevensauthor=L.+Hoskingauthor=O.+Dewitauthor=J.+C.+Richardsonauthor=C.+Chen&title=Pharmacokinetic+and+pharmacodynamic+profiling+of+a+P2X7+receptor+allosteric+modulator+GSK1482160+in+healthy+human+subjects&doi=10.1111%2Fj.1365-2125.2012.04320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects</span></div><div class="casAuthors">Ali, Zahid; Laurijssens, Bart; Ostenfeld, Thor; McHugh, Simon; Stylianou, Anastasia; Scott-Stevens, Paul; Hosking, Louise; Dewit, Odile; Richardson, Jill C.; Chen, Chao</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT â¢ P2X7 receptors are involved in the prodn. of pro-inflammatory cytokines, such as Il-1Î², by central and peripheral immune cells.  Il-1Î² has been implicated as an important mediator of inflammation.  Therefore, the P2X7 receptor is an attractive therapeutic target for inflammatory diseases.  WHAT THIS STUDY ADDS â¢ Findings in pharmacokinetics, pharmacodynamics, safety and tolerability of a P2X7 receptor modulator, GSK1482160, from the first human study for the mol. are described.  A pharmacokinetic/pharmacodynamic model for LPS-stimulated ATP-induced Il-1Î² prodn. in blood allowed the integration of all relevant data and provided in vivo evidence of the nature of the drug-receptor interaction.  The model has the potential to be used to simulate future trials.  AIMS This paper describes findings from the first-in-human study for GSK1482160, an orally available allosteric P2X7 receptor modulator.  The study aimed to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of the compd. in healthy subjects.  METHODS Escalating single doses of up to 1 g were administered to healthy subjects in a single-blind and placebo-controlled fashion.  Safety, tolerability, blood drug concns. and ex vivo Il-1Î² prodn. in blood were evaluated.  RESULTS. Drug concn. peaked within 3.5 h of dosing under fasting conditions and declined thereafter with a relatively short half-life of less than 4.5 h.  Exposure was proportional to dose with between subject variability of less than 60%.  A PK/PD model quantified Il-1Î² as a function of drug exposure.  The model allowed simulation of in vivo pharmacol. for various untested dose levels and regimens.  Furthermore, the mechanistic model supported the hypothesis that the compd. reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity.  No major safety or tolerability concerns were identified in this small study (n= 29), except for one case of asymptomatic accelerated idioventricular rhythm at the top dose.  CONCLUSION. The model-based approach maximized anal. power by integrating all biomarker data and revealed mechanistic insight into the pharmacol. of P2X7 modulation by GSK1482160.  Simulations by this model ultimately led to the discontinuation of the development of this compd.  The therapeutic relevance of the P2X7 receptor remains to be tested in patients.  The mechanistic-model-based approach can be applied widely to drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41Bz54gV-qLVg90H21EOLACvtfcHk0lj8tV6Mb-Ln9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGmsbnF&md5=835023636e0c5b039245344c2a9a207a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04320.x%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%26aulast%3DLaurijssens%26aufirst%3DB.%26aulast%3DOstenfeld%26aufirst%3DT.%26aulast%3DMcHugh%26aufirst%3DS.%26aulast%3DStylianou%26aufirst%3DA.%26aulast%3DScott-Stevens%26aufirst%3DP.%26aulast%3DHosking%26aufirst%3DL.%26aulast%3DDewit%26aufirst%3DO.%26aulast%3DRichardson%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520profiling%2520of%2520a%2520P2X7%2520receptor%2520allosteric%2520modulator%2520GSK1482160%2520in%2520healthy%2520human%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D197%26epage%3D207%26doi%3D10.1111%2Fj.1365-2125.2012.04320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Iwata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutheil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banasr, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duric, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamanashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glasebrook, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koester, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smagin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duman, R. S.</span><span> </span><span class="NLM_article-title">Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2 Ã 7 receptor</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">â</span> <span class="NLM_lpage">22</span><span class="refDoi">Â DOI: 10.1016/j.biopsych.2015.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.biopsych.2015.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26831917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2murw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2016&pages=12-22&author=M.+Iwataauthor=K.+T.+Otaauthor=X.+Y.+Liauthor=F.+Sakaueauthor=N.+Liauthor=S.+Dutheilauthor=M.+Banasrauthor=V.+Duricauthor=T.+Yamanashiauthor=K.+Kanekoauthor=K.+Rasmussenauthor=A.+Glasebrookauthor=A.+Koesterauthor=D.+Songauthor=K.+A.+Jonesauthor=S.+Zornauthor=G.+Smaginauthor=R.+S.+Duman&title=Psychological+stress+activates+the+inflammasome+via+release+of+adenosine+triphosphate+and+stimulation+of+the+purinergic+type+2+%C3%97+7+receptor&doi=10.1016%2Fj.biopsych.2015.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor</span></div><div class="casAuthors">Iwata, Masaaki; Ota, Kristie T.; Li, Xiao-Yuan; Sakaue, Fumika; Li, Nanxin; Dutheil, Sophie; Banasr, Mounira; Duric, Vanja; Yamanashi, Takehiko; Kaneko, Koichi; Rasmussen, Kurt; Glasebrook, Andrew; Koester, Anja; Song, Dekun; Jones, Kenneth A.; Zorn, Stevin; Smagin, Gennady; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-22</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The mechanisms underlying stress-induced inflammation that contribute to major depressive disorder are unknown.  We examine the role of the ATP (ATP)/purinergic type 2X7 receptor (P2X7R) pathway and the NLRP3 (nucleotide-binding, leucine-rich repeat, pyrin domain contg. 3) inflammasome in interleukin (IL)-1Î² and depressive behavioral responses to stress.  The influence of acute restraint stress on extracellular ATP, glutamate, IL-1Î², and tumor necrosis factor alpha in hippocampus was detd. by microdialysis, and the influence of acute restraint stress on the NLRP3 inflammasome was detd. by Western blot anal.  The influence of P2X7R antagonist administration on IL-1Î² and tumor necrosis factor alpha and on anxiety and depressive behaviors was detd. in the chronic unpredictable stress rodent model.  The role of the NLRP3 inflammasome was detd. by anal. of Nlrp3 null mice.  Acute restraint stress rapidly increased extracellular ATP, an endogenous agonist of P2X7R; the inflammatory cytokine IL-1Î²; and the active form of the NLRP3 inflammasome in the hippocampus.  Administration of a P2X7R antagonist completely blocked the release of IL-1Î² and tumor necrosis factor alpha, another stress-induced cytokine, and activated NLRP3.  Moreover, P2X7R antagonist administration reversed the anhedonic and anxiety behaviors caused by chronic unpredictable stress exposure, and deletion of the Nlrp3 gene rendered mice resistant to development of depressive behaviors caused by chronic unpredictable stress.  These findings demonstrate that psychol. "stress" is sensed by the innate immune system in the brain via the ATP/P2X7R-NLRP3 inflammasome cascade, and they identify novel therapeutic targets for the treatment of stress-related mood disorders and comorbid illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPT4PeBplcG7Vg90H21EOLACvtfcHk0ljdMG8nxBzCqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2murw%253D&md5=f17ad7ff32906696e07f3b9e52a7591e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2015.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2015.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DOta%26aufirst%3DK.%2BT.%26aulast%3DLi%26aufirst%3DX.%2BY.%26aulast%3DSakaue%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DDutheil%26aufirst%3DS.%26aulast%3DBanasr%26aufirst%3DM.%26aulast%3DDuric%26aufirst%3DV.%26aulast%3DYamanashi%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DK.%26aulast%3DRasmussen%26aufirst%3DK.%26aulast%3DGlasebrook%26aufirst%3DA.%26aulast%3DKoester%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DK.%2BA.%26aulast%3DZorn%26aufirst%3DS.%26aulast%3DSmagin%26aufirst%3DG.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DPsychological%2520stress%2520activates%2520the%2520inflammasome%2520via%2520release%2520of%2520adenosine%2520triphosphate%2520and%2520stimulation%2520of%2520the%2520purinergic%2520type%25202%2520%25C3%2597%25207%2520receptor%26jtitle%3DBiol.%2520Psychiatry%26date%3D2016%26volume%3D80%26spage%3D12%26epage%3D22%26doi%3D10.1016%2Fj.biopsych.2015.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Basso, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bratcher, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, L. E.</span><span> </span><span class="NLM_article-title">Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">â</span> <span class="NLM_lpage">90</span><span class="refDoi">Â DOI: 10.1016/j.bbr.2008.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bbr.2008.10.018" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2009&pages=83-90&author=A.+M.+Bassoauthor=N.+A.+Bratcherauthor=R.+R.+Harrisauthor=M.+F.+Jarvisauthor=M.+W.+Deckerauthor=L.+E.+Rueter&title=Behavioral+profile+of+P2X7+receptor+knockout+mice+in+animal+models+of+depression+and+anxiety%3A+relevance+for+neuropsychiatric+disorders&doi=10.1016%2Fj.bbr.2008.10.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2008.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2008.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DBasso%26aufirst%3DA.%2BM.%26aulast%3DBratcher%26aufirst%3DN.%2BA.%26aulast%3DHarris%26aufirst%3DR.%2BR.%26aulast%3DJarvis%26aufirst%3DM.%2BF.%26aulast%3DDecker%26aufirst%3DM.%2BW.%26aulast%3DRueter%26aufirst%3DL.%2BE.%26atitle%3DBehavioral%2520profile%2520of%2520P2X7%2520receptor%2520knockout%2520mice%2520in%2520animal%2520models%2520of%2520depression%2520and%2520anxiety%253A%2520relevance%2520for%2520neuropsychiatric%2520disorders%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2009%26volume%3D198%26spage%3D83%26epage%3D90%26doi%3D10.1016%2Fj.bbr.2008.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Savall, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">â</span> <span class="NLM_lpage">676</span><span class="refDoi">Â DOI: 10.1021/acsmedchemlett.5b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=671-676&author=B.+M.+Savallauthor=D.+Wuauthor=M.+De+Angelisauthor=N.+I.+Carruthersauthor=H.+Aoauthor=Q.+Wangauthor=B.+Lordauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Synthesis%2C+SAR%2C+and+pharmacological+characterization+of+brain+penetrant+P2X7+receptor+antagonists&doi=10.1021%2Facsmedchemlett.5b00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists</span></div><div class="casAuthors">Savall, Brad M.; Wu, Duncan; De Angelis, Meri; Carruthers, Nicholas I.; Ao, Hong; Wang, Qi; Lord, Brian; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and SAR of 1,2,3-triazolopiperidines, e.g., I, as a novel series of potent, brain penetrant P2X7 antagonists was described.  Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low soly.  Further work in this series, which focused on the SAR of the N-linked heterocycle, not only increased the potency at the human P2X7R but also provided compds. with good potency at the rat P2X7R.  These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochem. properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfae7yM_oV1bVg90H21EOLACvtfcHk0liw0epsLZdFMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFGisbo%253D&md5=11d93747bb8b71d0ca108a3946e3a758</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00089%26sid%3Dliteratum%253Aachs%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DSynthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520characterization%2520of%2520brain%2520penetrant%2520P2X7%2520receptor%2520antagonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D671%26epage%3D676%26doi%3D10.1021%2Facsmedchemlett.5b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Rudolph, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcazar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrovian, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3157</span><span class="NLM_x">â</span> <span class="NLM_lpage">3163</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2015.06.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3157-3163&author=D.+A.+Rudolphauthor=J.+Alcazarauthor=M.+K.+Ameriksauthor=A.+B.+Antonauthor=H.+Aoauthor=P.+Bonaventureauthor=N.+I.+Carruthersauthor=C.+C.+Chrovianauthor=M.+De+Angelisauthor=B.+Lordauthor=J.+C.+Rechauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=J.+I.+Andresauthor=M.+A.+Letavic&title=Novel+methyl+substituted+1-%285%2C6-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-yl%29methanones+are+P2X7+antagonists&doi=10.1016%2Fj.bmcl.2015.06.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%2BA.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DAnton%26aufirst%3DA.%2BB.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DDe%2BAngelis%26aufirst%3DM.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DAndres%26aufirst%3DJ.%2BI.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520methyl%2520substituted%25201-%25285%252C6-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-yl%2529methanones%2520are%2520P2X7%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3157%26epage%3D3163%26doi%3D10.1016%2Fj.bmcl.2015.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Dean, D. K.; Munoz-Muriedas, J.; Sime, M.; Steadman, J.; A, G.; Thewlis, R. A. E.; Trani, G.; Walter, D. S.</span> PCT Int. Appl. WO 2010125102,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dean%2C+D.+K.%3B+Munoz-Muriedas%2C+J.%3B+Sime%2C+M.%3B+Steadman%2C+J.%3B+A%2C+G.%3B+Thewlis%2C+R.+A.+E.%3B+Trani%2C+G.%3B+Walter%2C+D.+S.+PCT+Int.+Appl.+WO+2010125102%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DD.%2BK.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savall, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2015.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26707399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKrtbjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=257-261&author=M.+K.+Ameriksauthor=H.+Aoauthor=N.+I.+Carruthersauthor=B.+Lordauthor=S.+Ravulaauthor=J.+C.+Rechauthor=B.+M.+Savallauthor=J.+L.+Wallauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Preclinical+characterization+of+substituted+6%2C7-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-8%285H%29-one+P2X7+receptor+antagonists&doi=10.1016%2Fj.bmcl.2015.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists</span></div><div class="casAuthors">Ameriks, Michael K.; Ao, Hong; Carruthers, Nicholas I.; Lord, Brian; Ravula, Suchitra; Rech, Jason C.; Savall, Brad M.; Wall, Jessica L.; Wang, Qi; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-261</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis, SAR, and preclin. characterization of a series of substituted 6,7-dihydro[1,2,4]triazolo[4,3]pyrazin-8(5H)-one P2X7 receptor antagonists are described.  Optimized leads from this series comprise some of the most potent human P2X7R antagonists reported to date (IC50s < 1 nM).  They also exhibit sufficient potency and oral bioavailability in rat to enable extensive in vivo profiling.  Although many of the disclosed compds. are peripherally restricted, compd. I is brain penetrant and upon oral administration demonstrated dose-dependent target engagement in rat hippocampus as detd. by ex vivo receptor occupancy with radiotracer II (ED50 = 0.8 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre9WCgWhiM_rVg90H21EOLACvtfcHk0lglqCSmRfpYcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKrtbjL&md5=d1a36bd7f088f4533308ad49fee7fa5b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DRavula%26aufirst%3DS.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26aulast%3DWall%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520characterization%2520of%2520substituted%25206%252C7-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-8%25285H%2529-one%2520P2X7%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D257%26epage%3D261%26doi%3D10.1016%2Fj.bmcl.2015.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ziff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stenne, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shireman, B. T.</span><span> </span><span class="NLM_article-title">Substituted 5,6-(dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 antagonists</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span><span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00304</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00304" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvVemsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=498-504&author=J.+Ziffauthor=D.+A.+Rudolphauthor=B.+Stenneauthor=T.+Koudriakovaauthor=B.+Lordauthor=P.+Bonaventureauthor=T.+W.+Lovenbergauthor=N.+I.+Carruthersauthor=A.+Bhattacharyaauthor=M.+A.+Letavicauthor=B.+T.+Shireman&title=Substituted+5%2C6-%28dihydropyrido%5B3%2C4-d%5Dpyrimidin-7%288H%29-yl%29-methanones+as+P2X7+antagonists&doi=10.1021%2Facschemneuro.5b00304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists</span></div><div class="casAuthors">Ziff, Jeannie; Rudolph, Dale A.; Stenne, Brice; Koudriakova, Tatiana; Lord, Brian; Bonaventure, Pascal; Lovenberg, Timothy W.; Carruthers, Nicholas I.; Bhattacharya, Anindya; Letavic, Michael A.; Shireman, Brock T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">498-504</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the synthesis of a novel class of brain penetrating P2X7 antagonists with high potency at both the rat and human P2X7 receptors.  Disclosed herein are druglike mols. with demonstrated target engagement of the rat P2X7 receptors after an oral dose.  Specifically, compd. 20 occupied the P2X7 receptors >80% over the 6 h time course as measured by an ex vivo radioligand binding expt.  In a dose-response assay, this mol. has a plasma EC50 of 8 ng/mL.  Overall, 20 has suitable druglike properties and pharmacokinetics in rat and dog.  This mol. and others disclosed herein will serve as addnl. tools to elucidate the role of the P2X7 receptor in neuropsychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX4iuRhC8lPbVg90H21EOLACvtfcHk0lglqCSmRfpYcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvVemsA%253D%253D&md5=7f3f1afa4dad4db259189b98d97c8ae9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00304%26sid%3Dliteratum%253Aachs%26aulast%3DZiff%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DD.%2BA.%26aulast%3DStenne%26aufirst%3DB.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26atitle%3DSubstituted%25205%252C6-%2528dihydropyrido%255B3%252C4-d%255Dpyrimidin-7%25288H%2529-yl%2529-methanones%2520as%2520P2X7%2520antagonists%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D498%26epage%3D504%26doi%3D10.1021%2Facschemneuro.5b00304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Chrovian, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soyode-Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacani, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span> </span><span class="NLM_article-title">Novel phenyl-substituted 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists with robust target engagement in rat brain</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">â</span> <span class="NLM_lpage">497</span><span class="refDoi">Â DOI: 10.1021/acschemneuro.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XltlGmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=490-497&author=C.+C.+Chrovianauthor=A.+Soyode-Johnsonauthor=H.+Aoauthor=G.+M.+Bacaniauthor=N.+I.+Carruthersauthor=B.+Lordauthor=L.+Nguyenauthor=J.+C.+Rechauthor=Q.+Wangauthor=A.+Bhattacharyaauthor=M.+A.+Letavic&title=Novel+phenyl-substituted+5%2C6-dihydro-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazine+P2X7+antagonists+with+robust+target+engagement+in+rat+brain&doi=10.1021%2Facschemneuro.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain</span></div><div class="casAuthors">Chrovian, Christa C.; Soyode-Johnson, Akinola; Ao, Hong; Bacani, Genesis M.; Carruthers, Nicholas I.; Lord, Brian; Nguyen, Leslie; Rech, Jason C.; Wang, Qi; Bhattacharya, Anindya; Letavic, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">490-497</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists were optimized to allow for good blood-brain barrier permeability and high P2X7 target engagement in the brain of rats.  Compd. I (huP2X7 IC50 = 9 nM; rat P2X7 IC50 = 42 nM) achieved 80% receptor occupancy for 6 h when dosed orally at 10 mg/kg in rats as measured by ex vivo radioligand binding autoradiog.  Structure-activity relationships within this series are described, as well as in vitro ADME results.  In vivo pharmacokinetic data for key compds. is also included.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFc11o0pApUbVg90H21EOLACvtfcHk0liJwaD7c-B0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltlGmsA%253D%253D&md5=a51ac05ebd3115489ddbabecf0cd1170</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DSoyode-Johnson%26aufirst%3DA.%26aulast%3DAo%26aufirst%3DH.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26atitle%3DNovel%2520phenyl-substituted%25205%252C6-dihydro-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazine%2520P2X7%2520antagonists%2520with%2520robust%2520target%2520engagement%2520in%2520rat%2520brain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D490%26epage%3D497%26doi%3D10.1021%2Facschemneuro.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rech, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savall, B. M.</span><span> </span><span class="NLM_article-title">The evolution of P2X7 antagonists with a focus on CNS indications</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3838</span><span class="NLM_x">â</span> <span class="NLM_lpage">3845</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.bmcl.2016.06.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=27426304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOitL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3838-3845&author=J.+C.+Rechauthor=A.+Bhattacharyaauthor=M.+A.+Letavicauthor=B.+M.+Savall&title=The+evolution+of+P2X7+antagonists+with+a+focus+on+CNS+indications&doi=10.1016%2Fj.bmcl.2016.06.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of P2X7 antagonists with a focus on CNS indications</span></div><div class="casAuthors">Rech, Jason C.; Bhattacharya, Anindya; Letavic, Michael A.; Savall, Brad M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3838-3845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The P2X7 receptor is an ATP-gated nonselective cation channel that has been linked to a no. of inflammatory diseases.  Activation of the P2X7 receptor by elevated levels of ATP results in the release of proinflammatory cytokines and elevated levels of these cytokines has been assocd. with a variety of disease states.  A no. of research groups in both industry and academia have explored the identification of P2X7R antagonists as therapeutic agents.  Much of this early effort focused on the treatment of diseases related to peripheral inflammation and resulted in several clin. candidates, none of which were advanced to market.  The emerging role of the P2X7 receptor in neuroinflammation and related diseases has resulted in a shift in medicinal chem. efforts toward the development of centrally penetrant antagonists.  This review will highlight the biol. supporting the role of P2X7 in diseases related to neuroinflammation and review the recent medicinal chem. efforts to identify centrally penetrant antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdaLGUAKgul7Vg90H21EOLACvtfcHk0liJwaD7c-B0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOitL3L&md5=04046ec16457c856c96dd50632b96efe</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DRech%26aufirst%3DJ.%2BC.%26aulast%3DBhattacharya%26aufirst%3DA.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DSavall%26aufirst%3DB.%2BM.%26atitle%3DThe%2520evolution%2520of%2520P2X7%2520antagonists%2520with%2520a%2520focus%2520on%2520CNS%2520indications%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3838%26epage%3D3845%26doi%3D10.1016%2Fj.bmcl.2016.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Alcazar, J.; Andres, J. I.; Chrovian, C. C.; Coate, H. R.; De Angelis, M.; Dvorak, C. A.; Gelin, C. F.; Letavic, M. A.; Savall, B. M.; Soyode-Johnson, A.; Stenne, B. M.; Swanson, D. M.</span> PCT Int. Appl. US 20140275015,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alcazar%2C+J.%3B+Andres%2C+J.+I.%3B+Chrovian%2C+C.+C.%3B+Coate%2C+H.+R.%3B+De+Angelis%2C+M.%3B+Dvorak%2C+C.+A.%3B+Gelin%2C+C.+F.%3B+Letavic%2C+M.+A.%3B+Savall%2C+B.+M.%3B+Soyode-Johnson%2C+A.%3B+Stenne%2C+B.+M.%3B+Swanson%2C+D.+M.+PCT+Int.+Appl.+US+20140275015%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcazar%26aufirst%3DJ.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Altman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">4,7-Dimethoxy-1,10-phenanthroline: an excellent ligand for the Cu-catalyzed N-arylation of imidazoles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2779</span><span class="NLM_x">â</span> <span class="NLM_lpage">2782</span><span class="refDoi">Â DOI: 10.1021/ol0608505</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0608505" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSnt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=2779-2782&author=R.+A.+Altmanauthor=S.+L.+Buchwald&title=4%2C7-Dimethoxy-1%2C10-phenanthroline%3A+an+excellent+ligand+for+the+Cu-catalyzed+N-arylation+of+imidazoles&doi=10.1021%2Fol0608505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">4,7-Dimethoxy-1,10-phenanthroline: An excellent ligand for the Cu-catalyzed N-arylation of imidazoles</span></div><div class="casAuthors">Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2779-2782</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4,7-Dimethoxy-1,10-phenanthroline was found to be an efficient ligand for the copper-catalyzed N-arylation of imidazole with aryl iodides and bromides under mild conditions.  A variety of hindered and functionalized imidazoles and aryl halides were transformed in good to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhYwSzg5IKQ7Vg90H21EOLACvtfcHk0liJwaD7c-B0iA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSnt7c%253D&md5=83f85e6503605f82ef5e37c8a6974ac8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol0608505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0608505%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3D4%252C7-Dimethoxy-1%252C10-phenanthroline%253A%2520an%2520excellent%2520ligand%2520for%2520the%2520Cu-catalyzed%2520N-arylation%2520of%2520imidazoles%26jtitle%3DOrg.%2520Lett.%26date%3D2006%26volume%3D8%26spage%3D2779%26epage%3D2782%26doi%3D10.1021%2Fol0608505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Comins, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, A. H.</span><span> </span><span class="NLM_article-title">Regioselective addition of Grignard reagents to 1-acylpyridinium salts. A convenient method for the synthesis of 4-alkyl(aryl)pyridines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4315</span><span class="refDoi">Â DOI: 10.1021/jo00143a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00143a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADyaL38Xls1aktbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1982&pages=4315&author=D.+L.+Cominsauthor=A.+H.+Abdullah&title=Regioselective+addition+of+Grignard+reagents+to+1-acylpyridinium+salts.+A+convenient+method+for+the+synthesis+of+4-alkyl%28aryl%29pyridines&doi=10.1021%2Fjo00143a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective addition of Grignard reagents to 1-acylpyridinium salts.  A convenient method for the synthesis of 4-alkyl(aryl)pyridines</span></div><div class="casAuthors">Comins, Daniel L.; Abdullah, Abdul H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4315-19</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The addn. of Grignard reagents to 1-acylpyridinium salts afforded 1-acyl-2-alkyl(aryl)-1,2-dihydropyridines and 1-acyl-4-alkyl(aryl)-1,4-dihydropyridines.  The regioselectivity of this reaction, 1,2- vs. 1,4-addn., was dependent upon the structures of the Grignard reagent and the 1-acyl group.  Pyridine, 2-picoline, and 3-picoline were studied, and in most cases, significant amts. of 1,4-addn. occurred.  When a catalytic amt. of cuprous iodide was present, nearly exclusive 1,4-addn. resulted.  The crude 1,4-dihydropyridines were aromatized by heating with sulfur to provide 4-substituted pyridines and picolines in good yield and high isomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIy6pHYlQv6bVg90H21EOLACvtfcHk0lgm0Ng9SKgLsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xls1aktbs%253D&md5=07d917e4be8c04c0c5abdeecf19086bc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo00143a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00143a028%26sid%3Dliteratum%253Aachs%26aulast%3DComins%26aufirst%3DD.%2BL.%26aulast%3DAbdullah%26aufirst%3DA.%2BH.%26atitle%3DRegioselective%2520addition%2520of%2520Grignard%2520reagents%2520to%25201-acylpyridinium%2520salts.%2520A%2520convenient%2520method%2520for%2520the%2520synthesis%2520of%25204-alkyl%2528aryl%2529pyridines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1982%26volume%3D47%26spage%3D4315%26doi%3D10.1021%2Fjo00143a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Flack, H. D.</span><span> </span><span class="NLM_article-title">On enantiomorph-polarity estimation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. A: Found. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">881</span><span class="refDoi">Â DOI: 10.1107/S0108767383001762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1107%2FS0108767383001762" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1983&pages=876-881&author=H.+D.+Flack&title=On+enantiomorph-polarity+estimation&doi=10.1107%2FS0108767383001762"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS0108767383001762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767383001762%26sid%3Dliteratum%253Aachs%26aulast%3DFlack%26aufirst%3DH.%2BD.%26atitle%3DOn%2520enantiomorph-polarity%2520estimation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D1983%26volume%3D39%26spage%3D876%26epage%3D881%26doi%3D10.1107%2FS0108767383001762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ameriks, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourgeaud, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vliegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verluyten, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haspeslagh, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letavic, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A.</span><span> </span><span class="NLM_article-title">A novel radioligand for the ATP-gated ion channel P2X7: [H] JNJ-54232334</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">765</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">559</span><span class="refDoi">Â DOI: 10.1016/j.ejphar.2015.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2Fj.ejphar.2015.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=26386289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFOrs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=765&publication_year=2015&pages=551-559&author=B.+Lordauthor=M.+K.+Ameriksauthor=Q.+Wangauthor=L.+Fourgeaudauthor=M.+Vliegenauthor=W.+Verluytenauthor=P.+Haspeslaghauthor=N.+I.+Carruthersauthor=T.+W.+Lovenbergauthor=P.+Bonaventureauthor=M.+A.+Letavicauthor=A.+Bhattacharya&title=A+novel+radioligand+for+the+ATP-gated+ion+channel+P2X7%3A+%5BH%5D+JNJ-54232334&doi=10.1016%2Fj.ejphar.2015.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334</span></div><div class="casAuthors">Lord, Brian; Ameriks, Michael K.; Wang, Qi; Fourgeaud, Lawrence; Vliegen, Maarten; Verluyten, Willy; Haspeslagh, Pieter; Carruthers, Nicholas I.; Lovenberg, Timothy W.; Bonaventure, Pascal; Letavic, Michael A.; Bhattacharya, Anindya</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">765</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">551-559</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The ATP-gated ion channel P2X7 has emerged as a potential central nervous system (CNS) drug target based on the hypotheses that pro-inflammatory cytokines such as IL-1Î² that are released by microglia, may contribute to the etiol. of various disorders of the CNS including depression.  In this study, we identified two closely related P2X7 antagonists, JNJ-54232334 and JNJ-54140515, and then tritium labeled the former to produce a new radioligand for P2X7.  JNJ-54232334 is a high affinity ligand for the rat P2X7 with a pKi of 9.3Â±0.1.  In rat cortical membranes, [3H] JNJ-54232334 reached saturable binding with equil. dissocn. (Kd) const. of 4.9Â±1.3 nM.  The compd. displayed monophasic assocn. and dissocn. kinetics with fast on and off rates.  In rat brain sections, specific binding of [3H] JNJ-54232334 was markedly improved compared to the previously described P2X7 radioligand, [3H] A-804598.  In P2X7 knockout mouse brain sections, [3H] A-804598 bound to non-P2X7 binding sites in contrast to [3H] JNJ-54232334.  In rat or wild type mouse brain sections [3H] JNJ-54232334 bound in a more homogenous and region independent manner.  The ubiquitous expression of P2X7 receptors was confirmed with immunohistochem. in rat brain sections.  The partial displacement of [3H] A-804598 binding resulted in the underestimation of the level of ex vivo P2X7 occupancy for JNJ-54140515.  Higher levels of P2X7 ex vivo occupancy were measured using [3H] JNJ-54232334 due to less non-specific binding.  In summary, we describe [3H] JNJ-54232334 as a novel P2X7 radioligand, with improved properties over [3H] A-804598.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqr6Nqq14QSLVg90H21EOLACvtfcHk0lgm0Ng9SKgLsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFOrs7zP&md5=b7d9da772882fa3d9e405fa54444d0f3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DB.%26aulast%3DAmeriks%26aufirst%3DM.%2BK.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFourgeaud%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DM.%26aulast%3DVerluyten%26aufirst%3DW.%26aulast%3DHaspeslagh%26aufirst%3DP.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DLetavic%26aufirst%3DM.%2BA.%26aulast%3DBhattacharya%26aufirst%3DA.%26atitle%3DA%2520novel%2520radioligand%2520for%2520the%2520ATP-gated%2520ion%2520channel%2520P2X7%253A%2520%255BH%255D%2520JNJ-54232334%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D765%26spage%3D551%26epage%3D559%26doi%3D10.1016%2Fj.ejphar.2015.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mastey, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panneton, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varin, F.</span><span> </span><span class="NLM_article-title">Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography</span> <span class="citation_source-journal">J. Chromatogr., Biomed. Appl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">655</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">310</span><span class="refDoi">Â DOI: 10.1016/0378-4347(94)00096-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1016%2F0378-4347%2894%2900096-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=8081479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2mtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=655&publication_year=1994&pages=305-310&author=V.+Masteyauthor=A.+C.+Pannetonauthor=F.+Donatiauthor=F.+Varin&title=Determination+of+midazolam+and+two+of+its+metabolites+in+human+plasma+by+high-performance+liquid+chromatography&doi=10.1016%2F0378-4347%2894%2900096-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography</span></div><div class="casAuthors">Mastey, V.; Panneton, A.-C.; Donati, F.; Varin, F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B:  Biomedical Sciences and Applications</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">655</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-10</span>CODEN:
                <span class="NLM_cas:coden">JCBBEP</span>;
        ISSN:<span class="NLM_cas:issn">1387-2273</span>.
    </div><div class="casAbstract">A high-performance liq. chromatog. assay coupled with UV detection (254 nm) has been developed for the detn. of midazolam and two of its hydroxylated metabolites, 1-hydroxymidazolam (1-OH) and 4-hydroxymidazolam (4-OH), in human plasma.  Following a novel solid-phase extn. procedure, midazolam and its metabolites are well recovered from plasma.  The analytes were extd. with C1 cartridges and the exts. were evapd. to dryness.  The dry residues were dissolved in 200 Î¼L of mobile phase [0.02 M ammonium phosphate monobasic buffer-methanol-acetonitrile (60:35:5, vol./vol.) (300 mL), 600 Î¼L of 0.2 M tetrabutylammonium bromide soln., adjusted to a pH* (apparent pH) of 4.10].  The sepn. of the analytes was performed on a Spherisorb C8 column (10 cmÃ4.6 mm I.D.) maintained at 30Â°.  The mobile phase was pumped at a flow-rate of 1.5 mL/min.  The method has a lower limit of quantitation of 15 ng/mL of plasma for midazolam and proved to be reproducible (inter-assay precision 5.4%) and accurate (94%) over the therapeutic range of concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP33ulUfltLrVg90H21EOLACvtfcHk0lievK6wzF5twg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2mtr8%253D&md5=39e9e62c81924a169903923a8c32eac2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2F0378-4347%2894%2900096-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0378-4347%252894%252900096-4%26sid%3Dliteratum%253Aachs%26aulast%3DMastey%26aufirst%3DV.%26aulast%3DPanneton%26aufirst%3DA.%2BC.%26aulast%3DDonati%26aufirst%3DF.%26aulast%3DVarin%26aufirst%3DF.%26atitle%3DDetermination%2520of%2520midazolam%2520and%2520two%2520of%2520its%2520metabolites%2520in%2520human%2520plasma%2520by%2520high-performance%2520liquid%2520chromatography%26jtitle%3DJ.%2520Chromatogr.%252C%2520Biomed.%2520Appl.%26date%3D1994%26volume%3D655%26spage%3D305%26epage%3D310%26doi%3D10.1016%2F0378-4347%2894%2900096-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, X. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. M.</span><span> </span><span class="NLM_article-title">Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1311</span><span class="NLM_x">â</span> <span class="NLM_lpage">1319</span><span class="refDoi">Â DOI: 10.1124/dmd.30.12.1311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1124%2Fdmd.30.12.1311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=12433797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVyisrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=1311-1319&author=R.+Yuanauthor=S.+Madaniauthor=X.+X.+Weiauthor=K.+Reynoldsauthor=S.+M.+Huang&title=Evaluation+of+cytochrome+P450+probe+substrates+commonly+used+by+the+pharmaceutical+industry+to+study+in+vitro+drug+interactions&doi=10.1124%2Fdmd.30.12.1311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions</span></div><div class="casAuthors">Yuan, Rae; Madani, Soraya; Wei, Xiao-Xiong; Reynolds, Kellie; Huang, Shiew-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1311-1319</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pharmaceutical industry investigators routinely evaluate the potential for a new drug to modify cytochrome P 450 (P 450) activities by detg. the effect of the drug on in vitro probe reactions that represent activity of specific P 450 enzymes.  The in vitro findings obtained with one probe substrate are usually extrapolated to the compd.'s potential to affect all substrates of the same enzyme.  Due to this practice, it is important to use the right probe substrate and to conduct the expt. under optimal conditions.  Surveys conducted by reviewers in CDER indicated that the most common in vitro probe reactions used by industry investigators include the following: phenacetin O-deethylation for CYP1A2, coumarin 7-hydroxylation for CYP2A6, 7-ethoxy-4-trifluoromethyl coumarin O-dealkylation for CYP2B6, tolbutamide 4'-hydroxylation for CYP2C9, S-mephenytoin 4-hydroxylation for CYP2C19, bufuralol 1'-hydroxylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, and testosterone 6Î²-hydroxylation for CYP3A4.  We reviewed the validation information in the literature on these reactions and other frequently used reactions, including caffeine N3-demethylation for CYP1A2, S-mephenytoin N-demethylation for CYP2B6, S-warfarin 7'-hydroxylation for CYP2C9, dextromethorphan O-demethylation for CYP2D6, and midazolam 1'-hydroxylation for CYP3A4.  The available information indicates that we need to continue the search for better probe substrates for some enzymes.  For CYP3A4-based drug interactions it may be necessary to evaluate two or more probe substrates.  In many cases, the probe reaction represents a particular enzyme activity only under specific exptl. conditions.  Investigators must consider appropriateness of probe substrates and exptl. conditions when conducting in vitro drug interaction studies and when extrapolating the results to in vivo situations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplsZYxa2pKkbVg90H21EOLACvtfcHk0lievK6wzF5twg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVyisrY%253D&md5=336badc64bac1da8353f163e655cd89d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.12.1311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.12.1311%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DMadani%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DX.%2BX.%26aulast%3DReynolds%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DEvaluation%2520of%2520cytochrome%2520P450%2520probe%2520substrates%2520commonly%2520used%2520by%2520the%2520pharmaceutical%2520industry%2520to%2520study%2520in%2520vitro%2520drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D1311%26epage%3D1319%26doi%3D10.1124%2Fdmd.30.12.1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">van Breemen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span> </span><span class="NLM_article-title">Caco-2 cell permeability assays to measure drug absorption</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">â</span> <span class="NLM_lpage">185</span><span class="refDoi">Â DOI: 10.1517/17425255.1.2.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1517%2F17425255.1.2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=16922635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKltLbK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=175-185&author=R.+B.+van+Breemenauthor=Y.+Li&title=Caco-2+cell+permeability+assays+to+measure+drug+absorption&doi=10.1517%2F17425255.1.2.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Caco-2 cell permeability assays to measure drug absorption</span></div><div class="casAuthors">van Breemen, Richard B.; Li, Yongmei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-185</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Caco-2 cells are a human colon epithelial cancer cell line used as a model of human intestinal absorption of drugs and other compds.  When cultured as a monolayer, Caco-2 cells differentiate to form tight junctions between cells to serve as a model of paracellular movement of compds. across the mono-layer.  In addn., Caco-2 cells express transporter proteins, efflux proteins, and Phase II conjugation enzymes to model a variety of transcellular pathways as well as metabolic transformation of test substances.  In many respects, the Caco-2 cell monolayer mimics the human intestinal epithelium.  One of the functional differences between normal cells and Caco-2 cells is the lack of expression of the cytochrome P 450 isoenzymes and in particular, CYP3A4, which is normally expressed at high levels in the intestine.  However, Caco-2 cells may be induced to express higher levels of CYP3A4 by treatment with vitamin D3.  Caco-2 cell monolayers are usually cultured on semipermeable plastic supports that may be fitted into the wells of multi-well culture plates.  Test compds. are then added to either the apical or basolateral sides of the monolayer.  After incubation for various lengths of time, aliquots of the buffer in opposite chambers are removed for the detn. of the concn. of test compds. and the computation of the rates of permeability for each compd. (called the apparent permeability coeffs.).  Although radiolabeled compds. were used in the original Caco-2 cells monolayer assays, radio-labeled compds. have been replaced in most labs. by the use of liq. chromatog.-mass spectrometry (LC-MS) and LC-tandem mass spectrometry (LC-MS-MS).  Mass spectrometry not only eliminates the need for radiolabeled compds., but permits the simultaneous measurement of multiple compds.  The measurement of multiple compds. per assay reduces the no. of incubations that need to be carried out, thereby increasing the throughput of the expts.  Furthermore, LC-MS and LC-MS-MS add another dimension to Caco-2 assays by facilitating the investigation of the metab. of compds. by Caco-2 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcV-AZvy78ILVg90H21EOLACvtfcHk0lglu-Drip6T1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKltLbK&md5=7bd0b875ffa9c840f904bab6513b7e3f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.1.2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.1.2.175%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DCaco-2%2520cell%2520permeability%2520assays%2520to%2520measure%2520drug%2520absorption%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2005%26volume%3D1%26spage%3D175%26epage%3D185%26doi%3D10.1517%2F17425255.1.2.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Houston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetin, A.</span><span> </span><span class="NLM_article-title">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">â</span> <span class="NLM_lpage">951</span><span class="refDoi">Â DOI: 10.2174/138920008786485164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.2174%2F138920008786485164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=18991591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=940-951&author=J.+B.+Houstonauthor=A.+Galetin&title=Methods+for+predicting+in+vivo+pharmacokinetics+using+data+from+in+vitro+assays&doi=10.2174%2F138920008786485164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Methods for predicting in vivo pharmacokinetics using data from in vitro assays</span></div><div class="casAuthors">Houston, J. Brian; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">940-951</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Strategies for optimizing in vivo predictions from in vitro data on metabolic stability and CYP inhibition are discussed.  Potential pitfalls and areas of inaccuracy are highlighted together with recommendations for best practice.  The use of both hepatic microsomes and isolated hepatocytes for the assessment of metabolic stability is discussed in terms of scaling from the in vitro system up to whole liver.  The importance of integrating metabolic stability data together with other drug pharmacokinetic characteristics (e.g., protein binding and red blood cell uptake) as well as blood flow are presented within the context of different liver models.  The assessment of CYP inhibition potential requires in vitro data on the inhibitor potency either in the form of Ki (for reversible inhibition) or Kl and kinact (for time-dependent inhibition).  The integration of these in vitro parameters together with other pharmacokinetic information is essential for the in vivo prediction.  While a qual. assessment may be made from the I/Ki ratio, a no. of addnl. victim drug and enzyme-related parameters are required for quant. prediction.  Of particular importance is the parameter fmCYP (the fraction of the metabolic clearance of the victim drug that is catalyzed by the enzyme subject to the inhibition).  Impact of other victim drug properties (e.g., fractional importance of the intestine) and enzyme properties (e.g., kdeg for time-dependent inhibition) on the drug-drug interaction prediction is discussed.  In addn., mechanisms by which false negatives and false positives may result from in vitro strategies are summarized.  Finally perspectives for future application and improvements in these predictions strategies are outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SQoxJv6217Vg90H21EOLACvtfcHk0lglu-Drip6T1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nsbY%253D&md5=8ec402521f33f7704edc184f7cab9a35</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F138920008786485164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920008786485164%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DMethods%2520for%2520predicting%2520in%2520vivo%2520pharmacokinetics%2520using%2520data%2520from%2520in%2520vitro%2520assays%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2008%26volume%3D9%26spage%3D940%26epage%3D951%26doi%3D10.2174%2F138920008786485164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Hill, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortishire-Smith, R. J.</span><span> </span><span class="NLM_article-title">Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3111</span><span class="NLM_x">â</span> <span class="NLM_lpage">3118</span><span class="refDoi">Â DOI: 10.1002/rcm.2177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=10.1002%2Frcm.2177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1eht7jF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=3111-3118&author=A.+Hillauthor=R.+J.+Mortishire-Smith&title=Automated+assignment+of+high-resolution+collisionally+activated+dissociation+mass+spectra+using+a+systematic+bond+disconnection+approach&doi=10.1002%2Frcm.2177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach</span></div><div class="casAuthors">Hill, Alastair W.; Mortishire-Smith, Russell J.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3111-3118</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An essential component of the process of characterizing chem. unknowns via mass spectrometry is the anal. of collisionally activated dissocn. (CAD) mass spectra.  Existing tools for the automated assignment of CAD spectra typically use a rule-based approach which identifies those bonds that probably break.  While valuable, the failure of explicitly rule-based approaches to suggest rationalisations for a significant proportion of obsd. product ions led the authors to develop an alternative approach (elucidation of product ion connectivity, EPIC) based on high-resoln. mass spectrometry, systematic bond disconnection of the precursor structure, and ranking of the resulting substructures.  The authors exemplify this approach with a reanal. of published MS/MS data for two compds. taken from the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGombopgCxuQFLVg90H21EOLACvtfcHk0lgOjhzeiR7juQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1eht7jF&md5=c35ea9808c5794c3bf10379e1d190a13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Frcm.2177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.2177%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%26aulast%3DMortishire-Smith%26aufirst%3DR.%2BJ.%26atitle%3DAutomated%2520assignment%2520of%2520high-resolution%2520collisionally%2520activated%2520dissociation%2520mass%2520spectra%2520using%2520a%2520systematic%2520bond%2520disconnection%2520approach%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2005%26volume%3D19%26spage%3D3111%26epage%3D3118%26doi%3D10.1002%2Frcm.2177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00989">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_40748"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00989">10.1021/acs.jmedchem.6b00989</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_001.csv">CSV</a>)</p></li><li><p class="inline">Metabolite identification results and crystallography reports (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_001.csv">jm6b00989_si_001.csv (1.51 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00989/suppl_file/jm6b00989_si_002.pdf">jm6b00989_si_002.pdf (2.41 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00989&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00989%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-18" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00989" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679963eb8b1f3cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
